Functional Analysis of Interactions of Rotavirus NSP4 with Caveolin-1, Cyclophilin A, Cyclophilin 40, Heat Shock Protein 56, and Cholesterol by Yakshe, Krystle Ann
FUNCTIONAL ANALYSIS OF INTERACTIONS OF ROTAVIRUS NSP4 WITH 
CAVEOLIN-1, CYCLOPHILIN A, CYCLOPHILIN 40, HEAT SHOCK 
PROTEIN 56, AND CHOLESTEROL 
A Dissertation 
by 
KRYSTLE ANN YAKSHE 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
Chair of Committee, Judith M. Ball 
Committee Members, Julian Leibowitz 
Susan L. Payne 
Friedhelm Schroeder 
Head of Department, Roger Smith 
December 2015 
Major Subject: Veterinary Microbiology 
Copyright 2015 Krystle Yakshe 
 ii 
 
ABSTRACT 
 
The rotavirus enterotoxin, NSP4, is responsible for early secretory diarrhea 
associated with rotavirus infection and is critical for RV replication and morphogenesis. 
NSP4 interacts directly with caveolin-1 and cholesterol and traffics from the 
endoplasmic reticulum to the plasma membrane via an unconventional transport 
pathway for release prior to virus-induced lysis. In this study we demonstrate that NSP4 
interacts with the immunophilins, cyclophilin A, cyclophilin 40, and HSP56 using co-
immunoprecipitation and FRET analysis. We examined the roles of caveolin-1 and the 
immunophilins in NSP4 transport to the plasma membrane using silencing RNA, 
immunofluorescence analysis, and surface biotinylation. Cholesterol reduction was 
accomplished by statin inhibition of cholesterol synthesis. We found that knockdown of 
these cellular proteins altered the intracellular distribution of NSP4, but did not prevent 
NSP4 from trafficking to the PM. Cholesterol inhibition decreased the amount of NSP4 
that reached the PM, indicating a role of cholesterol in NSP4 transport. 
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NOMENCLATURE 
3AT 3-Amino-1,2,4-triazole 
5FOA 5-fluorouracil 
APS ammonium persulfate 
CaMKK-β calcium dependent calmodulin kinase kinase-β 
Cav-1 caveolin-1 
ConA Concanavalin A 
CPE cytopathic effect 
CsA cyclosporin A 
CSM complete synthetic media 
Cy2 cyanine 
Cy3 indocarbocyanine 
Cy5 indodicarbocyanine 
CyP40 cyclophilin 40 
CyPA cyclophilin A 
DMEM Dulbecco’s modified Eagle’s medium 
DLP double-layered particle 
ER endoplasmic reticulum 
ERGIC-53 endoplasmic reticulum-Golgi intermediate complex 53 
FBS fetal bovine serum 
FGF-2 fibroblast growth factor 2 
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FRET    Förster resonance energy transfer 
G    glycoprotein 
GAPDH   glyceraldehyde 3-phosphate dehydrogenase 
h    hour(s) 
HCV    Hepatitis C Virus 
his    histidine 
HIV    Human Immunodeficiency Virus 
hpi    hours post infection 
HPLC    high performance liquid chromatography 
HPV    Human Papilloma Virus 
HRP    horseradish peroxidase 
HSP56    heat shock protein 56 
IP    intraperitoneally or immunoprecipitation 
LB    Luria-Burtani 
leu    leucine 
LSCM    laser scanning confocal microscope 
LTR    long terminal repeat 
NFDM    non-fat dry milk 
MDCK   Madin-Darby canine kidney 
MEM    minimum essential medium 
MeOH    methanol 
MOC    Mander’s overlap coefficient 
 vii 
MOI    multiplicity of infection 
mTOR    mechanistic target of rapamycin 
MWCO   molecular weight cutoff 
NSP4    non-structural protein 4 
QMA    quaternary methylamine anion 
QS    quantity sufficient 
P    protease-sensitive protein 
PAGE    polyacrylamide gel elctrophoresis 
PB    Pacific Blue™ 
PBS    phosphate buffered saline 
PDI    protein disulfide isomerase 
pfu    plaque-forming units 
PM    plasma membrane 
PMSF    phenylmethanesulfonyl fluoride 
PPIase    peptidyl prolyl isomerase 
RV    rotavirus 
SDS-PAGE   sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sf9    Spodoptera frugiperda 9 
shRNA   short hairpin RNA 
siNT    non-targeting silencing RNA 
siRNA    silencing RNA 
trp    tryptophan 
viii 
TLP triple-layered particle 
UPR unfolded protein response 
VSV Vesicular Stomatitis Virus 
Y2H yeast two-hybrid 
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1. INTRODUCTION: AN OVERVIEW OF ROTAVIRUS, NSP4, CAVEOLIN-1, 
CYCLOPHILIN A, CYCLOPHILIN 40, HEAT SHOCK PROTEIN 56 AND 
UNCONVENTIONAL PROTEIN TRANSPORT  
1.1 Rotavirus  
Enteric pathogens remain one of the most deadly, and therefore one of the most 
important groups of pathogens in the world.  Diarrheal diseases caused by enteric 
pathogens are responsible for approximately 2 million deaths annually worldwide 
(Boschi Pinto, 2009), with 1.3 million deaths in children under the age of 5 (Black et al., 
2010).  Viruses are the most common causal agents of diarrheal disease (Estes, 2013), 
with rotaviruses (RV) as the most dangerous, responsible for ~450,000 deaths annually 
(Parashar et al., 2009).  Through the use of the RV vaccines, Rotarix® and RotaTeq®, 
infant deaths due to dehydration and associated symptoms of RV infection have been 
significantly decreased in the western world despite possible problems associated with 
the vaccines themselves, such as limited protective ability against new viral strains and 
the possibility of intussusception.  However, RV infection remains a tremendous 
problem in developing nations due to vaccine cost and availability (Hyser and Estes, 
2009).  
RV is spread through the fecal-oral route, usually in water, person to person, and by 
improperly heated food; therefore, countries with little or no water sanitation have the 
highest prevalence of infant death due to RV infection.  Although RV infects much of 
the population, generally children under the age of 5 are most symptomatic.  The high 
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rate of death in young children is due to the combination of secretory and malabsorptive 
diarrhea, which is caused primarily by the RV enterotoxin, nonstructural protein 4 
(NSP4) and destruction of absorptive enterocytes, respectively (Ball et al., 2005).  Other 
mechanisms of diarrhea have been noted, including activation of the enteric nervous 
system, villus ischemia, and mild inflammation (Lundgren et al., 2000). 
Although children are most commonly affected by RV infection, it is also a problem 
in the elderly and immunocompromised (Liakopoulou et al., 2005; Ziring, 2005). RV 
type B has been connected to large outbreaks in China and other parts of Asia (Fang et 
al., 1989; Kelkar and Zade, 2004). In the US and Europe, RV outbreaks have occurred in 
long-term care facilities, such as nursing homes and extended stay hospitals (Cubitt and 
Holzel, 1980; Halvorsrud and Orstavik, 1980; Marrie et al., 1982). Nevertheless, most 
adult infections are asymptomatic (Estes, 2013) and the number of adult deaths due to 
RV symptoms remains low. 
1.2 Vaccines  
The two RV vaccines currently in use in the US are not as protective in 
underdeveloped countries, due to a variety of circulating strains. RV is classified into 7 
distinct groups (A-G), but only A, B, and C are important for human infection. Group A 
RVs are grouped into serotypes by the circulating P and G types, which denote the 
presence of antibodies against VP4 (protease-sensitive protein, P) and VP7 
(glycoprotein, G). To date, there are 27 G types and 35 P types. The most important 
types for humans worldwide are G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] (Santos 
and Hoshino, 2005). Currently, type G1P[8] is the most common Group A RV 
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circulating in the United States (Jain et al., 2014). However, in India and China, types 
G2P[6], G3P[6], G12P[8], G12P[6] and G9P[6] are more common, and are not protected 
by Rotarix or RotaTeq. 
Before the vaccine program was introduced in the US, RV infection followed a 
seasonal pattern and was at its peak in winter and spring (Patel et al., 2013). It infected 
millions of children per year and was responsible for nearly 1 million deaths per year. 
After vaccination was introduced in the United States, disease incidence went down 
considerably and RV is now responsible for only 20-30 deaths annually in the US as 
opposed to about 200. In addition, the seasonality of the virus became less noticeable 
after introduction of the vaccine in the US (Staat et al., 2010). Although the two RV 
vaccines on the market are specific for the strains circulating in the Americas, they are 
still somewhat effective in Asian and African developing countries, although not as 
protective as they are in the US. 
Currently, there are several vaccines in use in various countries around the world. 
Many countries in Central and South America and several countries in Western Europe 
vaccinate children with Rotarix and RotaTeq and achieve efficacies similar to that seen 
in the US (Estes, 2013). In China, a vaccine derived from a lamb RV strain, LLV 
(G10P[12]) is effective in up to 81% of children under the age of 12 months (He et al., 
2013). The recent Rotashield vaccine (RV4) is being reformulated and tested in many 
African countries, and the new formulation is providing more protection in phase III 
trials than previously noted (Estes, 2013). Finally, in India, there is a strain 116E 
(G9P8[11]) that is undergoing testing and is proving to be highly immunogenic 
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(Bhandari et al.). There are several other candidates for vaccines in these countries, so 
the incidence of RV infections is declining worldwide, but still has proven to be a major 
problem in young children and the elderly. 
1.3 Structure  
RV is a non-enveloped, icosahedral, double stranded RNA virus, with a genome 
consisting of 11 double stranded RNA (dsRNA) segments.  The virion consists of three 
concentrically arranged protein layers surrounding 11 dsRNA segments and several viral 
proteins.  The outer layer is composed of 260 trimers of VP7, with 60 protruding spikes 
consisting of structurally asymmetric dimers of VP4.  The middle layer is composed of 
260 trimers of VP6, and the innermost layer consists of 60 dimers of VP2 (Figure 1.1).  
The proteins located within the inner VP2 core include a RNA-dependent RNA 
polymerase (VP1), a protein required for replicase activity (VP2), and a 
guanylyltransferase and methyltransferase (VP3).  Rotavirus also encodes an eIF-4G 
interacting protein (NSP3) involved in the preferential translation of RV mRNA 
transcripts in the cell, a helicase (NSP2), a phosphoprotein with kinase activity (NSP5), 
a RNA binding protein (NSP1), and a NSP5 binding protein (NSP6) (Estes, 2013; 
Jayaram et al., 2004). 
To gain entry into the cell, RV VP4 binds to one or more strain-dependent receptors 
and coreceptors, including sialic acid containing molecules, such as the GM1 
ganglioside, several integrin types, histo-blood group antigens, HSP70, and the more 
recently discovered JAM-A (Huang et al., 2012; Isa et al., 2006; Isa et al., 2004; Torres-
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Flores et al., 2015).  Although it is not an absolute requirement, the VP4 spikes of most 
RV strains undergo trypsin cleavage to produce VP5* and VP8*, which enhances 
 
   
Figure 1.1 Depiction of rotavirus triple layered particle (Estes, 2013). 
 
infectivity (Arias et al., 1996; Estes et al., 1981), stabilizes the virion and aids in receptor 
recognition (Crawford et al., 2006; Jayaram et al., 2004).  RV entry currently is thought 
to be a multistep process involving sequential binding of receptors and coreceptors, 
resulting in conformational changes in the virion that allow cellular penetration via an 
unknown mechanism (Estes, 2013).  There is evidence that receptor-mediated 
endocytosis may be involved (Arias et al., 2015; Gutierrez et al., 2010; Silva-Ayala et 
al., 2013), but other evidence points to direct entry (Estes, 2013). Once the virion enters 
the low Ca2+ environment of the cytosol, the calcium-dependent, outer VP7 layer is 
dismantled with the VP4 spike (Ruiz et al., 2000), and the double layered particles 
(DLPs) undergo a conformational shift to align and open 12 channels, allowing for entry 
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of nucleotides and hydrolysable ATP into the inner VP2 core (Jayaram et al., 2004; 
Spencer and Arias, 1981).  Transcription of viral RNA is performed exclusively through 
the use of viral enzymes housed within the inner core of the intact DLP (Estes, 2013).  
The resulting 5’ capped, but not polyadenylated viral mRNA exits through the channels 
into the surrounding cytoplasm (Patton et al., 2004).  The ability of RV to contain the 
dsRNA inside of the core is an effective way to avoid cellular detection of dsRNA and 
induction of IFN.   
The capped viral mRNAs are transported to ribosomes and translated by host cellular 
machinery (Jayaram et al., 2004). NSP3 serves to increase translation of viral mRNA by 
binding to the 3’ end of the viral mRNA (Poncet et al., 1993), and then outcompeting 
binding of cellular poly-A binding protein to eIF4G (Piron et al., 1998).  This not only 
preferentially increases viral mRNA translation, but also inhibits cellular mRNA 
translation (Padilla-Noriega et al., 2002).  NSP3 may also be involved in recruitment of 
viral mRNAs into the electron-dense viroplasm located near the ER for secondary 
replication (Jayaram et al., 2004; Suguna and Rao, 2010). Most of the proteins are 
translated by free ribosomes with the exception of NSP4 and VP7, which are synthesized 
by ER bound ribosomes and co-translationally inserted into the ER membrane for late 
viral assembly (Estes, 2013). 
During RV infection, electron-dense viroplasms (“virus factories”) form adjacent to 
the ER and contain RV proteins VP2, NSP2, NSP5, and NSP6, and VP6 (Gonzalez et 
al., 2000; Petrie et al., 1984).   The genomic dsRNA segments are replicated in the 
viroplasm and associate with some of the viral proteins before they are loaded into the 
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DLPs (Gallegos and Patton, 1989). There is an interaction between VP6 in the outer coat 
of the DLPs and the cytoplasmic C-terminus of NSP4 that facilitates the budding of the 
DLP into the lumen of the ER (Maass and Atkinson, 1990; Taylor et al., 1996). As the 
DLP enters the ER it acquires a transient envelope that is lost before the addition of the 
outer protein layer (Petrie et al., 1984; Tian et al., 1996). The outer layer consisting of 
VP7 is assembled within the Ca2 + rich ER, and the intact triple layered particles leave 
the ER and travel to plasma membrane (PM) lipid microdomains for release (Cuadras 
and Greenberg, 2003; Huang et al., 2004; Isa et al., 2004).  It is controversial whether 
the RV spike protein, VP4, associates with the triple layered particles (TLPs) in the ER 
or is assembled at the PM.  There is evidence that VP4 associates with lipid 
microdomains on the PM independently of TLPs (Delmas et al., 2004).  It also has been 
shown that VP4 co-localizes with β-tubulin and is associated with peroxisomes via a 
peroxisomal targeting sequence (Mohan et al., 2002).  Peroxisome association and 
accumulation of VP4 at the PM could be a mechanism for recruitment of the TLP to the 
PM for release, but the route of how the TLP gets from the ER to the PM remains 
unclear. 
1.4 NSP4  
RV NSP4, is a viral RNA synthesis modulator, an intracellular viral receptor, is 
integral to viral particle maturation, and plays an important role in pathogenesis.  NSP4 
is an 175 amino acid protein with a single transmembrane domain (residues 24-44) that 
overlaps the second hydrophobic domain (H2), 3 N-terminal hydrophobic domains, 2 N-
terminal, N-linked glycosylation sites at residues 8 and 18, and several C-terminal 
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protein binding domains (Ball et al., 2005; Bergmann et al., 1989).  The long 
cytoplasmic tail contains a coiled-coil amphipathic alpha helix (residues 93-137) 
(Bowman et al., 2000), which overlaps several protein binding sites, two of the four 
antigenic sites (Mori et al., 2002), the enterotoxic domain, and the oligomerization 
domain (Figure 1.2) (Ball et al., 1996; Bowman et al., 2000; Parr et al., 2006).  NSP4 
resides in the ER membrane and has been localized to several additional locations in the 
cell, as well as extracellularly (Berkova et al., 2006; Xu et al., 2000; Zhang et al., 2000).  
The pathways by which NSP4 traffics to these alternate locations and eventually out of 
the cell are largely unknown.  We propose to elucidate these mechanism(s) as this 
knowledge will contribute to the development of therapeutics and future vaccine 
strategies for RV infection. 
 
 
Figure 1.2. NSP4 structure and binding sites (Parr et al., 2006). H1-H3 represent the 
hydrophobic domains; CHO represents the glycosylation sites; TM represents the ER 
transmembrane domain; AAH is the amphipathic alpha-helix; CCD is the coiled-coil 
domain 
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The C-terminus of NSP4 functions as a receptor to bind VP6 and recruit DLPs into 
the ER (Taylor et al., 1992; Taylor et al., 1996), but its role in viral particle maturation 
does not end there.  Silencing of NSP4 using targeted silencing RNA (siRNA) leads to a 
75-80% reduction in the amount of infectious progeny released from cells, an 
accumulation of empty viral particles in the viroplasm and cytoplasm, an intracellular 
redistribution of several viral proteins, and an increase in viral RNA transcription 
(Cuadras et al., 2006; Lopez et al., 2005; Silvestri et al., 2005).  When NSP4 is silenced, 
NSP2, NSP5, VP2, and VP6 are dispersed throughout the cytoplasm, rather than residing 
in the viroplasm (Lopez et al., 2005).  Silencing of NSP4 also causes a 64% reduction of 
VP4 accumulation at PM lipid rafts (Cuadras et al., 2006).  In addition, NSP4 is thought 
to play a role in the removal of the transient envelope upon DLP entry into the ER (Tian 
et al., 1996). Taken together, NSP4 is essential for RV particle maturation. 
In addition to acting as a regulator of viral particle maturation and trafficking, NSP4 
functions as an enterotoxin, and is thought to be a major contributing factor to the early 
secretory diarrhea during RV infection (Ball et al., 1996).  The toxin alone, or a peptide 
(residues 114-135) corresponding to part of the enterotoxic domain, induces diarrhea in 
rodent pups, induces an increase in intracellular calcium (Dong et al., 1997; Tian, 1995), 
and causes chloride secretion across unstripped mouse intestinal mucosa without causing 
morphological change (Ball et al., 1996).   
RV NSP4 interacts with a number of host proteins, including calnexin, caveolin-1, 
and tubulin, and has been shown to influence the concentration and intracellular 
distribution of several more, including cofilin, BiP, endoplasmin, β-coatamer protein, 
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and ERGIC53 (Berkova et al., 2007; Mirazimi et al., 1998; Parr et al., 2006; Xu et al., 
1998, 2000).  Each of these molecules plays a role in some type of cellular transport 
mechanism, whether involved in protein folding, vesicular transport, or cytoskeletal 
rearrangement.  By interacting with, or affecting levels or cellular distribution of these 
proteins, NSP4 is able to traffic through the cell to specific loci and to the PM via an 
unconventional transport route. 
Full length NSP4 remains endoglycosidase H sensitive and Brefeldin A resistant, 
indicating that it does not travel through the Golgi to undergo oligosaccharide processing 
(Bergmann et al., 1989; Ericson et al., 1983; Taylor et al., 1992).  NSP4 production and 
glycosylation is not affected in RV-infected HT29 cells treated with Nocodozole or 
Cytochalasin D, which disrupt microtubule and actin filament polymerization, 
respectively; however, secretion of the NSP4112-175 cleavage product is abolished upon 
addition of these agents to infected cells (Zhang et al., 2000).  Also, NSP4 expression in 
Cos-7 cells blocks classical transport of the vesicular stomatitis virus glycoprotein 
(VSV-G) from the ER to the Golgi and redistributes endoplasmic reticulum-Golgi 
intermediate complex protein 53 (ERGIC-53) to dispersed cytoplasmic structures, 
suggesting that NSP4 has an inhibitory effect on transport from the ERGIC to the Golgi 
(Xu et al., 2000).  NSP4 also co-localizes with ERGIC-53 in Cos-7 cells, but the co-
localization was dependent on the C-terminal tubulin-binding domain of NSP4 (Xu et 
al., 2000).  Another study shows NSP4 traffics via a Golgi-independent pathway and co-
localizes with autophagasomal marker LC3 in HEK 293 cells (Berkova et al., 2007; 
Chwetzoff and Trugnan, 2006; Cuadras et al., 2006; Jourdan et al., 1997).   
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NSP4 localizes to the PM, and has been isolated with purified-caveolae fractions 
using a novel non-detergent PM isolation method (Storey et al., 2007). NSP4 also 
traffics to the PM with cell type-dependent transport kinetics (Gibbons et al., 2011). 
Together, these findings strongly suggest that NSP4 is being transported via a Golgi-
independent pathway, but it remains to be determined if NSP4 follows a vesicular or 
soluble route from the ER to the PM.  We propose that transport is not only cell-type 
dependent, but that NSP4 is likely using both vesicular and soluble routes to reach the 
PM. 
1.5 Unconventional Protein Transport  
Conventional protein transport of secreted proteins begins by translation and 
translocation of the protein into the rough ER. The proteins often contain a signal 
sequence that directs them to their final destination. Once folded properly, the proteins 
traffic from the ER, through the ER-Golgi intermediate compartment (ERGIC) to the 
tiered Golgi apparatus. The different compartments of the Golgi have specialized 
functions that process oligosaccharides on the proteins and direct them to their final 
destination. 
In recent years, several proteins have been shown to traffic via unconventional 
protein trafficking mechanisms, either bypassing the Golgi on the way from the ER to 
the PM, reaching the PM in a COPII vesicle-independent manner from the ER, or 
bypassing the ER completely due to the lack of an ER signal peptide or other 
unconventional pathways (Nickel and Rabouille, 2009).  Proteins that follow 
unconventional trafficking have several common characteristics, such as 
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endoglycosidase H sensitivity, Brefeldin A insensitivity, lack of a signal peptide, and 
rapid transport to the PM (Nickel and Rabouille, 2009).  Nickel proposed 4 models as to 
how proteins lacking signal peptides may reach the PM and the extracellular space by an 
unconventional route: 1) Direct translocation across the PM from the cytosol to the 
extracellular space 2) lysosome-dependent secretion 3) secretion via multivesicular body 
(MVB)-derived exosomes, and 4) secretion via membrane blebbing/microvesicular 
secretion (Nickel and Rabouille, 2009).  These mechanisms export proteins that function 
strictly extracellularly, such as FGF-2 and galectin-1, as well as those that have both 
intracellular and extracellular functions, including interleukin-1β (IL-1β) and caspase-1.  
It is likely that NSP4 follows one or more of Nickel’s proposed mechanisms or a new 
mechanism to reach and traverse the PM.   
 In addition to trafficking via unconventional mechanism(s), translocation of these 
proteins across the PM is not well defined.  Fibroblast growth factor 2 (FGF-2) has been 
studied by Walter Nickel’s group, and is one of the best-characterized proteins that 
follows an unconventional trafficking pathway.  FGF-2 is a soluble protein that contains 
an amphipathic α-helix and bypasses the Golgi for transport directly from the ER to the 
PM.  FGF-2 likely is first recruited to the PM via an interaction with the 
phosphoinositide phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), but it is unclear 
whether it is transported via a membrane transporter, by direct insertion into the PM, or 
by formation of a pore (Nickel and Seedorf, 2008).  NSP4 contains an amphipathic α-
helix, as well as three hydrophobic domains that have the potential of inserting directly 
into membranes, which may play a part in the translocation of NSP4 across the PM. 
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NSP4 deletion constructs and mutants have been used to show that the transmembrane 
domain and a cluster of lysine residues near the amphipathic alpha helix are responsible 
for formation of a pore in the ER membrane called a viroporin (Hyser et al., 2010). A 
model has been proposed for the direct membrane insertion, but it is unknown if it plays 
a role at the PM. 
1.6 Immunophilins and Caveolin-1  
A previously identified protein/cholesterol complex termed the Caveolin Chaperone 
Complex has been described and was thought to be involved in transport of de novo 
synthesized cholesterol from the ER to the PM (Uittenbogaard et al., 2002; 
Uittenbogaard and Smart, 2000; Uittenbogaard et al., 1998).  Recently, the studies 
describing this complex have been retracted (Office of the Secretary, 2012), but the 
proteins have been shown to interact in other ways intracellularly. The proposed 
complex consisted of the chaperone proteins cyclophilin A (CyPA), cyclophilin 40 
(CyP40), heat shock protein 56 (HSP56, FKBP4), caveolin-1 (Cav-1), and cholesterol 
(Uittenbogaard et al., 1998).  Direct interaction of NSP4 with Cav-1, raft-like model 
membranes, and cholesterol have been shown in our laboratory (Huang et al., 2004; Parr 
et al., 2006; Schroeder, 2009).  In addition, NSP4 is associated with the CyPA and 
CyP40 as evidenced by co-immunoprecipitation and FRET experiments (Yakshe, et al. 
in preparation).  Mutagenesis and yeast two-hybrid (Y2H) protein interaction studies 
mapped the Cav-1 binding site to NSP4 residues 112-140, and later to 3 hydrophobic 
residues (Huang et al., 2004; Parr et al., 2006).  These data indicate that the NSP4-Cav-1 
interaction is due to three hydrophobic residues, leaving the charged face of the 
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amphipathic helix free to interact with the negative phosphates of the membrane. Despite 
this evidence, it remains unknown if the association of these protein components 
influences intracellular transport of NSP4.   
Cav-1 is a scaffolding protein that is expressed in the Golgi or PM of cells, and 
assists in formation of caveolae on the cell surface and contributes to cell signaling. 
CyPA and CyP40 are both chaperone proteins with peptidyl prolyl isomerase (PPIase) 
activity and are commonly complexed with viral proteins (Fischer et al., 2010). HSP56 
is a heat shock protein that is known to complex with several chaperone protein and also 
contains PPIase activity (Davies and Sanchez, 2005). Both CyP40 and HSP56 are known 
to be HSP90-binding immunophilins and are complexed with a nuclear steroid receptor 
complex (Ratajczak et al., 2009). These immunophilins also have been described as 
binding dynein and assisting with retrograde transport of receptor complexes 
(Galigniana et al., 2002; Galigniana et al., 2001). In addition, CyPA binds dynein, but 
has not been found in association with CyP40 or HSP56 in this capacity. 
1.7 Autophagy  
Autophagy is a degradation pathway used to dispose of and recycle intracellular 
components. A common initiator of autophagy is ER stress and this process can be 
inhibited by mechanistic target of rapamycin (mTOR). Autophagy starts when a 
complex of proteins, Atg101/FIP200/ULK1/Atg13, that combine and inhibit mTOR 
suppression of autophagy (Crawford et al., 2012; Mizushima et al., 2011). This complex 
initiates membrane formation and another complex consisting of Atg5/Atg12/Atg16 
combine and act similarly to an E3 ubiquitin ligase, which contributes to removing and 
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recycling the amino acids of unfolded or incorrectly folded proteins. The 
Atg5/Atg12/Atg16 complex regulates ethanolamine addition to LC3 resulting in 
maturation to LC3-II. LC3-II, in turn, positively regulates autophagy vesicle double 
membrane formation. Once the autophagy vesicles are mature, they are transported to 
lysosomes, where they fuse and the cellular contents are degraded (Mizushima et al., 
2011). 
It is known that NPS4 traffics to multiple intracellular sites and co-localizes with 
autophagy protein, LC3 (Berkova et al., 2006). Recently it has been shown that NSP4 
can initiate autophagy, and that autophagy initiation is required for viral maturation 
(Crawford et al., 2012). Autophagy is initiated after NSP4 forms a viroporin in the ER 
membrane, releasing calcium into the cytoplasm. The increased cytoplasmic calcium 
activates a calcium dependent calmodulin kinase kinase-β (CaMKK-β), which initiates 
autophagy. Interestingly, RV NSP4 prevents the fusion of the autophagosome to 
lysosomes (autophagy maturation), which may play a role in viral maturation. 
This work uses siRNA directed toward the host-cell immunophilins and Cav-1 
proteins to dissect the functional roles of these proteins in the transport of RV NSP4 
from the ER to the PM. We reveal that although NSP4 does associate intracellularly with 
each of the host proteins, they are not responsible for the transport of NSP4 from the ER 
to the PM. Hence, NSP4 is using another means to traffic to the PM, likely a vesicular 
pathway, rather than a soluble one. 
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2. NSP4 INTERACTIONS WITH AND FUNCTIONAL STUDIES OF 
CAVEOLIN-1, CYCLOPHILIN A, CYCLOPHILIN 40, HEAT SHOCK 
PROTEIN 56, AND CHOLESTEROL   
2.1 Introduction 
Rotavirus (RV) infects infants and young children worldwide and is responsible for 
up to 450,000 deaths annually (Tate et al., 2012). The current live vaccines, Rotateq® 
and Rotarix®, are reported to provide significant protection against infant deaths due to 
dehydration and associated symptoms of RV infection, but do not prevent all symptoms 
or spread of the virus. They offer limited protection against emerging RV strains, and 
may be associated with intussusception (Angel et al., 2007). The high mortality rate in 
young, unvaccinated children results from a combination of secretory and malabsorptive 
diarrhea due to the activity of the RV enterotoxin, non-structural protein 4 (NSP4), and 
destruction of absorptive enterocytes, respectively (Ball et al., 2005). 
RV is composed of 3 concentric capsids that enclose 11 double-stranded, RNA 
genome segments that encode 12 proteins, 6 structural and 6 non-structural. Viral 
transcription occurs within the inner capsid of the double-layered particle (DLP). Most 
of the viral proteins travel to a unique structure near the endoplasmic reticulum (ER), the 
viroplasm, where replication and initial assembly occur (Fabbretti et al., 1999). The 
mRNAs that encode NSP4 and VP7 are synthesized by ER-bound ribosomes and co-
translationally are inserted into the ER membrane (Berkova et al., 2007). The short, 
hydrophobic N-terminus of NSP4 initially resides in the ER lumen, followed by a 
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transmembrane domain and a C-terminus that extends into the cytoplasm (Bergmann et 
al., 1989).  
NSP4 is a multifunctional glycoprotein that localizes to several areas in the cell. 
Some of its functions include RV particle maturation, viral transcription, and induction 
of Ca2+-mediated signaling events resulting in Cl- secretion and diarrhea. NSP4 has been 
identified in the cytosol, ER, caveolae (Storey et al., 2007), and LC3 positive 
autophagosomes (Berkova et al., 2006), and directly binds host-cell molecules including 
tubulin (Xu et al., 2000), calnexin (Mirazimi et al., 1998), caveolin-1 (Cav-1) (Parr et al., 
2006), laminin-ß3, fibronectin (Boshuizen et al., 2004), and cholesterol (Schroeder, 
2009). Native NSP4 is sensitive to endoglycosidase H, resistant to brefeldin A, fails to 
co-localize with Golgi proteins (Prudovsky et al., 2008; Zhang et al., 2000), and lacks a 
signal peptide (Mirazimi et al., 1998). Thus, NSP4 traffics to the plasma membrane 
(PM) via an unconventional transport pathway.  
Association of NSP4 and the autophagosomal marker, LC3, depends on the presence 
of a hydrophobic NSP4 membrane-interacting domain (Hyser et al., 2010). Autophagic 
vesicles can fuse with several cellular components of the endocytic pathway, including 
multi-vesicular bodies and lysosome-associated bodies, both of which are associated 
with unconventional transport (Chua et al., 2011; Nickel, 2010). The co-localization of 
NSP4 with autophagosomes and the punctate intracellular staining of NSP4 (Berkova et 
al., 2006) also support an unconventional vesicular pathway. Gibbons, et al. has 
described differential transport kinetics of NSP4 in two cell lines, HT29.f8 and MDCK, 
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and showed NSP4 can use both soluble and vesicular pathways to travel from the ER to 
the PM (Gibbons et al., 2011).  
Cyclophilins are a large family of immunophilins that possess peptidyl prolyl 
isomerase activity and accelerate protein folding by catalyzing the initial folding steps in 
proline-containing proteins (Fischer et al., 1989). Cyclophilin A (CyPA) is the major 
cytosolic cyclophilin while cyclophilin 40 (CyP40) is expressed primarily in the 
mitochondria (Fruman et al., 1994). Both of these cyclophilins bind tightly to 
cyclosporin A (CsA), an immunosuppressant drug (Fischer et al., 2010). The cyclophilin 
family associates with viruses. For example, CyPA assists in viral uncoating in HIV 
infection, regulates replication of VSV and HCV, and interacts with influenza M1 
protein, while cyclophilin B plays a role in oncogenic HPV infection (Fischer et al., 
2010). Heat shock protein 56 (HSP56, also known as FKPB52) is an immunophilin that 
contains rotamase activity and binds ATP and GTP (Ratajczak et al., 2009). CyP40 is 
important for initiation of starvation-induced autophagy as part of the mitochondrial 
permeability transition pore (Carreira et al., 2010). Together, these proteins are active in 
protein folding and protein transport, thus contributing to many cellular processes 
(Walsh et al., 1992). 
The focus of our laboratory has been dissecting the intracellular transport of NSP4 
by examining NSP4-host cell protein interactions. Our previous studies show a direct 
interaction of NSP4 with Cav-1 and cholesterol (Parr et al., 2006; Schroeder, 2009), but 
the function of these interactions was not explored. In this study, we examined the 
interactions of NSP4 with the immunophilins, Cav-1, and cholesterol in both MA104 
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and the cloned human intestinal, HT29.f8 (Mitchell and Ball, 2004), cell lines using a 
variety of imaging and biochemical techniques. To explore the function(s) of the 
interactions, siRNA or small-molecule inhibitors were employed. The affect(s) on both 
NSP4 and the host cell were monitored post silencing. NSP4 transport to the PM was 
altered only by inhibition of HMG-CoA reductase, indicating that cholesterol is a key 
player in NSP4 transport from the ER to the PM. 
2.2 Materials and Methods 
2.2.1 Cells and Viruses 
African green monkey kidney cells MA104 (ATCC, Manassas, VA), a cloned human 
intestinal HT29.f8 cells from parental HT29 cells (Mitchell and Ball, 2004), and Madin-
Darby canine kidney (MDCK) cells (ATCC) were cultured in Dulbecco’s modified 
Eagle’s media (DMEM; CellGro, Manassas, VA) supplemented with 10% fetal bovine 
serum (FBS; Caisson Labs, North Logan, UT), 0.1 mM non-essential amino acids 
(NEAA; Gibco, Grand Island, NY), 1 mM sodium pyruvate (Gibco), and 2 mM L-
glutamine (Lonza, Basel, Switzerland) at 37°C with 5% CO2 in a humidified 
environment. Penicillin-streptomycin was not used in the culture mixture to prevent 
perturbing cell-signaling pathways. RV SA11 clone 4F (SA11.4F; gift from Mary Estes, 
Baylor College of Medicine, Houston, TX) was expanded in MA104 cells (Yakshe, 
2015) and stored at -80°C. 
2.2.2 Infection 
Cells were serum starved by incubation in serum-free DMEM for 14 hours before 
infection, except in the case of siRNA-treated cells. Cells were infected with SA11.4f at 
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a multiplicity of infection (MOI) of 2 for imaging, and a MOI of 5 for surface 
biotinylation studies. In brief, virus was thawed on ice and sonicated using a cuphorn 
attachment with ice for 5 min using a Misonix sonicator 3000 at 45W (Misonix, Inc., 
Farmingdale, NY). Virus then was activated in serum-free DMEM with 1μg/ml trypsin 
(Worthington Biochemical, Lakewood, NJ) at 37°C for 30 min. The activated virus was 
added to cells diluted in serum-free DMEM supplemented with 1μg/ml trypsin at the 
specified MOI and rocked at 37°C with 5% CO2 in a humidified environment for 1 h. 
The viral inoculum was removed, cells were washed with media to remove unbound 
virus, and serum-free DMEM was added for various times of infection as indicated in 
the results section. 
2.2.3 Antibodies 
Primary antibodies to NSP4-specific peptides were generated in mice, rabbits and 
rats as previously described (Storey et al., 2007) and included mouse anti-NSP4150-175, 
rabbit anti-NSP4150-175, rabbit anti-NSP4112-140, and rat anti-NSP4150-175. Purchased 
primary antibodies included rabbit anti-Cav-1 (ab18199, Abcam, Cambridge, MA), 
rabbit anti-CyPA (ab42408, Abcam), mouse anti-CyPA (ZC001, Zymed, Calsbad, CA), 
rabbit anti-CyP40 (ab3562, Abcam), rabbit anti-HSP56 (ab97306, Abcam), mouse anti-
sodium-potassium ATPase (ab96292, Abcam), rabbit anti-giantin (Covance, Emeryville, 
CA), mouse anti-protein disulfide isomerase (PDI; Stressgen, Ann Arbor, MI), mouse 
anti-glyceraldehyde-3-phosphate dehydrogenase (1A10A10, BioChain Institute, 
Newark, CA), and rabbit anti-lamin A (Poly6135, BioLegend, San Diego, CA). 
Purchased secondary antibodies included F(ab’)2 fragments of goat anti-rabbit IgG 
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(H+L) conjugated to indocarbocyanine (Cy3) (Jackson Immunoresearch, West Grove, 
PA), F(ab’)2 fragments of goat anti-rabbit IgG (H+L) conjugated to cyanine (Cy2) 
(Jackson Immunoresearch), F(ab’)2 fragments of goat anti-mouse IgG (H+L) conjugated 
to indodicarbocyanine (Cy5) (Jackson Immunoresearch), and goat anti-rabbit IgG-
Pacific Blue™ (Invitrogen) for imaging; and goat anti-mouse IgG (H+L) conjugated to 
horse radish peroxidase (HRP) (Zymed) and goat anti-rabbit IgG (H+L)-HRP (Thermo 
Fisher) for Western blot. 
2.2.4 Generation and Labeling of Anti-NSP4150-175 F(ab)2 Fragments  
NSP4-specific peptide antibodies were affinity purified against the immunizing 
peptide before use in confocal microscopy, and F(ab)2 fragments were generated for 
fluorescent resonance energy transfer (FRET) analyses to reduce the distances of the 
fluorophores from the target proteins. Rabbit anti-NSP4150-175 was affinity purified on an 
NSP4150-175 peptide column prepared with pre-activated cyanogen bromide Sepharose 4B 
beads by following the instructions of the manufacturer (Pharmacia Biotech, Piscataway, 
NJ) (Axen et al., 1967). The bound peptide-IgG was eluted by altering the elution buffer 
pH to 4 and then 2 while reading absorbance on a UV detector.  
The ImmunoPure F(ab)2 preparation kit (Pierce, Rockford, IL) was utilized, and the 
recommended protocol was followed to produce peptide-specific F(ab)2 fragments 
(Wines and Easterbrook-Smith, 1991). Briefly, the peptide-specific IgG was added to the 
immobilized pepsin tube provided with the kit. The resin separator was placed inside the 
tube above the mixture and the tube was incubated with shaking at 37°C for 4 h. The 
resin was separated from the digested mixture by pressing the resin separator to the 
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bottom of the tube. The digested mixture was run on an immobilized Protein A column 
to remove Fc fragments and the F(ab)2-containing mixture was collected for dialysis. 
The F(ab)2 fragments were dialyzed against 3 changes of 50 mM ammonium bicarbonate 
(2 L) in a 50,000 MW cutoff dialysis bag (Spectrum Laboratories, Rancho Dominguez, 
CA). The dialyzed F(ab)2 was shell frozen in 1:1 ethanol:dry ice and lyophilized until 
dry. A small sample of the F(ab)2 fragments was separated on an SDS-PAGE gel and 
stained with GelCode Blue (Thermo Fisher) to verify successful generation and 
purification of the fragments. 
Cy3 or Cy5 monofunctional reactive dye was conjugated to the affinity-purified 
NSP4150-175 F(ab)2 to produce aliquots of Cy3 and Cy5 NSP4150-175  F(ab)2 for FRET 
exactly as described by the manufacturer (Amersham Bioscience, Piscataway, NJ). 
Briefly, 1.0 mg Cy3 or Cy5 dye was reconstituted in 500 µL of 0.2 M sodium 
bicarbonate. The lyophilized F(ab)2 fragments were reconstituted by diluting 0.65 mg of 
F(ab)2 in 350 µl of 1X PBS. An equal volume (350 µl) of reconstituted dye was added to 
the reconstituted F(ab)2 fragments and incubated at room temperature for 20 min. The 
dye-conjugated F(ab)2 fragments were dialyzed in an iCON™ concentrator with a 20 kD 
cutoff (Fisher Scientific) two times with 1X PBS. After concentration, the final volume 
(750 µl) was adjusted to 900 µl by adding 150 µl of 2 mg/ml BSA and incubating at 
room temperature for 20 min. The conjugated antibody was aliquoted and stored at -
20°C.  
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2.2.5 Laser Scanning Confocal Fluorescent Microscopy (LSCM) 
Cells were plated on #2 German borosilicate Labtek well coverslips (Nalge Nunc 
International, Naperville, IL). At various time points, the medium was removed, cells 
were washed with ice-cold PBS and fixed and permeabilized with ice-cold 
methanol:acetone (1:1, vol/vol) for 20 min at -20°C. The fixed and permeabilized cells 
were prepared for immunofluorescence using a modification of a previously described 
method (Storey et al., 2007). Briefly, fixed cells were blocked with 3% non-fat dry milk 
(NFDM; Carnation, Wilkes-Barre, PA) in PBS and incubated with primary antibodies 
(Table 2.1) diluted in 0.5% NFDM in PBS for 3 h at 27°C. After the cells were washed 
three times with PBS the secondary antibodies (Table 2.2) were diluted in 0.5% NFDM, 
and incubated for 1 h at room temperature in the dark. Primary and secondary antibody 
controls were included to exclude non-specific reactivity of the antibodies. Cells were 
washed as above in the dark and the fluorescent images were captured with a MRC- 
124MP BioRad LSCM system (BioRad) using a Zeiss inverted Axiovert microscope 
(Carl Zeiss, Inc., Thornwood, NY), a 63X Zeiss oil apochromat objective, and the 488-, 
568- or 647-nm excitation lines of an argon/krypton ion laser source or the 405 nm line 
of a Ti:Sapphire diode laser. Fluorescence emission from the labeled cells cultured on 
coverslips was detected using 405-nm excitation with a bandpass emission filter for the 
Pacific Blue™ fluorophore (ex=410 nm, em=455 nm) (blue channel), 488 nm excitation 
with a HQ530/40 band-pass emission filter for Cy2 fluorophore (ex =492 nm, em=510 
nm) (green channel) and 568 nm excitation with a HQ598/40 band-pass emission filter 
for Cy5 fluorophore (ex=650nm, em=670) (red channel). LaserSharp 3.0 (BioRad) and 
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Image J (public domain Java image-processing program inspired by NIH Image) were 
used to capture the pixilated photomultiplier tube (PMT) data, convert the image data to 
.tiff format, and adjust for contrast curves to construct the final images. 
 
Table 2.1. Primary Antibodies Used in LSCM 
Primary Antibody Target Host 
Animal 
Antibody 
Dilution 
Comments 
Caveolin-1 Rabbit 1:100 caveolae structural protein  
Cyclophilin A Rabbit 1:50 chaperone; cytoplasm localized peptidyl-
prolyl isomerase 
Cyclophilin 40 Rabbit 1:200 chaperone; mitochondrial localized peptidyl-
prolyl isomerase 
Heat Shock Protein 56 Rabbit 1:75 chaperone; heat shock protein 
Golgin-97 Mouse 1:50 Trans-Golgi complex marker 
Lamin A Rabbit 1:100 Nuclear lamina protein; positive control 
Protein Disulfide 
Isomerase 
Mouse 1:50 Endoplasmic Reticulum marker 
Sodium-Potassium ATPase Mouse 1:50 Exofacial plasma membrane marker 
Rotavirus NSP4 Rabbit 1:100 Peptide fragment; residues 112-140 
Rotavirus NSP4 Rabbit 1:100 Peptide fragment; residues 150-175 
 
 
 
Table 2.2 Secondary Antibodies Used in LSCM 
Secondary Antibody 
Target 
Host  
Animal 
Antibody  
Dilution 
Comments 
Mouse IgG (H+L) Goat 1:100 Cy5 conjugated  
Rabbit IgG (H+L) Goat 1:100 Cy5 conjugated 
Rabbit IgG (H+L) Goat 1:100 Cy3 conjugated 
Rabbit IgG (H+L) Goat 1:100 Cy2 conjugated 
Rabbit IgG (H+L) Goat 1:100 Pacific Blue™ conjugated 
 
 
 
2.2.6 Co-localization 
Cells were infected and treated as above, incubated with antibodies targeting the 
immunophilins and a secondary antibody labeled with Pacific Blue™ with Cy-5 labeled 
rabbit anti-NSP4150-175 together. Images were collected on a Zeiss LSM 780 NLO 
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multiphoton confocal microscope. The extent of co-localization of the pixels in the 
confocal images were calculated with the Image J Coloc 2 plugin using the overlap 
coefficient (MOC) according to Manders (Manders, 1993), 
 
where Ri and Gi represent the intensity values of the red and green channels, 
respectively, in a given pixel, i  (Manders et al., 1992). 
2.2.7 Co-immunoprecipitation 
Aliquots of soluble protein fractions derived from RV infected cells were subjected 
to co- immunoprecipitation reactions with antibodies to select immunophilins. The 
soluble protein fractions were incubated with either rabbit anti-CyPA or rabbit anti-
CyP40 for 1 h at room temperature with rotation. The mixtures containing anti-CyPA or 
anti-CyP40 were incubated with protein A sepharose (Pierce, Rockford, IL.) for 2 h at 
room temperature and pelleted at 2,500 x g for 5 min. The bound protein A beads were 
washed with RIPA buffer 3 times and boiled with SDS-loading buffer, and the released 
proteins were separated by SDS-PAGE and detected by Western blot. Controls were 
treated the same way using normal rabbit serum instead of epitope-specific antibodies. 
The primary antibodies used in Western blot analyses were generated in mice so that 
non-specific signals created by the secondary antibodies were avoided.  
2.2.8 FRET by Acceptor Photobleaching 
FRET by acceptor photobleaching was selected because of the ease of analysis. 
FRET is non-radiative energy transfer from a donor fluorophore to an acceptor 
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fluorophore when they are in close proximity (1-100 nm) to each other. In FRET by 
acceptor photobleaching, the acceptor fluorophore (Cy5) is bleached and the subsequent 
increase in the intensity of the donor fluorophore (Cy3) is measured (Karpova et al., 
2003).  The Cy3 and Cy5 fluorophores have overlapping emission and excitation 
wavelengths, respectively, and the photon released upon the emission of Cy3 will excite 
Cy5, as long as the fluorophores are within 10 nm of each other. Infected cells were 
fixed, permeabilized, and reacted with epitope-specific antibodies directed against the 
immunophilins followed by the addition of secondary antibodies, Cy3-conjugated F(ab)2 
fragments against IgG. NSP4 was directly labeled with Cy5-conjugated F(ab)2 fragments 
against NSP4150-175. Images were collected by exciting the fluorophores at 568 nm and 
647 nm prior to photobleaching of the Cy5 fluorophore. The 647 nm line was set to 
100% power for 3 min for photobleaching. An increase in the 568 nm signal was 
measured following photobleaching to determine if there was a positive FRET reaction. 
For each protein, a minimum of 3 fields was analyzed. Two areas outside of the 
photobleached area served as an internal control, while 2 areas inside the photobleached 
area served as the sample measurement. Percent FRET was calculated by subtracting the 
Cy3 signal post-photobleaching from the Cy3 signal pre-photobleaching and dividing it 
by the Cy3 signal post-photobleaching: ((Cy3pre – Cy3post)/Cy3pre). Image analyses were 
performed using Image J software by NIH Image.  
2.2.9 Silencing 
Silencing RNAs (siRNAs) directed against Cav-1, CyPA, CyP40, and HSP56 were 
purchased from Dharmacon (Thermo-Fisher, Pittsburgh, PA). SMARTpool siRNA was 
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used from the siGENOME collection. For each protein, the pooled siRNA mixture 
consisted of four individual siRNAs of 19 base pairs each (Table 2.3). The siRNA was 
diluted to 5nmol in 200μL of sterile ultrapure dH2O for a working stock of 20μM 
siRNA. 
 
Table 2.3. siRNA Sequences in SMARTpool siGENOME Silencing Mixtures 
Silenced Protein                     siRNA Sequences 
Caveolin-1 • CUAAACACCUCAACGAUGA 
• GCAGUUGUACCAUGCAUUA 
• AUUAAGAGCUUCCUGAUUG 
• GCAAAUACGUAGACUCGGA 
Cyclophilin A • UCCUAGAGGUGGCGGAUUU 
• AGAAUUAUUCCAGGGUUUA 
• GGAAUGGCAAGACCAGCAA 
• AGACAAGGUCCCAAAGACA 
Cyclophilin 40 • UAAGAUACGUGGACAGUUC 
• GGAUGCGGAUAUAGAUUUA 
• GAAUAUUGGUGCUUGUAAA 
• GAGCCAAGCUGCAACCUAU 
Heat Shock Protein 56 • GCGGUGAAGGCUAUGCUAA 
• GCUCUAUGCCAAUAUGUUU 
• GAGAACAUUCCAUCGUGUA 
• AGGGAGAAGAUCUGACGGA 
 
 
 
Cells were transfected using a reverse transfection method adapted from the method 
provided by Dharmacon (Gutierrez et al., 2010) and Life Technologies (Protocol # 
MAN0007825 Rev.1.0). Briefly, for MA104 cells, Lipofectamine RNAiMax (Life 
Technologies, Grand Island, NY) was added to serum free DMEM at a concentration of 
60 μl/ml and incubated for 10 min at room temperature to allow for equilibration. The 
mixture was added to a 24-well tissue culture plate containing the siRNA diluted to 2.0 
μM in serum free DMEM to allow for incorporation of siRNA into the Lipofectamine 
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liposomes. After incubation for 5 min at room temperature, 2.0 × 105 MA104 cells or 5.0 
x 105 HT29.f8 cells were added to the 24-well tissue culture plate containing the 
transfection mixture, and the cells were incubated at 37°C with 5% CO2 in a humid 
environment. Serum was added to the cells to a final concentration of 10% FBS at 4 h 
post transfection and cells were incubated for a total of sixty h post transfection to allow 
for silencing. To infect, the transfection mixture was removed and the cells were washed 
twice with serum-free DMEM and infected with rotavirus as described above. 
2.2.10 Surface Biotinylation and Recovery of Exofacial Plasma Membrane Proteins 
Silenced, infected cells plated in 24-well tissue culture plates were surface 
biotinylated as described previously (Gibbons et al., 2011). Briefly, at 6 hpi, cells were 
washed with ice-cold PBS-CM (1X PBS supplemented with 0.1 mM CaCl2 and 1 mM 
MgCl2) three times to remove unbound extracellular material. A solution of 6 mg/ml 
membrane-impermeable EZ Link® Sulfo-NHS-SS-Biotin (Pierce-Thermo) in ice-cold 
PBS-CM was added to the cells at a 10 mM concentration, and was incubated with 
rocking for 30 min at 4°C. Excess biotin was quenched by adding cold DMEM 
supplemented with 10% FBS for 10 min at 4°C. Protease inhibitor cocktail (1.2mM 
AEBSF, 0.46μM Aprotinin, 12.3μM E-64, 14μM Bestatin, 112μM Leupeptin and 
1.16μM Pepstatin; Amresco, Solon, OH) and 0.2 mM phenylmethylsulfonyl fluoride 
(PMSF; Sigma, St. Louis, MO) were added to SDS-free RIPA lysis buffer (150 mM 
NaCl, 50 mM Tris-base, 10% NP-40, 0.5% DOC, pH=8.0) and immediately added to the 
cells for 20 min at 4°C. The cell lysates were transferred to sterile microcentrifuge tubes, 
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to which 30 μL of streptavidin-agarose slurry (Pierce-Thermo, Rockford, IL) was added 
per 1 ml of lysate. The mixture was incubated with rotation at 4°C for 16 h. 
     The biotinylated proteins were collected by pelleting the bound streptavidin-agarose 
at 2500 x g for 5 min to pellet the streptavidin-agarose. The supernatant was collected 
and saved for analysis of the protein silencing experiments, and the pellet was washed 
three times in ice-cold SDS-free RIPA lysis buffer with protease inhibitors. The 
biotinylated proteins were removed from the streptavidin-agarose beads by suspending 
them in sample reducing buffer (Laemmli, 1970) (62.5 mM Tris pH=6.8, 10% glycerol, 
2% SDS, 5% 2-mercaptoethanol, and 0.001% bromophenol blue) and boiling for 10 min. 
The beads were centrifuged for 5 min at 2500 x g, and the sample reducing buffer 
supernatant containing biotinylated exofacial plasma membrane proteins was collected 
for electrophoretic analysis. To ensure that there was a lack of non-specific binding to 
the streptavidin-agarose beads, mock-biotinylated samples were analyzed as controls. 
2.2.11 Cyclosporin A Treatment 
MA104 and HT29.f8 cells were plated in 12-well tissue culture plates and grown 
until ~80% confluent. Cells were treated with 120 μg/ml cyclosporine A (CsA) in 
methanol (MeOH) for 24 h. Control cells were treated with the same volume of MeOH 
only. After 24 h of treatment, cells were infected with SA11.4f at a MOI of 2.0. Cells 
were then surface biotinylated for analysis of NSP4 transport to the exofacial PM. 
2.2.12 SDS-PAGE and Western Blotting 
Western blotting was used to confirm the extent of silencing of each of the silenced 
proteins and to determine the presence of NSP4 at the plasma membrane. Briefly, equal 
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amounts of samples were dissolved and dissociated in sample reducing buffer, loaded 
and resolved on a 12% or 15% SDS-polyacrylamide gel (NEXT GEL; Amresco). The 
proteins were electroblotted to a 0.45 μM-pore size nitrocellulose membranes (Bio-Rad, 
Hercules, CA) as per the manufacturer’s instructions (Mini-Protean II and Trans-Blot, 
Bio-rad). The nitrocellulose membranes were blocked in 10% (wt/vol) NFDM in PBS 
for 1 h at room temperature. The membranes then were incubated with primary 
antibodies diluted in 2.5% NFDM in PBS for 3 h at 27°C with rocking. The membranes 
were washed once with PBS, twice with PBS-Tween-20 (0.5%), and again with PBS. 
Secondary antibodies were diluted in 2.5% NFDM in PBS, added to the membranes, and 
incubated with rocking for 1 h at 27°C. The membranes were washed as above and 
reacted with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, 
MA) per the manufacturer’s instructions. The protein-specific bands were visualized 
using the ImageQuant LAS 4000 gel imager (GE Healthcare Life Sciences, Pittsburgh, 
PA), and densitometric analyses were performed using ImageJ. 
2.2.13 Densitometry 
Gel images were analyzed via ImageJ using the gel analysis function. Briefly, the 
intensity of each protein band was given a value for the silenced protein and for the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control in the same lane. Each 
band was background subtracted and measured within the linear range. The intensity 
value of the protein band was divided by the intensity value of the GAPDH control band 
to obtain a ratio of the protein amount to protein loading control (GAPDH band 
intensity). The non-targeting siRNA (siNT) control ratio was set to 0% silencing. The 
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ratio in silenced cells was divided by the ratio in siNT cells, subtracted from 1, and 
multiplied by 100 to obtain the percentage of silencing: 
% 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 =  1 − � 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠𝑠𝑠𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠 𝑁𝑁𝑁𝑁 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺
�  𝑥𝑥 100 
 The experiments were performed in triplicate and the standard error was calculated 
using: 
𝑆𝑆𝑆𝑆 =  √∑(𝑋𝑋 −𝑀𝑀)2
𝑠𝑠 − 1  
where X is the sample value, M is the mean, and n is the number of experimental 
replicates.  
2.2.14 Lovastatin Treatment 
MA104 and HT29.f8 cells were plated in 25-cm2 tissue culture flasks at a density of 
2.8 x 106 and 5 x 106, respectively. The cells were grown until ~80% confluent and 
treated with 5 μg/ml lovastatin (from a 5 mg/ml lovastatin in ethanol stock) for 24 h at 
37°C. ‘Untreated’ control cells were treated with the same amount of pure ethanol for 24 
h at 37°C. Cells were infected as described above but incubated with serum-free DMEM 
containing no lovastatin during the adsorption period. After adsorption, cells were 
washed to remove unbound virus and replaced with serum-free DMEM containing 5 
μg/ml lovastatin. Cells were incubated for 6 h and surface biotinylated as described 
above. To avoid interaction of the lysis buffer components with the subsequent 
cholesterol assay, cells were lysed mechanically by scraping in PBS with protease 
inhibitors (Roche) and PMSF, homogenized with a microcentrifuge tube pestle, passed 
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through a 22 g needle 10 times, and sonicated at 45 W for 10 min on ice. Biotinylated 
proteins were pulled down with streptavidin agarose as described above and supernatants 
were saved for cholesterol analysis. 
2.2.15 Cholesterol Quantification 
Cholesterol was quantitated with the Wako Cholesterol E kit (Wako Diagnostics, 
Richmond, VA), which measures total cholesterol, using a modified protocol (Martin et 
al., 2015). Briefly, cells were lysed via mechanical lysis as described above in PBS. 
Standards were prepared to measure the cholesterol concentration from 0-4 mg/ml. Each 
standard (20 µl) was placed in a borosilicate glass test tube and 20 µl of each sample was 
placed in a separate borosilicate glass test tube. The Color Reagent was mixed with the 
Buffer Solution, both provided in the kit, and 2 ml of the mixture was added to each test 
tube. The color was allowed to develop for 5 min at room temperature. Two-hundred µl 
of the developed solution was added to a 96-well microplate and the absorbance was 
read using an BMG Labtech FLUOstar Omega microplate reader at 600 and 700 nm. 
The cholesterol concentrations of the samples were determined from the standard curve. 
2.3 Results 
2.3.1 NSP4 Co-localized with CyPA, CyP40, and HSP56 
It is known that NSP4 directly binds Cav-1 and cholesterol (Parr et al., 2006; 
Schroeder, 2009). Our goal was to determine the extent of co-localization of NSP4 and 
the immunophilins. MA104 cells were infected with RV SA11.4f (MOI=2) for 6 hours, 
fixed, permeabilized and labeled with antibodies against caveolin-1 or the 
immunophilins followed by Pacific Blue™-conjugated secondary antibodies. NSP4 was 
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labeled with a peptide specific Cy5-conjugated anti-NSP4150-175. Uninfected controls 
were labeled with either primary or secondary antibodies only. Images were collected 
and analyzed via the Coloc2 plugin from Image J. We calculated the Mander’s Overlap 
Coefficients (MOCs) for the two proteins, which indicates co-occurrence of two signals 
in one pixel. The MOC in an image with two signals shows high overlap between the 
signals when it approaches 1 and little overlap between the signals as it approaches 0 
(Dunn et al., 2011). The MOCs are displayed in Figure 2.1. CyPA, CyP40 and HSP56 
all show substantial co-localization with NSP4 in all images. NSP4 and CyPA display 
MOCs of 0.878 ± 0.02 and 0.841 ± 0.03, NSP4 and CyP40 display MOCs of 0.830 ± 
0.04 and 0.780 ± 0.05, and NSP4 and HSP56 display MOCs of 0.971 ± 0.01  and 0.903 
± 0.02  (n=10). A graphical representation of the MOCs are shown in intensity 
histograms with the NSP4 signal plotted on the y-axis and the immunophilin signal 
plotted on the x-axis. The high Mander’s coefficients suggest that NSP4 resides within 
close proximity of the immunophilins intracellularly. 
2.3.2 NSP4 Co-immunoprecipitated with Chaperone Proteins  
Since NSP4 co-localized intracellularly with CyPA, CyP40, and HSP56, we wanted 
to further demonstrate an association of NSP4 with immunophilin proteins CyPA and 
CyP40 using a biochemical assay. We were unable to find a precipitating antibody that 
recognized HSP56. Co-immunoprecipitations of the cyclophilins were performed on the 
soluble fraction of SA11.4f RV-infected HT29.f8 cells (MOI=2). Infected cells were 
lysed with RIPA buffer, and the soluble fraction collected via high-speed centrifugation. 
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Figure 2.1 Co-localization analyses of CyPA, CyP40, and HSP56 with RV NSP4 in MA104 cells. MA104 cells were infected with RV 
SA11.4f for 6 h. Cells were fixed and permeabilized, and labeled with antibodies directed against the immunophilins (green) or NSP4 
(red). Primary and secondary antibody controls are shown in the bottom right panel. Intensity histograms are shown in the fourth column. 
The Mander’s Overlap Coefficients (MOC’s) were calculated for each signal and are depicted in the last column.
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Proteins were immunoprecipitated with Protein A-conjugated rabbit anti-CyPA or 
rabbit anti- CyP40. A control was immunoprecipitated with normal rabbit antisera. The  
immunoprecipitated proteins were released from the bound antibodies by boiling in SDS 
sample loading buffer and subjected to SDS-PAGE, transferred to a nitrocellulose 
membrane, followed by Western blot with anti-NSP4150-175 antibody. Both anti-CyPA 
and anti-CyP40 bound NSP4 upon precipitation of the protein A beads, indicating a 
direct or indirect interaction between NSP4 the cyclophilin proteins (Figure 2.2). The 
blots were also probed with anti-CyPA and anti-CyP40 to ensure the immunophilins  
were reactive with their respective antibodies. Controls displayed no co-
immunoprecipitation with the cyclophilins or with NSP4 (Figure 2.2, lanes 2). Co-
immunoprecipitation with rabbit anti-HSP56 was performed, but neither NSP4 nor 
HSP56 were detected in the western blot (data not shown), indicating a lack of reactivity 
with the antibody.  
2.3.3 NSP4 Was Resolved to Within 10 nm Intracellularly Using FRET 
To verify that NSP4 directly interacts with the chaperone proteins intracellularly, 
FRET by acceptor photobleaching experiments were performed using F(ab)2 fragments 
directed against peptide NSP4150-175 and antibodies directed against one of three 
immunophilin proteins, CyPA, CyP40, or HSP56. FRET by acceptor photobleaching 
allows for measurement of protein proximity, by bleaching the donor fluorophore and 
measuring the recovery of the acceptor fluorophore if the proteins are within 10 nm of 
each other when using Cy3 and Cy5. MDCK cells were infected with RV SA11.4f at an 
MOI of 2 for 7 h. Cells were fixed, permeabilized, and stained with antibodies or F(ab)2 
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fragments conjugated to either Cy3 or Cy5. Cy5 was photobleached and recovery of the 
Cy3 signal was assessed as a percentage of initial fluorescence intensity (%FRET = 
(Cy3post-Cy3pre)/Cy3post). All three immunophilins displayed a positive FRET, indicating 
that NSP4 associates with these three proteins intracellularly within a distance of 10 nm 
(Figure 2.3). In each panel, 4 areas are depicted post-photobleaching (A-D): Two areas 
in which Cy5 was not photobleached, and where NSP4 is densely or sparsely stained (A 
and B), and 2 areas in which Cy5 was photobleached, and where NSP4 is densely or 
sparsely stained (C and D). 
 
 
 
 
Figure 2.2 Co-immunoprecipitation of NSP4 and cyclophilin A and NSP4 and 
cyclophilin 40. Cyclophilin A (A) and Cyclophilin 40 (B) were precipitated from 
aliquots of soluble post-nuclear supernatants (PNS) of RV infected HT29.f8 cell lysates. 
The precipitated samples (lanes 1) and the controls precipitated with normal rabbit sera 
(lanes 2) were subjected to SDS PAGE and transferred to nitrocellulose. Molecular 
weight markers are indicated to the right of the blots. Both samples were blotted with 
mouse anti-NSP4 and either CyPA or CyP40. Reprinted with permission (Gibbons, 
2007). 
 
 
The percent FRET varied from 37.2% with HSP56 to 73% with CyPA and is 
indicated to the right of each row (Figure 2.3). Use of the donor and acceptor pair, Cy3 
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and Cy5 with F(ab)2 fragments places the interacting proximity of these immunophilins 
with NSP4 within 10 nm in distance. Proteins located this closely to each other generally  
 
 
 
Figure 2.3. FRET analysis of NSP4 and immunophilins by acceptor photobleaching. 
Each row depicts pre- and post-bleaching of Cy5-NSP4 (left and center panel 
respectively), while the right panel shows the respective Cy3-immunophilin signal post 
bleaching of NSP4. The PM was biotinylated and labeled with Cy2-streptavidin. A 
shows the NSP4/CyP40 FRET, B shows the NSP4/CyPA, and C shows the NSP4/HSP 
56 FRET. In the last column, A-D are indicated and were used to determine % FRET. A: 
Areas with intense staining but little FRET; B: Areas with minimal staining and little 
FRET; C: Areas with intense staining and positive FRET; and D: Areas with minimal 
staining and positive FRET. Areas (B) and (D) serve as the internal controls. 
Biotinylated PM proteins are depicted in red. Reprinted with permission (Gibbons, 
2007). 
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are considered to be directly interacting or interacting within a multi-subunit protein 
complex. Akin to the co-localization data, all 3 immunophilins tested showed an 
intracellular interaction with NSP4 via FRET.  
2.3.4 NSP4 Expression Increased Expression of CyPA, CyP40, and HSP56 
Co-localization studies revealed that there is a different expression pattern of the 
immunophilins in RV-infected and uninfected cells. To determine if this expression 
pattern was altered in the presence of NSP4 only, MA104 cells were transiently 
transfected with a plasmid expressing full length NSP4. In transfected MA104 cells 
NSP4 expression increases expression of the immunophilins (Figure 2.4A). MA104 
cells transfected with a V5-chloarmphenicol acetyltransferase fusion protein as a control, 
which exhibited no increase in expression heat shock protein 56 (Figure 2.4B). 
Therefore, NSP4 expressed in the absence of RV is able to increase expression of the 
immunophilins, which intracellularly distribute in a pattern similar to that of NSP4. 
2.3.5 Silencing Cav-1, CyPA, and CyP40 Altered Intracellular Distribution of NSP4 
To begin to examine the functional link between NSP4 and the immunophilins or 
Cav-1, siRNA was transfected into MA104 cells or HT29.f8 cells using Lipofectamine 
RNAiMax (Invitrogen), and reduction of expression was verified by Western blot using 
GAPDH as a loading control (Figure 2.5). Protein expression of all silenced proteins 
was decreased by at least 57%. HSP56 was not detected in cell lysates and could not be 
measured by Western blot because of limited antibody reactivity by Western blot. As 
shown in Figure 2.6, silenced cells infected with RV SA11.4f at an MOI of 2 were fixed 
and permeabilized at 8 hours post infection (hpi) for confocal microscopy. The fixed 
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cells were labeled with antibodies directed against one of the immunophilins or Cav-1 
and NSP4 followed by imaging via LSCM. NSP4 has been localized to the ER (Berkova 
et al., 2006) , in distinct cytosolic pools (Berkova et al., 2007), in caveolae on the PM 
 
 
 
Figure 2.4 Expression of immunophilins was up-regulated in MA104 cells transfected 
with NSP4. CyPA, CyP40, and HSP56 expression is increased in cells transfected with 
NSP4 in the absence of virus. Transfected NSP4 is labeled with anti-NSP4150-175 
followed by a Cy2-F(ab)2 fragment (A; red), and the immunophilins are labeled with 
their respective antibodies followed by a Cy3-F(ab)2 fragment (A; green). A 
chloramphenicol acetyltransferase-V5 control does not increase expression of HSP56 
(B). Reprinted with permission (Gibbons, 2007). 
 
 
 
 40 
 
Fig. 2.5. Silencing in MA104 and HT29.f8 cells. Silencing RNA that targets Cav-1, 
CyPA, or CyP40 transfected into MA104 and HT29.f8 cells were effective at knocking 
down the proteins to near 60% of the original levels at 60 h post transfection. Samples 
were analyzed via Western blot with GAPDH serving as the internal control. A and B 
depict the reduction in protein expression upon silencing, which is graphed in C and D, 
respectively, with standard error indicated by bars (n=3). All densitometry was 
normalized to the non-targeting (NT) siRNA control. 
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Fig. 2.6 Silencing of Cav-1, CyPA, and CyP40 caused intracellular redistribution of 
NSP4. Cells were treated with one of four silencing RNA mixtures targeting Cav-1, 
CyPA, CyP40, or HSP56 for 60 h, infected with RV SA11.4f for 6 h and fixed and 
permeabilized. Cells were stained with one of the four proteins in the left panels (green) 
and NSP4 in the right panels (red). Columns 1 and 3 depict cells that were not treated 
with siRNA, whereas columns 2 and 4 depict cells that were treated with siRNA. In 
column 4, the abnormal distribution of NSP4 can be seen. NSP4 moves out of its 
normal, punctate cellular structures (denoted with long arrows) and into a different 
distribution (denoted by arrowheads), depending on the protein silenced, except in the 
case of HSP56, which had no effect.
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Fig. 2.7 Redistribution of NSP4 and organelle markers in silenced MDCK cells. MDCK cells were silenced for Cav-1 and the 
immunophilins and infected for 6 h. Cells were fixed and permeabilized at 6 hpi and labeled for Cav-1, CyPA, CyP40, or HSP56 and an 
organelle marker (PDI for the ER, golgin-97 for the Golgi, and Na+/K+-ATPase for the PM). Untransfected, infected (UT I) cells serve as a 
control. NSP4 was pseudocolored red and the organelles and PM were pseudocolored green. Overlap of the signals from NSP4 and the 
protein markers can be seen in yellow.
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(Storey et al., 2007), and is secreted from infected cells (Bugarcic and Taylor, 2006; 
Didsbury et al., 2011). NSP4 also is seen in punctate structures similar to that seen in our 
confocal analysis (Figure 2.6, arrows).  
When select intracellular components were silenced, NSP4 was distributed in 
patterns different from those of non-silenced, infected cells (Figure 2.6). When Cav-1  
was silenced, NSP4 was redistributed from punctate structures (arrows) to a more diffuse 
cytoplasmic pattern with less intense staining (Figure 2.6A). When CyPA was silenced, 
NSP4 was not distributed as widely throughout the cytoplasm but was localized to 
distinct, unidentified areas that were less brightly stained (Figure 2.6B, arrowheads). 
When CyP40 was silenced, NSP4 was not distributed as widely throughout the 
cytoplasm and punctate structures, although present, were not as pronounced as in the 
non-silenced cells (Figure 2.6C, arrowheads). However, when HSP56 was silenced, 
there was little change in the intracellular distribution of NSP4 (Figure 2.6D, arrows). 
Therefore, silencing of Cav-1, CyPA, and CyP40 altered the intracellular distribution of 
NSP4, but HSP56 has little effect. In general, silencing of the immunophilins caused a 
dramatic decrease in fluorescent signal (Figure 2.6, columns 1 and 2), agreeing with the 
Western blot silencing data (Figure 2.5).  
When NSP4 and organelle markers were compared in silenced cells, the abnormal 
distribution of NSP4 was more evident (Figure 2.7). In cells silenced for Cav-1 and 
CyPA, there was a limited amount of co-localization of NSP4 with the Golgi marker 
golgin-97 (Figure 2.7-A1 and -B1) as opposed to untreated, infected cells (UT I), where 
NSP4 and golgin-97 did not co-localize (Figure 2.7-E1). To determine whether this co- 
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localization was due to redistribution of golgin-97 or to altered NSP4 transport, the 
infected cell lysates were treated with Endoglycosidase H and subjected to SDS-PAGE. 
Upon silencing of CyPA, NSP4 was still sensitive to Endo H (Figure 2.8), suggesting 
that silencing of CyPA caused abnormal distribution of the Golgi protein golgin-97 and 
not transport of NSP4 to the Golgi. Notably, when Cav-1 or CyPA were silenced, there 
was little co-localization of NSP4 with the ER marker, PDI (Figure 2.7-A2 and -B2), as 
opposed to untreated cells (Figure 2.7-E2), where co-localization of NSP4 and PDI was 
marked. When CyPA was silenced there was significant co-localization of NSP4 with 
the PM marker, Na+/K+-ATPase, although the co-localization appeared in the cytosol of 
the cells rather than on the exofacial PM (Figure 2.7-B3). It is unclear what is 
responsible for the redistribution of Na+/K+-ATPase. 
2.3.6 Silencing Cav-1, CyPA, and CyP40 Failed to Alter Transport of NSP4 to the 
PM 
Since NSP4 is known to traffic to PM caveolae (Storey et al., 2007), we wanted to 
determine if the interaction of NSP4 with Cav-1, CyPA, and CyP40 contributes to the 
mechanism utilized by NSP4 to reach the cell surface. Cells were surface biotinylated to 
detect NSP4 at the PM of silenced and infected cells. Cells were treated with siRNA for 
60 h prior to infection with RV SA11.4f at a MOI of 5. At 6 hpi, cells were washed and 
incubated with a 10 mM solution of a cell-impermeable biotin at 4°C for 30 min for 
biotinylation of surface proteins. Cells were lysed with RIPA buffer and biotinylated 
proteins were precipitated with streptavidin agarose at 4°C overnight. Proteins were 
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dissociated from the streptavidin beads, separated via SDS-PAGE, transferred to 
nitrocellulose, and blotted with rabbit anti-NSP4112-140. Silencing of Cav-1, CyPA, and  
CyP40 failed to alter the transport of NSP4 to the surface of the cell in both MA104 
and HT29.f8 cells (Figure 2.9A). A non-targeting siRNA (siNT) was used as a control 
to confirm that the silencing procedure does not interfere with NSP4 transport. The 
untreated and uninfected cells (UT UI) were evaluated as negative controls and 
confirmed there was an absence of nonspecific interactions of the antibodies with the 
surface biotinylation components. 
 
 
Fig. 2.8 NSP4 was endoglycosidase H sensitive in CyPA silenced cells. Cells were 
silenced for CyPA, infected with RV SA11.4f and treated with Endoglycosidase H. 
NSP4 remained sensitive to Endo H digestion when CyPA was silenced. 
 
 
 
To further verify that the cyclophilins were not involved in NSP4 transport, cells 
were treated with cyclosporin A (120 μg/mL; CsA) for 24 h prior to infection with RV. 
CsA is a small molecule inhibitor of the peptidyl-prolyl isomerase (PPIase) domain of 
cyclophilin proteins. In the presence of CsA or MeOH only, NSP4 continued to traffic to 
the exofacial PM, similar to the results seen upon siRNA treatment (Figure 2.9B).   
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Fig. 2.9 Silencing of Cav-1, CyPA, and CyP40 or treatment with cyclosporin A failed to 
prevent NSP4 from trafficking the cell surface. A. MA104 and HT29.f8 cells that were 
infected (I) with RV or uninfected (UI), and were untreated (UT) (A; lanes 1 and 2) or 
treated with siRNA (siCav-1, siCyPA, siCyP40) (A; lanes 3-6) for 60 h. Cells were surface 
biotinylated 6 h post infection and biotinylated cells were precipitated with streptavidin 
agarose. Lysates were separated by SDS-PAGE and subjected to a Western blot with 
rabbit antibody directed against NSP4112-140. B. MA104 and HT29.f8 cells were infected 
(I) or uninfected (UI), and were treated with 1.2 μg/ml cyclosporine A (CsA) for 24 h. 
Surface biotinylation and further analyses were performed as in A. 
 
 
2.3.7 Lovastatin Treatment Lowers the Amount of NSP4 That Reaches the Cell 
Surface 
We know that NSP4 directly interacts with cholesterol (Schroeder, 2009), so it was 
reasonable to determine the effect of inhibiting the production of de novo synthesized 
cholesterol on NSP4 transport to the PM. Cells were treated with Lovastatin (5 µg/ml), 
an HMG-CoA Reductase inhibitor, for 24 h prior to infection with SA11.4f at an MOI of 
5. After a 6 h infection cells were washed, surface biotinylated, scraped into PBS with 
protease inhibitors (PI), and homogenized. Biotinylated proteins were precipitated with 
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streptavidin agarose at 4°C overnight, dissociated from the streptavidin, separated via 
was measured as described in methods.  
In Figure 2.10, the Western blots depicted that although some NSP4 reached the PM 
when cholesterol production was decreased (based on densitometry analysis), it was 
consistently less than that in cholesterol-depleted samples. The role of cholesterol in the 
transport of NSP4 needs to be investigated further, but it may play an important role in 
transport of the toxin to the exofacial surface. 
 
 
 
Figure 2.10. NSP4 expression upon intracellular cholesterol depletion. MA104 and 
HT29.f8 cells were treated with lovastatin to deplete intracellular cholesterol and 
infected with SA11.4f at an MOI of 5. A. Cells were surface biotinylated at 6 h post 
infection, proteins were precipitated with streptavidin agarose, separated via SDS-PAGE 
and subjected to Western blot with rabbit anti-NSP4112-140. B. The concentration of 
cholesterol (mg/ml) was quantitated with the Wako CholE Kit. 
 
 
 
2.4 Discussion 
RV NSP4 is a multifunctional glycoprotein with roles in viral replication, 
pathogenesis, and viral particle assembly (Ball et al., 2005). It serves as a viroporin, 
eliciting Ca2+ efflux from the ER and initiates autophagy, a step required for particle 
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maturation (Crawford et al., 2012; Hyser et al., 2010). RV NSP4 also is known to 
interact with caveolin-1 (Parr et al., 2006), to localize to caveolae on the PM (Storey et 
al., 2007), and to be secreted from cells in different forms (Bugarcic and Taylor, 2006; 
Gibbons et al., 2011; Zhang et al., 2000). Our lab has shown that NSP4 traverses the PM 
with the C-terminus exposed to the extracellular environment and the full-length protein 
is secreted into culture media (Gibbons et al., 2011). Zhang, et al. showed that a 
cleavage product of NSP4 (residues 112-175) is released into the culture media of 
MA104 cells when over-expressed (Zhang et al., 2000) and Bugarcić, et al. shows a full-
length and partially EndoH-resistant form secreted into the culture media of Caco-2 cells 
(Bugarcic and Taylor, 2006). Our lab has shown that transport kinetics of NSP4 differ in 
cultured cells of different tissue origins (Gibbons et al., 2011), suggesting that NSP4 
uses multiple pathways with different kinetics to reach the PM, including both a soluble 
and a vesicular pathway. The precise mechanism by which NSP4 traffics from the ER to 
the PM and is secreted remains unclear.  
In this study we set out to show that NSP4 interacts with CyPA, CyP40 and HSP56, 
which would influence NSP4 transport. RV NSP4 directly interacted with the 
cyclophilins by co-localization, co-immunoprecipitation, and FRET analyses and with 
HSP56 by co-localization and FRET analyses. CyPA, CyP40, and HSP56 are 
immunophilins that possess PPIase activity and are important for protein folding (Davies 
and Sanchez, 2005; Fischer et al., 1989). HSP56 and CyP40 are also capable of binding 
HSP90 and are found as part of steroid heterocomplexes in the nucleus (Davies and 
Sanchez, 2005). HSP56 is a calmodulin binding protein (Davies and Sanchez, 2005), and 
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localizes to microtubules (Czar et al., 1994). CyPA, CyP40, and HSP56 all bind dynein, 
and play a role in retrograde transport of proteins (Czar et al., 1994; Galigniana et al., 
2002; Galigniana et al., 2004; Galigniana et al., 2001). Even with evidence that CyP40 
and HSP56 are complexed with steroid receptors as well as with a dynein/dynactin 
complex, it remains unknown whether CyPA is directly involved in the complex. 
However, it is known that the PPIase subunit of these immunophilins, including CypA, 
are required for dynein binding (Pratt et al., 2006).  
Our findings revealed that these proteins interact with NSP4, but are not solely 
responsible for the transport pathway of NSP4 to the PM. We demonstrated that 
silencing the expression of Cav-1, CyPA, and CyP40 with silencing RNA failed to 
reduce PM-localized NSP4. Blocking the expression of these proteins disturbed the 
normal intracellular distribution of NSP4, contributing to a more dispersed pattern 
throughout the cytoplasm. It is likely that the immunophilins are playing a role in protein 
folding to the non-native RV NSP4. Alternatively, the immunophilins could be 
necessary for some aspects of the intracellular transport of NSP4, but not for transport of 
NSP4 to reach the PM. Silencing of the immunophilins and Cav-1 did not affect NSP4 
expression intracellularly (detected by Western blot and digital imaging), nor did it 
affect the amount of virus produced (detected by fluorescent focus assay; data not 
shown). 
Chaperone proteins including this group of immunophilins are known to prevent 
aggregation of proteins under ER stress. It is well known that rotavirus infection induces 
ER stress and alters intracellular Ca2+ levels (Hyser et al., 2010; Michelangeli et al., 
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1991; Zambrano et al., 2008). The up-regulation of the expression of chaperone proteins 
BiP and endoplasmin (HSP90B1) by both RV infection and NSP4 expression also have 
been demonstrated (Xu et al., 1998). HSP56 and CyP40 are known binding partners of 
HSP90 (Ratajczak et al., 2009), which could be involved in the folding of non-native 
intracellular proteins. These roles in chaperoning activity could account for the 
intracellular redistribution of NSP4 seen upon silencing of HSP56 and CyP40, but 
additional studies are needed to determine their exact roles. 
In RV-infected cells, NSP4 leaves the ER and is found in punctate structures in the 
cytoplasm (Crawford et al., 2012), associates with microtubules (Berkova et al., 2007; 
Xu et al., 2000), and localizes at the PM caveolae (Storey et al., 2007). RV NSP4 travels 
by an unconventional protein transport pathway, bypassing the Golgi apparatus as it 
traffics from the ER to the PM (Jourdan et al., 1997; Nickel, 2005). Characteristics of the 
unconventional transport pathway include: (i) lack of a conventional signal peptide within 
the protein, (ii) exclusion from the ER and/or Golgi combined with the lack of Golgi-
dependent modifications, and (iii) transport not affected by Brefeldin A (Nickel, 2003). 
NSP4 clearly fits these criteria and can be added to the growing list of proteins that traffic 
by an unconventional route.  
When we silenced Cav-1 and CyPA, there was a redistribution of NSP4 to co-
localize with a Golgi marker protein, golgin-97 (Figure 2.5). Yet, Endo H digestion of 
NSP4 from CyPA silenced cells remained sensitive to digestion (Figure 2.6). Therefore, 
silencing of Cav-1 and CyPA are contributing to a redistribution of the Golgi protein and 
not to NSP4 transport to the Golgi. NSP4 and the ER marker, PDI, in Cav-1- and CyPA-
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silenced cells co-localized less than in untreated cells, indicating that silencing Cav-1 
and CyPA have some influence on the intracellular distribution of NSP4, although the 
affect remains unknown. 
He, et al. have reported that CyPA is a restrictive factor in RV replication by 
contributing to the host cell IFN-β production, and that silencing CyPA results in 
enhanced RV production (He et al., 2013; He et al., 2012). Other reports suggest that 
CyPA is a positive regulator of coronavirus, hepatitis C virus, and cytomegalovirus 
maturation and transport (Anderson et al., 2011; Keyes et al., 2012; Tanaka et al., 2013). 
Our data failed to show a significant effect of silencing CyPA on RV replication, but 
there was a notable change in the cellular architecture upon silencing of CyPA. In 
particular, the PM marker that is expressed on the exofacial surface in untreated cells, 
Na+/K+ATPase, also was expressed intracellularly in RV-infected, CyPA-silenced cells 
(Figure 7-B3). While further investigation is necessary to determine the function of 
CyPA in redistribution of these proteins and organelles, our studies clearly showed that 
inhibiting CyPA expression does not prevent NSP4 from reaching the cell surface.  
A previous study indicated that CyPA is important for intracellular lipid trafficking 
during HCV infection (Anderson et al., 2011). Reports show that the HCV protein NS5A 
is displaced upon inhibition of CyPA with a small molecule inhibitor in addition to 
changes in lipid droplet size (Anderson et al., 2011).  Inhibition of cholesterol 
production by lovastatin in the present study resulted in decreased NSP4 transport to the 
cell surface. It is possible that CyPA may be involved in the regulation of lipid and 
cholesterol transport during RV infection as well, but is not sufficient alone for efficient 
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NSP4 transport. Many questions remain. The answers to these questions may reveal 
additional roles of NSP4 and disclose a more complete picture of NSP4 transport and 
activity. 
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3. INTRACELLULAR CO-LOCALIZATION OF CAVEOLIN-1 AND THE 
IMMUNOPHILINS, YEAST TWO-HYBRID ANALYSIS OF NSP4 AND HSP56, 
AND EXPRESSION OF CAVEOLIN-1 AND THE CYCLOPHILINS IN 
ROTAVIRUS INFECTION  
3.1 Introduction 
 
Rotavirus NSP4 interacts with Cav-1, CyPA, CyP40, HSP56, and cholesterol but the 
roles of these interactions need additional exploration (Gibbons, 2007; Parr et al., 2006; 
Schroeder, 2009). Silencing of these proteins using siRNA fails to inhibit NSP4 from 
reaching the exofacial PM in both MA104 and HT29.f8 cells (Yakshe, In Preparation). 
Upon completion of the studies discussed in Section 2, several things were noticed that 
elicited further questions and experimentation. First, it was noted that the fluorescence 
intensities of the cyclophilins consistently were higher in cells infected with RV than in 
uninfected cells while performing LSCM indicating RV up-regulates expression of the 
cyclophilins. Second, the intracellular distributions of Cav-1 and the immunophilins 
were very different from each other. Lastly, the difficulty of analyzing HSP56 by 
Western blot led us to explore another method to evaluate the interaction of NSP4 with 
this immunophilin, the yeast two-hybrid system. This study further evaluated the roles of 
these proteins in intracellular trafficking of RV NSP4. We used Western blot analysis, 
immunofluorescence imaging techniques, and yeast two-hybrid studies to investigate 
intracellular NSP4 interactions with Cav-1 and the immunophilins. 
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3.2 Materials and Methods 
3.2.1 Cells and Viruses 
African green monkey kidney cells MA104 (ATCC, Manassas, VA), a cloned human 
intestinal cell line HT29.f8 from parental HT29 cells (Mitchell and Ball, 2004), and 
Madin-Darby canine kidney (MDCK) cells (ATCC) were cultured in Dulbecco’s 
modified Eagle’s media (DMEM; CellGro, Manassas, VA) supplemented with 10% fetal 
bovine serum (FBS; Caisson Labs, North Logan, UT), 0.1 mM non-essential amino 
acids (NEAA; Gibco, Grand Island, NY), 1 mM sodium pyruvate (Gibco), and 2 mM L-
glutamine (Lonza, Basel, Switzerland) at 37°C with 5% CO2 in a humidified 
environment. Penicillin-streptomycin was not used in the culture mixture to prevent 
perturbation cell-signaling pathways. RV SA11 clone 4F (SA11.4F; gift from Mary 
Estes, Baylor College of Medicine, Houston, TX) was expanded in MA104 cells 
(Yakshe, 2015) and stored at -80°C. 
3.2.2 Infection 
Cells were serum starved by incubation in serum-free DMEM for 14 hours before 
infection. Cells were infected with SA11.4f at a multiplicity of infection (MOI) of 2 for 
imaging. In brief, virus was thawed on ice and sonicated using a cuphorn attachment 
with ice for 5 min using a Misonix Sonicator 3000 at 45W (Misonix, Inc., Farmingdale, 
NY). Virus then was activated in serum-free DMEM with 1 μg/ml trypsin (Worthington 
Biochemical, Lakewood, NJ) at 37°C for 30 min. The activated RV was added to cells 
diluted in serum-free DMEM supplemented with 1 μg/ml trypsin at the specified MOI 
and rocked at 37°C with 5% CO2 in a humidified environment for 1 h. The viral 
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inoculum was removed, cells were washed with media to remove unbound virus, and 
serum-free DMEM was added for various times of infection as indicated in the results 
section. 
3.2.3 Time Course of Expression of Cav-1, CyPA, and CyP40 in RV-infected Cells 
MA104 and HT29.f8 cells were plated in 24-well plates and grown until ~80% 
confluent and serum starved overnight by replacing DMEM with 10% FBS with serum-
free DMEM. Cells were infected with SA11.4f RV at an MOI of 2.0. One well of cells 
was lysed immediately following virus adsorption and every 30 minutes thereafter until 
7 hpi. Cells were collected at these time points by addition of 300 μl ice-cold SDS-free 
RIPA lysis buffer (150 mM NaCl, 50 mM Tris-base, 10% NP-40, 0.5% DOC, pH=8.0) 
containing protease inhibitors (1.2mM AEBSF, 0.46μM Aprotinin, 12.3μM E-64, 14μM 
Bestatin, 112μM Leupeptin and 1.16μM Pepstatin) and 0.2 mM phenylmethylsulfonyl 
fluoride (PMSF). Cell lysates were transferred to 1.2 ml microcentrifuge tubes and 
stored at -20°C for analysis. The protein concentrations were measured using the Pierce 
Micro BCA Protein Assay Kit according to the manufacturer’s instructions and equal 
concentrations of protein were loaded and separated on a 12% SDS-PAGE gel, 
transferred to a 0.45 μm nitrocellulose membrane, and subjected to Western blotting. 
3.2.4 Protein Separation by SDS-PAGE and Western Blotting 
Western blotting was used to determine the expression of Cav-1, CyPA, and CyP40 
at different time points following RV infection. Briefly, equal protein concentrations 
were dissolved and dissociated in sample reducing buffer, loaded and resolved on a 12% 
or 15% SDS-polyacrylamide gel (NEXT GEL; Amresco). The proteins were 
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electroblotted to a 0.45 μM-pore size nitrocellulose membrane (Bio-Rad, Hercules, CA) 
as per the manufacturer’s instructions (Mini-Protean II and Trans-Blot, Bio-rad) at 4°C 
in Tris-Glycine buffer containing 20% methanol. The nitrocellulose membranes were 
blocked in 10% (wt/vol) NFDM in PBS for 1 h at room temperature. The membranes 
then were incubated with primary antibodies diluted in 2.5% NFDM in PBS for 3 h at 
room temperature with rocking. The membranes were washed once with PBS, twice 
with PBS-Tween-20 (0.5%), and again with PBS. Secondary antibodies conjugated to 
HRP were diluted in 2.5% NFDM in PBS, added to the membranes, and incubated for 1 
h at room temperature with rocking. The membranes were washed as above and reacted 
with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA) 
as per the manufacturer’s instructions. The protein-specific bands were visualized using 
the ImageQuant LAS 4000 gel imager (GE Healthcare Life Sciences, Pittsburgh, PA), 
and densitometric analyses were performed using ImageJ (NIH). 
3.2.5 Densitometry 
Gel images were analyzed via ImageJ using the gel analysis function. Briefly, the 
intensity of each protein band was given a value for the protein being evaluated and for 
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control in the same lane. 
Each band was background subtracted and measured within the linear range. The 
intensity value of the protein band was divided by the intensity value of the GAPDH 
control band to obtain a ratio of the protein amount to protein loading control (GAPDH 
band intensity).  
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 The experiments were performed in triplicate and the standard error was calculated 
using: 
𝑆𝑆𝑆𝑆 =  √∑(𝑋𝑋 −𝑀𝑀)2
𝑠𝑠 − 1  
where X is the sample value, M is the mean, and n is the number of experimental 
replicates.  
3.2.6 Laser Scanning Confocal Fluorescent Microscopy (LSCM) 
MDCK cells were plated on #2 German borosilicate Labtek well coverslips (Nalge 
Nunc International, Naperville, IL). At specific time points, the medium was removed, 
cells were washed with ice-cold PBS and fixed and permeabilized with ice-cold 
methanol:acetone (1:1, vol/vol) for 20 min at -20°C. The fixed and permeabilized cells 
were prepared for immunofluorescence using a modification of a previously described 
method (Storey et al., 2007). Briefly, fixed cells were blocked with 3% NFDM in PBS 
and incubated with primary antibodies (Table 3.1) diluted in 0.5% NFDM in PBS for 3 
h at room temperature. After the cells were washed three times with PBS the secondary 
antibodies conjugated to a fluorescent dye (Table 3.2) were diluted in 0.5% NFDM, and 
incubated for 1 h at room temperature in the dark. Primary and secondary antibody 
controls were included to exclude non-specific reactivity of the antibodies. Cells were 
washed as above in the dark and the fluorescent images were captured with a MRC- 
124MP BioRad LSCM system (BioRad) using a Zeiss inverted Axiovert microscope 
(Carl Zeiss, Inc., Thornwood, NY), a 63X Zeiss oil apochromat objective, and the 488-, 
568- or 647-nm excitation lines of an argon/krypton ion laser source or the 405 nm line 
of a Ti:Sapphire diode laser. Fluorescence emission from the labeled cells cultured on 
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coverslips was detected using 405-nm excitation with a bandpass emission filter for the 
Pacific Blue™ fluorophore (ex=410 nm, em=455 nm) (blue channel) and 568 nm 
excitation with a HQ598/40 band-pass emission filter for Cy5 fluorophore (ex=650 nm, 
em=670 nm) (red channel). LaserSharp 3.0 (BioRad) and Image J (public domain Java 
image-processing program inspired by NIH Image) were used to capture the pixilated 
photomultiplier tube (PMT) data, convert the image data to .tiff format, and adjust for 
contrast curves to construct the final images. 
 
Table 3.1. Primary Antibodies Used in Immunofluorescence 
Primary Antibody Target Host  
Animal 
Antibody  
Dilution 
Comments 
Caveolin-1 Rabbit 1:100 caveolae structural protein  
Cyclophilin A Rabbit 1:50 chaperone; cytoplasm localized peptidyl-
prolyl isomerase 
Cyclophilin 40 Rabbit 1:200 chaperone; mitochondrial localized 
peptidyl-prolyl isomerase 
Heat Shock Protein 56 Rabbit 1:75 chaperone; heat shock protein 
Caveolin-1 Mouse 1:50 caveolae structural protein  
Cyclophilin A Mouse 1:50 chaperone; cytoplasm localized peptidyl-
prolyl isomerase 
 
 
 
Table 3.2. Secondary Antibodies Used in Immunofluorescence 
Secondary Antibody 
Target 
Host  
Animal 
Antibody  
Dilution 
Comments 
Mouse IgG (H+L) Goat 1:100 Cy5 conjugated  
Rabbit IgG (H+L) Goat 1:100 Pacific Blue™ conjugated 
 
 
 
3.2.7 Co-localization 
Cells were infected and treated as above, incubated with antibodies targeting the 
immunophilins and a secondary antibody labeled with Pacific Blue™ and Cy-5 labeled 
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rabbit anti-NSP4150-175 together. Images were collected as above. The extent of co-
localization of the pixels in the confocal images were calculated with the Image J Coloc 
2 plugin using the overlap coefficient (MOC) according to Manders (Manders, 1993), 
 
where Ri and Gi represent the intensity values of the red and green channels, 
respectively, in a given pixel, i  (Manders et al., 1992). 
3.2.8 Cloning of HSP56 into Gateway® Entry-level Vector, pENTR11 
The HSP56 cDNA clone in a pCMV6-XL5 vector was purchased from OriGene 
Technologies. (Rockville, MD) and amplified using a cloned Pfu DNA polymerase 
(Stratagene, La Jolla, CA) with primers that produce a blunt end and an XhoI site 
(Forward-ATGATGCAAATCTGCGACACCTACAA, Reverse with XhoI site-
TCTAGATATCTCGAGTCAGTGGCCCCAATTGCCGA). The resulting PCR product 
was digested with XhoI (Fermentas, Thermo-Fisher) and the pENTR11 vector was 
digested with XhoI and XmnI (Fermentas, Thermo-Fisher) for 10 min at 37°C. The PCR 
fragment was isolated with the UltraClean® PCR Clean-Up kit (Mo Bio, Carlsbad, CA) 
according to the manufacturer’s instructions. The linear fragment of pENTR11 was 
separated on an 1% agarose gel and purified with the UltraClean® GelSpin® DNA 
Extraction Kit (Mo Bio) according to the manufacturer’s instructions. DNA 
concentrations of the purified PCR fragment and linearized vector were determined by 
measuring the absorbance on a Nano Drop 1000 spectrophotometer. 
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3.2.9 Ligation of HSP56 PCR Fragment into pENTR11 Vector and Amplification of 
pENTR11-HSP56 
The HSP56 PCR fragment and pENTR11 vector were ligated in a 3:1 ratio using 1 μl 
T4 ligase (NEB) in a 20 μl reaction. The ligation mixture was incubated at room 
temperature for 10 min. The T4 ligase was inactivated at 65°C for 10 min. Five μl of the 
inactivated ligation mixture was transformed into chemically competent DH5α E. coli. 
Briefly, the Escherichia coli (E. coli) were incubated with the ligation mixture for 15 
min on ice, heat shocked at 42°C for 60 sec and added to 1 ml pre-warmed to 37°C 
Luria-Burtani media (LB; 10 g/L tryptone, 5 g/L yeast extract, and 5 g/L NaCl). The 
mixture was shaken at 250 rpm for 1 h at 37°C. The E. coli was pelleted by 
centrifugation at 2500 rpm for 5 min and resuspended in 50 μl LB media. The E. coli 
were plated on LB agar plates containing 50 μg/ml kanamycin and grown at 37°C 
overnight.  
Individual colonies were picked and expanded in 5 ml LB media with 50 μg/ml 
kanamycin with shaking at 250 rpm and 37°C until the optical density at 600 nm (OD600) 
reached 0.4. The E. coli was pelleted at 2500 rpm for 10 min and the media decanted and 
discarded. The pENTR11-HSP56 plasmid was isolated from the E. coli using the 
GeneJET Plasmid MiniPrep Kit (Fermentas, Thermo Scientific) as per the 
manufacturer’s protocol. The concentration of the resulting plasmid was measured by 
absorbance on a NanoDrop 1000 spectrophotometer and was stored at -20°C. Restriction 
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enzyme digestion of the plasmid and sequencing of the insert were used to verify correct 
plasmid construction. 
3.2.10 Recombination of pENTR11 Vectors with Y2H Plasmids 
pENTR11 contains attL sites while the bait and prey plasmids, pDEST™32 and 
pDEST22™, respectively, contain attR sites. The entry vector (pENTR11) and 
destination vector (bait or prey) were mixed 1:1 (150 ng/μl) with 2 μl of LR Clonase II 
enzyme and incubated for 1 h at room temperature. LR Clonase II is a proprietary 
mixture that catalyzes a recombination reaction between attL and attR sites. The enzyme 
was inactivated with 1 μl of Proteinase K and incubated at 37°C for 10 min. The 
resulting recombinant plasmids were transformed into DH5α E. coli for amplification. 
Briefly, the E. coli was incubated with the ligation mixture for 15 min on ice, heat 
shocked at 42°C for 45 sec and added to 1 ml 37°C LB media. The mixture was shaken 
at 250 rpm for 1 h at 37°C. The E. coli was pelleted by centrifugation at 2500 rpm for 5 
min and resuspended in 50 μl LB media. The E. coli transformed with the pDEST22™ 
recombinants were plated on LB agar plates containing 100 μg/ml ampicillin and the 
pDEST32™ recombinants were plated on LB agar plates containing 10 μg/ml 
gentamycin and grown at 37°C overnight. Both pDEST22™ and pDEST32™ contain 
the ccdB gene within the attR recombination sites, so vectors that have not undergone 
recombination will not grow on LB media. Vector sequences were verified using the 
manufacturer’s suggested sequencing primers for the PDEST22™ and pDEST32™ 
vectors. 
 
 62 
3.2.11 Yeast Two-hybrid Analysis of NSP4 Interaction with HSP56 
The ProQuest™ Two-Hybrid System was used for yeast two-hybrid analysis as 
described previously (Parr et al., 2006). NSP4 was used as the prey while HSP56 was 
used as the bait. The prey vector, pDEST22™, contains a transcription factor activation 
domain, while the bait vector, pDEST32™, contains a transcription factor DNA-binding 
domain specific to the GAL4 gene in the MAV-203 S. cerevisiae strain, which has been 
engineered to control the reporter gene lacZ, and auxotrophic markers, HIS3 and URA3. 
Genes inserted into the pDEST22™ and pDEST32™ vectors will be produced as fusion 
proteins with the GAL4 activation domain and DNA-binding domains, respectively. 
When the proteins interact with each other, the activation and DNA-binding domains 
come within interacting distance of each other and cause activation of transcription of 
the GAL4 gene. The transcription of GAL4 can be verified by analysis of lacZ, HIS3, and 
URA3 activation. When lacZ has been transcribed, an X-gal (5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside) assay is performed and yeast will turn blue. When HIS3 
has been transcribed, cells will grow in the presence of 3-Amino-1,2,4-triazole (3AT) 
and absence of histidine. When URA3 has been transcribed, cells will grow in the 
absence of uracil and not grow in the presence of 5-fluorouracil (5FOA). 
 To perform the yeast two-hybrid analyses, yeast are grown on complete synthetic 
media (CSM) lacking leucine (leu) and tryptophan (trp) for 24 h at 30°C. Yeast are then 
replica plated using sterile velvet squares and grown for 24 h at 30°C on CSM 
containing 12.5 μg/ml 3AT, 50 μg/ml 3AT, or 100 μg/ml 3AT and lacking histidine 
(his), leu, and trp (CSM-leu-trp-his+3AT), CSM containing 0.2% 5FOA and lacking leu 
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and trp (CSM-leu-trp+5FOA), CSM lacking leu, trp, and uracil (ura) (CSM-leu-trp-ura), 
and YPAD yeast medium (1% bacto yeast extract, 2% bacto peptone, 2% glucose, and 
2% bacto agar) overlayed with a 125-mm Whatman 541 filter paper for X-gal analysis 
(GE Life Sciences, Pittsburgh, PA) Table 3.3. The plates are replica cleaned after 24 h 
of growth and allowed to grow for 48 h at 30°C until analysis. Replica cleaning is 
performed using sterile velvet squares and pressing the plates with moderate pressure to 
remove as many yeast as possible. All yeast growth was recorded after 48 h of growth 
following replica cleaning.  
 
Table 3.3. Media Used for Plating and Selecting Yeast Transformed with Plasmids 
Expressing pDEST22™-NSP4 and pDEST32™-HSP56 
 
Media Base Additives Media Deficiency Purpose 
CSM - -leucine Transformation Controls 
CSM - -leucine, -tryptophan All controls and 
interaction test 
CSM +12.5mM 3AT, 
+50mM 3AT, 
+100mM 3AT 
-leucine, -tryptophan,  
-histidine 
Evaluate growth while 
HIS3 is inhibited by 3AT 
CSM +0.2% 5FOA -leucine, -tryptophan Evaluate growth while 
uracil production is 
inhibited by 5FOA 
CSM - -leucine, -tryptophan, -
uracil 
Evaluate growth without 
uracil 
YPAD - - X-Gal Assay 
 
 
 Controls included MAV-203 transformed with the plasmids listed in Table 3.4. A 
negative control consists of MAV-203 with no plasmids, two self-activation controls, 
pDEST22™ with pDEST32™-HSP56 and pDEST32™ with pDEST22™-NSP4, and 5 
controls provided with the ProQuest Y2H system, which ranks protein interactions from 
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no interaction to very strong interaction (Table 3.5). 
 
 
Table 3.4. Yeast Two-hybrid Plasmid Combinations for Each Interaction Test 
Plate Binding Domain Activation Domain Media Purpose 
1 None None CSM-Leu 
CSM-Leu-Trp 
Transformation 
Control 
2 pDBLeu None CSM-Leu Transformation 
Control 
3 pDEST32™-
HSP56 
pEXP-AD502 CSM-Leu-Trp Self-activation 
Control 
4 pDBLeu pEXP-AD502 CSM-Leu-Trp Self-activation 
Control 
5 pDBLeu pDEST22™-NSP4 CSM-Leu-Trp Self-activation 
Control 
6 pDEST32™-
HSP56 
pDEST22™-NSP4 CSM-Leu-Trp Interaction Test 
*Two controls in this table test for self-interactions of HSP56 and NSP4 with the GAL4 
activation and binding domains in the bait and prey plasmids. Negative controls include the 
MAV-203 yeast strain with no plasmids, the GAL4 activation domain alone, the GAL4 binding 
domain alone, and the GAL4 binding and activation domains together. 
 
 
 
Table 3.5. Control Yeast Strains Provided with the ProQuest™ Two-Hybrid 
System 
 
Control 
Strain* 
Plasmids Insert Interaction 
A pPC97 
pPC86 
None 
None 
None 
B pPC97-RB 
pPC86-E2F1 
Human RB aa 302-928 
Human E2F1 aa 342-437 
Very Weak 
C pPC97-CYH2S-dDP 
pPC86-dE2F 
Drosophila DP aa 1-377 
Drosophila E2F aa 225-433 
Weak 
D pPC97-Fos 
pPC86-Jun 
Rat cFos aa 132-211 
Mouse cJun aa 250-325 
Strong 
E pCL1 
pPC86 
GAL4 aa 1-881 
None 
Very Strong 
*A is the weakest interaction and E is the strongest interaction (Chevray and Nathans, 1992; Du 
et al., 1996; Fields and Song, 1989; Vidal, 1997; Vidal et al., 1996). This table is adapted from 
the manufacturer’s manual. 
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3.3 Results 
3.3.1 CyPA and CyP40 Expression, but Not Cav-1 Expression Were Up-regulated 
During RV Infection 
It was previously determined that the RNA levels for CyPA and CyP40 remain 
constant during RV infection (Gibbons, 2007). However, during immunofluorescence 
assays, an increase in signal of CyP40 was consistently noted (data not shown). To 
determine if the intracellular protein expression of Cav-1, CyPA, and CyP40 were 
increased, time course experiments were performed in SA11.4f-infected cells. MA104 
and HT29.f8 cells were infected with RV at an MOI of 2.0. Cells were collected and 
lysed before infection, after virus adsorption, and every 30 min to 1 h after infection 
until 7 hpi. Cell lysates were separated by SDS-PAGE, transferred to a nitrocellulose 
membrane, and blotted with either rabbit anti-CyPA, rabbit anti-Cyp40, or rabbit anti-
Cav-1 followed by goat anti-rabbit-HRP. Western blots revealed that both CyPA and 
CyP40 expression were up-regulated after infection in both cell lines. CyP40 remained at 
undetectable levels until 4 hpi, while CyPA was slightly enhanced starting at 4 hpi, 
where it remained at a constant level (data not shown). Cav-1 expression remained 
constant up to 7 h post-infection, indicating that RV infection had no effect on Cav-1 
expression (Figure 3.1). 
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3.3.2 Cav-1, CyPA, CyP40, and HSP56 Interacted at Differing Levels 
Intracellularly 
Immunofluorescence was performed to determine the co-localization of Cav-1 and 
each of the immunophilins with each other. Only certain pairings were analyzed due to 
limited antibody selection. HSP56 co-localization with CyP40 was not determined 
 
 
Figure 3.1. Expression of Cav-1 and CyP40 in MA104 and Cav-1 in HT29.f8 cells. 
Cells were uninfected or infected with RV SA11.4f at an MOI of 2.0 and collected at 
various timepoints post-infection (post adsorption to 6 h). Equal concentrations of cell 
lysates were separated on an SDS-PAGE, transferred to nitrocellulose and blotted with 
indicated antibodies.  
 
 
 
because the antibodies were synthesized in the same host species. In each pairing, a 
rabbit host antibody and a mouse host antibody were used, and goat anti-mouse-Cy5 and 
goat anti-rabbit-PB secondary antibodies were used. Examples of images showing co-
localization are displayed in Figure 3.2 with the mean MOCs displayed to the right of 
the images. In all cases, the Costes value was above 0.95, indicating that the co-
localization was not due to random signal correlation. The Costes value is obtained from 
a statistical significance test whereby the pixels from the analyzed images are scrambled 
and the signal correlations between the scrambled image and analyzed image are 
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measured. A Costes value of 0 indicates that the MOCs occur by random chance and a 
Costes value  
 
Figure 3.2 Co-localization of Cav-1, CyPA, CyP40, and HSP56 with each other. MDCK 
cells were fixed and permeabilized and incubated with antibodies directed against 2 of 
the proteins in pairs. Rabbit anti-PB and mouse anti-Cy5 were used to visualize the 
proteins. The first protein listed is seen in red and the second is seen in green. Mander’s 
overlap coefficients are listed next to each protein pair (n=3).  
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Table 3.6. Results of Yeast Two-hybrid Assay 
Yeast CSM  
-leu-trp 
CSM  
-leu-trp 
-his+3AT* 
CSM  
-leu 
-trp+5FOA 
CSM 
-leu-trp 
-ura 
YPAD/ 
X-gal 
Control A + -/-/- - - - 
Control B + +/-/- + - - 
Control C + +/-/- - - + 
Control D + +/+/+ - + ++ 
Control E + +/+/+ - ++ ++ 
Self-Activation 
Bait 
+ -/-/- + - - 
Self-Activation 
Prey 
+ -/-/- + - - 
NSP4/HSP56 
Interaction Test 
+ -/-/- + - - 
*CSM-leu-trp-his+3AT are plated at 3 concentrations 12.5 mM/ 50 mM/ 100 mM of 3AT 
 
 
 
of 1 indicates that no randomized image has better co-localization than the analyzed 
image (Costes et al., 2004).  
The results indicated that Cav-1 co-localized somewhat with CyPA (MOC=0.668) 
and CyP40 (MOC=0.532), and co-localized more with HSP56 (MOC=0.855). CyPA co-
localized significantly with Cav-1 (MOC=0.903), and slightly with CyP40 
(MOC=0.553), and HSP56 (MOC=0.418). CyP40 co-localized marginally with Cav-1 
(MOC=0.506) and slightly more with CyPA (MOC=0.674), and we were not able to 
evaluate the co-localization with HSP56 due to antibody limitations. HSP56 co-localized 
more than anticipated with Cav-1 (MOC=0.646), and very little with CyPA 
(MOC=0.249). These results indicate that while some of the proteins co-localize with 
each other intracellularly, they do not associate with each other exclusively. These data 
support that a complex consisting of Cav-1 and these immunophilins likely does not 
exist in MA104 cells.  
 69 
3.3.3 Yeast Two-hybrid Analysis of the HSP56 Interaction with NSP4 
Yeast two-hybrid screening was performed with vectors containing full-length 
HSP56 and full-length NSP4. Protein expression of HSP56 from this vector was not 
confirmed because of limited antibody reaction using the Western blot technique. 
However, sequencing of the vector showed that HSP56 was correctly inserted into 
pDEST32™ for yeast two-hybrid analysis. In this system, there are four phenotypes 
analyzed to determine whether there is a protein-protein interaction: 1) yeast growth in 
the presence of (3AT), a HIS3 inhibitor, 2) yeast color in the presence of X-gal, 3) yeast 
growth in the presence of uracil, and 4) absence of yeast grown in the presence 5-
fluorouracil (5FOA). After plating on CSM-leu-trp, and replica plating onto the selective 
media (Table 3.3), the self-activation controls and transformation controls all grew as 
expected (Table 3.6). The control yeast strains (A-E) showed expected growth on 
selection media (Table 3.6). The interaction pair, pDEST22™-NSP4 and pDEST32™-
HSP56, grew in a similarly to yeast control strain A (Table 3.6), indicating that HSP56  
and NSP4 do not interact directly using yeast two-hybrid system analysis. However, 
these results cannot be proved without verifying yeast expression of HSP56. 
3.4 Discussion 
Rotavirus infection is known to up-regulate the unfolded protein response (UPR), as 
well as the expression of several proteins related to ER stress and Ca2+ homeostasis 
(Cuadras et al., 2002; Zambrano et al., 2011). Up-regulated proteins include 
immunophilin cyclophilin B, several chaperone proteins including endoplasmin and BiP, 
and caveolins (Cuadras et al., 2002; Xu et al., 1998). We know that NSP4 directly or 
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indirectly interacts with Cav-1 (Parr et al., 2006) and immunophilins, CyPA, CyP40, and 
HSP56 (Section 2), but the roles of these proteins in RV infection have not been fully 
determined. 
This study further evaluated the amount of protein expression of Cav-1, CyPA, and 
CyP40 over time via Western blot analysis. The amount of CyP40 noticeably increased 
starting at around 4 hpi, the amount of CyPA increased, although less than CyP40, and 
the Cav-1 expression pattern didn’t change throughout infection (Figure 3.1). This 
increase in protein expression simply could be the result of the host cell’s need for 
chaperone proteins to fold the excess proteins in the ER. However, the reason for up-
regulation of CyPA and CyP40 expression remains unknown. 
We also evaluated the co-localization of Cav-1 and the immunophilins to determine 
whether they are interacting with each other under normal cellular conditions. It had 
become evident during previous microscopy studies that the intracellular distribution 
patterns of these four proteins varied significantly from each other. It is known that 
CyP40 and HSP56 compete for binding in a complex containing endoplasmin (Davies 
and Sanchez, 2005), and that CyPA, CyP40, and HSP56 all bind dynein and are involved 
in retrograde transport (Czar et al., 1994; Galigniana et al., 2004). Therefore, we wanted 
to determine if these proteins were co-localizing intracellularly with each other, since 
they were once reported to interact in a complex with each other. Co-localization 
analysis revealed that while the proteins do co-localize with each other, most of the co-
localization was nominal Figure 3.2. Thus, while the proteins do co-localize somewhat, 
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they clearly are playing individual roles intracellularly rather than functioning as a 
complex. 
Finally, we had a great difficulty detecting HSP56 on a conventional Western blot or 
by other techniques, such as a non-denaturing gel and dot-blot to determine if HSP56 
was interacting directly with NSP4. We tried several different antibodies from several 
companies without success. We previously reported that HSP56 and NSP4 do resolve 
within 10 nm of each other via intracellular FRET, but this does not conclusively prove a 
direct interaction. In this study, we tested a direct interaction using the ProQuest™ Yeast 
Two-Hybrid System. We found that NSP4 and HSP56 likely do not interact directly 
using this method, confirming some of our co-localization data, which revealed little co-
localization of NSP4 with HSP56 (Section 2). However, we know that NSP4 and HSP56 
localize very close to each other intracellularly by FRET, so they may be both binding a 
common protein intermediate. 
The roles of the Cav-1, CyPA, CyP40, and HSP56 proteins in the transport of NSP4 
need to be further evaluated. Whether they interact simply to assist in protein folding or 
to aid in intracellular protein transport, it remains our interest to determine their function. 
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4. CONSTRUCTION OF A RECOMBINANT LENTIVIRUS EXPRESSING 
SHORT-HAIRPIN RNA TARGETING CAVEOLIN-1, CYCLOPHILIN A, 
CYCLOPHILIN 40, AND HEAT SHOCK PROTEIN 56 
 
 
4.1 Introduction 
In our studies, we have determined that NSP4 transport to the PM is not affected by 
silencing of Cav-1, CyPA, or CyP40 using surface biotinylation. The method of 
silencing (siRNA) is costly and therefore is limited to examination of a small number of 
cells. This led us to investigate a more cost-effective way to scale up our reactions so 
that we could quantify the amount of NSP4 that traffics to the exofacial PM. We chose 
to use a lentivirus-vector system that expresses a short hairpin RNA (shRNA), blocking 
the synthesis of a specific protein, similarly to siRNA. 
A shRNA is processed in a similar fashion to a siRNA, but lentivirus delivery allows 
for continuous expression of the shRNA, instead of a transient transfection. A lentivirus-
vector based delivery system allows for incorporation of the shRNA into the cellular 
genome for creation of a stable expressing cell line. After transduction of the lentivirus, 
the shRNA is incorporated into the cellular genome. Upon expression of the primary 
shRNA transcript, it associates with Drosha and DGCR8 in the nucleus for processing 
into a pre-shRNA. The pre-shRNA is transported into the cytoplasm, where it is further 
processed by Dicer and loaded onto the RISC complex (Rao et al., 2009). 
We were unsure of how well cells would grow without Cav-1 or the immunophilins 
for an extended time, so we chose a system that would allow for inducible expression of 
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the shRNA. The TripZ system is a Tet-inducible shRNA expression system that allows 
for reversible protein knockdown. We obtained the proper packaging vectors, 
pCMVΔR8.91 containing the necessary lentivirus proteins driven by a CMV promoter, 
and pMD.G, which contains VSV-G. 
In this study, we report construction of the vectors expressing shRNA directed 
against Cav-1, CyPA, CyP40 and HSP56.  Stable HEK-293T cell lines expressing 
shRNA against Cav-1 and the immunophilins, and MA104 cell lines expressing shRNA 
against CyP40 and HSP56 were created. We also report the knockdown of these CyP40 
and HSP56 and the transport of NSP4 to the cell surface in the presence of shRNA in 
MA104 cells. 
An overview of the steps to create a shRNA-expressing lentivirus are outlined as 
follows: 
• Design shRNA using siRNA design tools from Invitrogen, Dharmacon, and
guidelines from Reynolds, et al. (Reynolds et al., 2004)
• Use the RNAi Central website to obtain a shRNA including the siRNA molecule
with miR30 ends (Lab)
• Add restriction enzyme site to the shRNA inserts
• Ligate the shRNA sequence into the pTripZ vector
• Sequence vector
• Transfect HEK-293T cells with the pTripZ shRNA vector
• Select for cells containing the incorporated vector with puromycin
• Transfect cells with lentivirus packaging vectors, pCMVΔ8.91 and pMD.G
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• Collect budded lentiviruses from media 
• Titer lentiviruses by fluorescence forming units using VSV-G antibody 
• Infect MA104 and HT29.f8 cells with lentiviruses 
• Generate stable transgene-expressing MA104 and HT29.f8 cell lines 
• Induce transgene expression and analyze for knockdown of specific proteins by 
WB 
4.2 Materials and Methods 
4.2.1 Vectors and E. coli Cells 
Dr. Charles Long kindly provided us with all vectors needed for establishment of the 
lentivirus vector system. In addition, Dr. Long provided us with the HEK-293T cell line 
for stable expression of the shRNA insert and Stbl3 E. coli cells (Invitrogen) for growth 
of the large pTripZ vector containing the LTRs (Dharmacon). The lentivirus system 
consisted of pTripZ, pCMVΔR8.91, and pMD.G (Appendix A).  
4.2.2 Expansion of Chemically Competent Stbl3 E. coli Stocks 
Stbl3 E. coli were isolated from a single colony and grown in super optimal broth 
(SOB) media (20 g/L tryptone, 5 g/L yeast extract 5 g/L NaCl, and 2.5 mM KCl) 
overnight with shaking at 200 rpm at 37°C. Five ml of the started colony was placed in a 
250 ml Erlenmeyer flask and shaken overnight at 200 rpm at room temperature until 
cultures reached an OD600of 0.4. Cells were pelleted by centrifugation at 2500 rpm for 
10 min at 4°C. All media was removed and cells were gently resuspended in 80 ml Inoue 
solution (55 mM MnCl2, 15mM CaCl2, and 250 mM KCl) at 4°C. Cells were pelleted at 
2500 rpm for 10 min at 4°C, Inoue solution was removed and cells were gently 
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resuspended in 20 ml fresh Inoue solution with 15% sterile glycerol at 4°C. Cells were 
aliquoted into 50 μl aliquots and stored at -80°C. Transformation efficiency was checked 
with the pUC19 vector (Invitrogen). 
4.2.3 shRNA Design 
The shRNA were designed based on the rational outlined by Reynolds, et al 
(Reynolds et al., 2004). Three siRNA sequences were designed for each protein to be 
silenced to ensure the most efficient silencing results. The siRNA sequences were 
incorporated into primers that have miR30 sequences flanking each end using the 
website: http://cancan.cshl.edu/RNAi_central/RNAi.cgi?type=shRNA. The shRNA 
inserts were ordered as long oligonucleotides from Life Technologies (Table 4.1). An 
XhoI and EcoRI site was added to the 5’ and 3’ ends of the shRNA inserts, respectively, 
using the forward primer  
5’-CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3’ and reverse 
primer 5’-CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA-3’. Briefly, the 
shRNA inserts were amplified with the primers containing the restriction endonuclease 
cleavage sites using Phusion® High-Fidelity DNA polymerase. The inserts were purified 
using the UltraClean® PCR Clean-Up Kit (Mo Bio) according the manufacturer’s 
instructions. 
4.2.4 Amplification and Isolation of pTripZ, pCMVΔR8.91, and pMD.G Vectors 
The pTripZ vector was amplified in Stbl3 E. coli, while pCMVΔR8.91 and pMD.G 
were amplified in DH5α E. coli. Briefly, E. coli was placed on ice, mixed with 1 μl of 
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the vector, and incubated for 15 min. E. coli then were heat shocked at 42°C for 45 
seconds and immediately placed on ice for 5 min. One ml of SOC media was added to 
 
 
Table 4.1 shRNA Inserts Ordered from Life Technologies.  
 
Protein shRNA sequence* 
Cav-1 TGCTGTTGACAGTGAGCGAGCAGACGAGCTGAGCGAGAAGTAGTGAAGCCAC
AGATGTACTTCTCGCTCAGCTCGTCTGCCTGCCTACTGCCTCGGA 
TGCTGTTGACAGTGAGCGAACCTTCACTGTGACGAAATACTAGTGAAGCCACA
GATGTAGTATTTCGTCACAGTGAAGGTGTGCCTACTGCCTCGGA 
TGCTGTTGACAGTGAGCGCAGTTCCAAGTTGCTAATACAGTAGTGAAGCCACA
GATGTACTGTATTAGCAACTTGGAACTTTGCCTACTGCCTCGGA 
CyPA TGCTGTTGACAGTGAGCGACTAGCTGGATTGCAGAGTTAATAGTGAAGCCACA
GATGTATTAACTCTGCAATCCAGCTAGGTGCCTACTGCCTCGGA 
TGCTGTTGACAGTGAGCGCGTGGTGTTTGGCAAAGTGAAATAGTGAAGCCACA
GATGTATTTCACTTTGCCAAACACCACATGCCTACTGCCTCGGA 
TGCTGTTGACAGTGAGCGATGGCATCTTGTCCATGGCAAATAGTGAAGCCACA
GATGTATTTGCCATGGACAAGATGCCAGTGCCTACTGCCTCGGA 
CyP40 TGCTGTTGACAGTGAGCGCGCTGCAACCTATAGCTTTAAGTAGTGAAGCCACA
GATGTACTTAAAGCTATAGGTTGCAGCTTGCCTACTGCCTCGGA 
TGCTGTTGACAGTGAGCGAGGAGCAATTGACAGTTGTTTATAGTGAAGCCACA
GATGTATAAACAACTGTCAATTGCTCCCTGCCTACTGCCTCGGA 
TGCTGTTGACAGTGAGCGCGGACAGTTCAAAGGCTGTTATTAGTGAAGCCACA
GATGTAATAACAGCCTTTGAACTGTCCATGCCTACTGCCTCGGA 
HSP56 TGCTGTTGACAGTGAGCGAGCAAGGACAAATTCTCCTTTGTAGTGAAGCCACA
GATGTACAAAGGAGAATTTGTCCTTGCGTGCCTACTGCCTCGGA 
TGCTGTTGACAGTGAGCGCGGTGGAGTTGTTTGAGTTTAATAGTGAAGCCACA
GATGTATTAAACTCAAACAACTCCACCTTGCCTACTGCCTCGGA 
TGCTGTTGACAGTGAGCGCGGGAGAAGATCTGACGGAAGATAGTGAAGCCAC
AGATGTATCTTCCGTCAGATCTTCTCCCTTGCCTACTGCCTCGGA 
* The siRNA sequences are seen in bold letters. 
 
 
 
each tube and the tubes were shaken at 250 rpm for 1 h. The transformed E. coli were 
pelleted at 2500 rpm for 5 min, resuspended in fresh SOC, plated on LB agar with 
appropriate antibiotics, and grown overnight at 37°C. pTripZ was selected for with 
ampicillin (100 μg/ml) and zeocin (25 μg/ml), and pCMVΔR8.91 and pMD.G were 
selected for with ampicillin (100 μg/ml). Individual colonies were picked and expanded 
in 5 ml LB with shaking at 250 rpm overnight at 30°C for Stbl3 E. coli and 37°C for 
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DH5α E. coli. Each 5 ml culture was pelleted at 2500 rpm for 10 min and the media 
removed. The plasmids were isolated from the E. coli using the GeneJET Plasmid 
MiniPrep Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
DNA concentrations were determined by measuring the absorbance on a NanoDrop 
1000. Vectors were verified using restriction enzyme digestion. 
4.2.5 Construction of shRNA-expressing Vectors 
The pTripZ vector and amplified primers were subjected to endonuclease restriction 
with EcoRI and XhoI, gel purified, and ligated together using the T4 Ligase enzyme. 
Briefly, TripZ or shRNA oligonucleotides containing restriction enzyme sites were 
added to 2 μl of 10X FastDigest buffer, 1 μl each of EcoRI and XhoI (Fermentas 
FastDigest), and enough water to bring the reaction to a final volume of 20 μl. The 
reaction was incubated in a 37°C water bath for 1 h. pTripZ and the shRNA 
oligonucleotides were gel-purified through a 1% agarose gel and the correct band was 
isolated with the UltraClean® GelSpin® DNA Extraction Kit (Mo Bio) according to the 
manufacturer’s directions. 
The linearized pTripZ vector and the restricted shRNA oligonucleotides were ligated 
together with T4 DNA Ligase (NEB). Molar ratios were calculated for the vector and 
insert and added to the reaction in a 1:3 molar ratio. Two μl 10X T4 ligase buffer (NEB), 
1 μl T4 DNA Ligase, and nuclease-free water were added for a final volume of 20 μl. 
The reaction was incubated at room temperature for 10 min, or in some cases, 16°C 
overnight. The reaction then was heated to 60°C for 10 min to inactivate the ligase and 
the resulting TripZ vector was transformed into Stbl3 E. coli as described above. The E. 
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coli was grown at 30°C because the 14 kb vector was very large and could not be 
maintained if the bacteria were grown at higher temperatures. The vector was isolated 
from E. coli as above and the concentration read by absorbance on a NanoDrop 1000. 
4.2.6 Puromycin Kill Curve for HEK-293T, MA104, and HT29.f8 Cells 
HEK-293T, MA104 and HT29.f8 cells were plated in 48-well plates and grown until 
~85% confluent. Puromycin dissolved in DMSO was added to the media at 0-15 μg/ml 
in triplicate. Media and puromycin were refreshed every 2 days and cells were assessed 
by light microscopy every day from the third day of treatment until the sixth day of 
treatment. DMSO was added to cells at the same volumes as a control. 
4.2.7 Transfection of pTripZ-shRNA Vectors into HEK-293T Cells 
HEK-293T cells were grown until ~85% confluent and transfected with pTripZ using 
Lipofectamine 2000. Briefly, 1 μl of Lipofectamine was added to 100 μl of serum-free 
DMEM, and 500-1000 ng pTripZ vector was added to 100 μl of serum-free DMEM. The 
solutions were mixed, incubated for 5 min at room temperature, and added to the cells 
without removing the growth media. The cells were treated with 1 μg/ml doxycycline 
and incubated for 48 h at 37°C. Induced cells were analyzed for transgene expression 
using an Olympus IX-70 epi-fluorescence microscope equipped with a mercury arc lamp 
and a Texas Red™ filter cube (Olympus).  
4.2.8 Selection of HEK-293T Cells for Stable Expression of pTripZ-shRNA 
Transfected HEK-293T cells were grown in 48-well plates in DMEM supplemented 
with 5 μg/ml puromycin. Media was replaced every two days. At 10 days post-
transfection the cells were treated with 1 μg/ml doxycycline and incubated for 48 h at 
 79 
37°C. Induced cells were analyzed for transgene expression using an Olympus IX-70 
epi-fluorescence microscope. Most cells were expressing the transgene at 14 days post-
transfection. Cells were expanded into 6-well plates and then into 25-cm2 tissue-culture 
flasks. Stocks of cells were frozen down in 10% DMSO and 50% FBS. 
4.2.9 Transfection of Packaging Vectors, pCMVΔR8.91 and pMD.G into HEK-
293T Cells and Purification of Lentivirus Particles 
HEK-293T cells expressing the transgenes and under selection of puromycin were 
grown until ~85% confluent in 6-well plates. Transfection of pCMVΔR8.91 and pMD.G 
was performed with Lipofectamine as above, scaled up appropriately in a ratio of 1 μg 
pCMVΔR8.91 to 1.7 μg pMD.G. The transfected cells were incubated overnight and the 
media was removed and replaced with DMEM containing 5% FBS. Cells were incubated 
for and additional 48 h for lentivirus production. 
Supernatants were collected from transfected cells and centrifuged at 1000 rpm for 
10 min to remove cellular debris. The supernatant containing the budded lentivirus was 
collected, mixed well and aliquoted into 250 μl fractions. The lentivirus stocks were 
frozen for further use at -80°C. 
4.2.10 Titer of Lentivirus Particles Containing shRNA Inserts 
HEK-293T cells were plated in 24-well plates and grown until ~85% confluent. 
Lentivirus was serial diluted in triplicate and added to the HEK-293T cells. After 
incubation for 48 h post-transduction, the cells were fixed with 1:1 methanol:acetone for 
15 min at -20°C. The cells were blocked with 5% non-fat dry milk (NFDM) and RV 
particles were labeled with rabbit anti-inactivated SA11.4f and goat anti-rabbit-Cy5. 
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Fluorescent colonies were counted using an Olympus IX70 inverted epi-fluorescence 
microscope and titers were determined. 
4.2.11 Transduction of Lentivirus Particles into MA104 and HT29.f8 Cells and 
Construction of Stable Transgene-expressing Cell Lines 
MA104 and HT29.f8 cells were grown until ~85% confluent. Recombinant lentivirus 
was added to the cells at an MOI of 1.0 in serum-free DMEM. DMEM with 10% FBS 
and 7.5 μg/ml puromycin was added to the cells without removing the lentivirus 
inoculum 6 hours post transduction. The cells were maintained in DMEM with 10% FBS 
and 7.5 μg/ml puromycin for 10 days with media changes every 2 days. The HT29.f8 
cells did not survive and were discarded. The MA104 cell lines were expanded and 
stocks were frozen at -80°C. 
4.2.12 Doxycycline Induction of shRNA Expression and Quantification of 
Knockdown in Transduced MA104 Cells  
Transduced MA104 cells under puromycin selection were grown in 24-well plates 
until ~85% confluent. Doxycycline (1 μg/ml) was added to the cells and cells were 
incubated for 48 h. Cells were visualized via epi-fluorescence to verify transgene 
expression. Cells were lysed with SDS-free RIPA lysis buffer (150 mM NaCl, 50 mM 
Tris-base, 10% NP-40, 0.5% DOC, pH=8.0) containing protease inhibitors (1.2mM 
AEBSF, 0.46μM Aprotinin, 12.3μM E-64, 14μM Bestatin, 112μM Leupeptin and 
1.16μM Pepstatin; Amresco, Solon, OH) and 0.2 mM phenylmethylsulfonyl fluoride 
(PMSF; Sigma, St. Louis, MO). Cell lysates were separated on a 12% SDS-PAGE gel, 
transferred to a nitrocellulose membrane, and subjected to Western blot. 
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4.2.13 RV Infection and Surface Biotinylation of Transduced MA104 Cells 
Cells were infected with SA11.4f at a MOI of 5. Briefly, virus was thawed on ice and 
sonicated using a cuphorn attachment with ice for 5 min using a Misonix Sonicator 3000 
at 45W (Misonix, Inc., Farmingdale, NY). RV was then was activated in serum-free 
DMEM with 1 μg/ml trypsin (Worthington Biochemical, Lakewood, NJ) at 37°C for 30 
min. The activated virus was added to cells diluted in serum-free DMEM supplemented 
with 1μg/ml trypsin at the specified MOI and rocked at 37°C with 5% CO2 in a 
humidified environment for 1 h. The viral inoculum was removed, cells were washed 
with media to remove unbound virus, and serum-free DMEM was added for the 
remainder of the infection. 
Infected cells expressing shRNA were plated in 24-well flat bottom tissue culture 
plates and were surface biotinylated as described previously (Gibbons et al., 2011). 
Briefly, at 6 hpi, cells were washed with ice-cold PBS-CM (1X PBS supplemented with 
0.1 mM CaCl2 and 1 mM MgCl2) three times to remove unbound extracellular material. 
A solution of 6 mg/ml membrane-impermeable EZ Link® Sulfo-NHS-SS-Biotin 
(Pierce-Thermo) in ice-cold PBS-CM was added to the cells at a 10 mM concentration, 
and was incubated with rocking for 30 min at 4°C. Excess biotin was quenched by 
adding cold DMEM supplemented with 10% FBS for 10 min at 4°C. Cell were lysed 
with SDS-free RIPA lysis buffer containing protease inhibitors and immediately added 
to the cells for 20 min at 4°C. The cell lysates were transferred to sterile microcentrifuge 
tubes, to which 30 μL of streptavidin-agarose slurry (Pierce-Thermo, Rockford, IL) was 
added per 1 ml of lysate. The mixture was incubated with rotation at 4°C for 16 hours. 
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     The biotinylated proteins were collected by pelleting the bound streptavidin-agarose 
at 2500 x g for 5 min. The supernatant was collected and saved for analysis of the 
protein silencing experiments, and the pellet was washed three times in ice-cold SDS-
free RIPA lysis buffer with protease inhibitors. The biotinylated proteins were removed 
from the streptavidin-agarose beads by suspending them in sample reducing buffer 
(Laemmli, 1970) (62.5 mM Tris pH=6.8, 10% glycerol, 2% SDS, 5% 2-
mercaptoethanol, and 0.001% bromophenol blue) and boiling for 10 min. The beads 
were centrifuged for 5 min at 2500 x g, and the sample reducing buffer supernatant 
containing the biotinylated exofacial plasma membrane proteins was collected for 
electrophoretic analysis. To ensure that there was a lack of non-specific binding to the 
streptavidin-agarose beads, un-infected and mock-biotinylated samples were analyzed as 
controls. 
4.2.14 Western Blotting 
Western blotting was used to confirm the extent of silencing of each of the silenced 
proteins and to determine the presence of NSP4 at the plasma membrane. Briefly, the 
samples were dissolved and dissociated in sample reducing buffer, loaded and resolved 
on a 12% or 15% SDS-polyacrylamide gel (NEXT GEL; Amresco). The proteins were 
electroblotted to a 0.45 μM-pore size nitrocellulose membranes (Bio-Rad, Hercules, CA) 
as per the manufacturer’s instructions (Mini-Protean II and Trans-Blot, Bio-rad). The 
nitrocellulose membranes were blocked in 10% (wt/vol) NFDM in PBS for 1 h at room 
temperature. The membranes then were incubated with primary antibodies (rabbit anti-
CyP40, rabbit anti-HSP56 and mouse anti-GAPDH) diluted in 2.5% NFDM in PBS for 3 
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h at 27°C with rocking. The membranes were washed once with PBS, twice with PBS-
Tween-20 (0.5%), and again with PBS. Secondary antibodies (goat anti-rabbit-HRP or 
goat anti-mouse-HRP) were diluted in 2.5% NFDM in PBS, added to the membranes, 
and incubated with rocking for 1 h at 27°C. The membranes were washed as above and 
reacted with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, 
MA) per the manufacturer’s instructions. The protein-specific bands were visualized 
using the ImageQuant LAS 4000 gel imager (GE Healthcare Life Sciences, Pittsburgh, 
PA), and densitometric analyses were performed using ImageJ. 
4.2.15 Densitometry 
Gel images were analyzed via ImageJ using the gel analysis function. Briefly, the 
intensity of each protein band was given a value for the silenced protein and for the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control in the same lane. Each 
band was background subtracted and measured within the linear range. The intensity 
value of the protein band was divided by the intensity value of the GAPDH control band 
to obtain a ratio of the protein amount to protein loading control (GAPDH band 
intensity).  
4.3 Results 
4.3.1 Construction, Growth, and Isolation of the pTripZ Vectors Were Successful 
The pTripZ vectors are very large vectors that do not grow as well as smaller 
vectors. We attempted to grow the vectors in DH5α E. coli cells before we discovered 
the Stbl3 E. coli cell line. This cell line is designed for unstable vectors that are large and 
contain direct repeat sequences such as the long terminal repeats in pTripZ. The 
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competency of our Stbl3 cells was greater than 1 x 107 cfu/ml. Although it was difficult 
to grow the TripZ vector, we were finally successful in growing the Stbl3 cells at 30°C 
instead of 37°C and shaking at 175 rpm rather than 250 rpm (Figure 4.1). The vectors 
containing shRNA were digested with SalI to verify the correct construction (Figure 
4.2).  The restricted DNA sizes should be 7104 bp, 4028 bp, and 2188 bp, so the correct 
vectors were produced. 
To further verify that the inserts were correctly inserted into the vector, we attempted 
to sequence the shRNA insert. Unfortunately, we tried several methods to sequence the 
vectors and were able only to sequence up to the shRNA insert, but not through the 
actual hairpin sequence. We are still attempting to sequence the shRNA to verify the 
correct sequences. However, we continued the planned experiments with the pTripZ-
shRNA vectors. 
 
 
Figure 4.1 TripZ vectors isolated from Stbl3 cells. Six individual colonies were 
expanded in LB media and pTripZ vectors were isolated. The vectors were digested with 
SalI and run on a 2% agarose gel, which should yield three bands at 2188 bp, 4028 bp, 
and 7104 bp. Four of the six vectors were good. 
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4.3.2 Construction of Stable-expressing HEK-293T Cell Lines 
Before transfection of the pTripZ-shRNA constructs, a puromycin kill curve was 
performed in HEK-293T cells. HEK-293T cells were sensitive to puromycin at 5 μg/ml 
and the DMSO control had no effect. All 12 of the pTripZ-shRNA vectors were 
transfected into HEK-293T cells with Lipofectamine 2000. The transfected cells were 
selected for with puromycin and maintained for 14 days in selective media. At 10 days 
post-transfection, cells were treated with 1 μg/ml doxycycline and checked every 2 days 
to determine that the majority of them were expressing the transgene.  
 
 
Figure 4.2 TripZ vectors containing shRNA sequences for CyP40 and HSP56. Three or 
four colonies were picked and expanded for each shRNA insert. The vectors were 
isolated, and digested with SalI. The vector isolated from each colony is named C1, C2, 
and C3 for CyP40 and H1 or H3 for HSP56. No colonies grew for the second HSP56 
shRNA insert. Only the vectors that were digested correctly were used in subsequent 
experiments. 
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4.3.3 Production of Lentivirus Containing the shRNA Insert 
To produce recombinant lentivirus, both the pCMVΔR8.91 and pMD.G vectors were 
transfected into the HEK-293T cell line using Lipofectamine 2000 at a ratio of 1:1.7. 
Virus was collected, cell debris was pelleted and discarded, and the recombinant 
lentivirus was titered in HEK-293T cells. The titers for the lentivirus containing the 
shRNA inserts for CyP40 were between 1.0 x 106-2.4 x 106 transduction units (TU)/ml. 
The titers for the lentivirus containing the shRNA inserts for HSP56 were between 1.0 x 
106-8.0 x 106 TU/ml. The titers for lentivirus expressing shRNA inserts targeting Cav-1 
and CyPA have not been calculated. 
4.3.4 Construction of Stable Transgene-expressing MA104 and HT29.f8 Cell Lines 
Before transduction, a puromycin kill curve was performed on MA104 and HT29.f8 
cells. MA104 cells were sensitive to puromycin at a concentration of 7.5 μg/ml, while 
HT29.f8 cells were sensitive at 10 μg/ml. For consistency, all experiments with the 
TripZ-shRNA vectors were carried out using 7.5 μg/ml puromycin. MA104 and HT29.f8 
cells were plated in 24-well plates and grown until ~85% confluent. Cells were 
transduced at an MOI of 1.0. Six hours after transduction, puromycin and FBS were 
added to the media. DMEM with puromycin was changed every 2-3 days and the cells 
were monitored for growth. HT29.f8 cells did not survive puromycin treatment 
following the transduction of lentiviruses. MA104 cells grew well and were expanded 
under puromycin selection 10 days following transduction. Eventually, stocks of MA104 
cells were frozen down for future use.  
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Transduction was repeated in HT29.f8 cells and the virus inoculum was removed 
before puromycin treatment to reduce toxicity. The HT29.f8 cells survived for 4 days 
under puromycin selection and once again died. The puromycin concentration was 
lowered to 5 μg/ml and the cells still died. Thus, generation of HT29.f8 cell lines that are 
stable transgene-expressing lines was unsuccessful. 
4.3.5 TripZ-shRNA Vectors Containing an Insert That Targets CyP40 Efficiently 
Knocked Down CyP40 in Uninfected MA104 Cells 
MA104 cells expressing the shRNA targeting CyP40-1 or CyP40-2 were induced 
with 1 μg/ml doxycycline. Cells were incubated for 48 h and checked via epi-
fluorescence microscopy to verify transgene expression. Cells were lysed every 24 h for 
4 days to determine the time for the most effective silencing. The cell lysates were 
separated by SDS-PAGE, proteins were transferred to a nitrocellulose membrane, and 
the membranes were blotted with rabbit anti-CyP40 and mouse anti-GAPDH (Figure 
4.3). CyP40 was silenced effectively at 4 days following transgene induction. We 
attempted to measure the HSP56 concentration by Western blot, but due to antibody 
limitations we were unable to detect HSP56.  
4.3.6 NSP4 Continued to Traffic to the Exofacial PM in Cells Expressing shRNA 
Targeting CyP40 and HSP56 
Transduced and doxycycline-treated MA104 cells under puromycin selection and 
expressing shRNA targeting CyP40 and HSP56 were infected with RV at an MOI of 5 
for 6 h. Cells were surface biotinylated, pulled down with streptavidin-agarose, and 
released from the agarose by boiling. Recovered proteins were separated by SDS-PAGE, 
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Figure 4.3 CyP40 expression in MA104 cells expressing shRNA targeting CyP40. 
MA104 cells expressing shRNA targeting CyP40 were induced with doxycycline and 
lysed every 24 h for 98 h. Cell lysates were separated by SDS-PAGE, transferred to a 
nitrocellulose membrane and subjected to Western blot. CyP40 expression is shown with 
GAPDH expression serving as an internal control. 
 
 
 
transferred to a nitrocellulose membrane, and blotted with rabbit anti-NSP4112-140. NSP4 
continued to traffic to the exofacial PM when shRNA targeting CyP40 and HSP56 were 
expressed in MA104 cells (Figure 4.4), corroborating our silencing data. Therefore, 
NSP4 transport is not dependent upon CyP40 or HSP56 expression for transport to the 
PM. 
 
 
Figure 4.4 NSP4 reached the PM in cells expressing shRNA targeting CyP40 or HSP56. 
Stable MA104 cells expressing the shRNA targeting CyP40 or HSP56 were induced 
with doxycycline, or not, and infected with RV, or not. Cells were surface biotinylated, 
proteins were separated via SDS-PAGE, transferred to nitrocellulose, and blotted with 
peptide antibodies targeting NSP4.  
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4.4 Discussion 
Recombinant lentiviruses expressing shRNA have become very useful tools for 
studying cellular processes. There are now many available systems for construction of 
lentiviral vectors to express shRNA, such as the TripZ™ system. The TripZ™ system 
allowed for inducible expression of shRNA targeting Cav-1, CyPA, CyP40, and HSP56, 
so that cells would grow properly and expression could be silenced when ready for 
analysis.  
The construction of this particular system proved to be very difficult due to several 
factors. First, the growth of large vectors that contain long terminal repeats are very 
difficult in many commonly used E. coli strains. There are now strains available, such as 
the Stbl E. coli cell lines through Life Technologies. These cell lines often have their 
drawbacks, but make the production of vectors with LTRs much easier. Second, 
sequencing through a hairpin structure is often difficult. Whether this is due to the 
secondary structure or the sequence depends on the particular hairpin. However, there 
are special methods that can be used to make sequencing easier, such as transferring the 
shRNA segment to a smaller vector that can be sequenced easily. Third, creation of a 
stable cell-line is dependent on the cell line chosen. Some cell lines, such as the cloned 
HT29.f8 cell line tend to be very susceptible to toxicity due to the vectors. We attempted 
to lower toxicity by lowering the puromycin concentration used for selection, but it 
appeared that the recombinant lentivirus itself was toxic to the cells. There are ways to 
reduce the toxicity due to lentivirus transduction, but we found that these methods did 
not work for HT29.f8 cells. 
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We attempted many different methods to obtain a sequence from the TripZ vectors. 
Initially, we used the sequencing primer recommended by the manufacturer. When that 
did not work, we designed our own primers to sequence the shRNA insert. We attempted 
to melt the shRNA structure before addition of the DNA polymerase. We tried designing 
primers that would partially bind to the shRNA structure, thereby keeping it open and 
making it easier to sequence. While we were able to sequence the DNA segment before 
and after the shRNA, we were not able to sequence through the shRNA segment. We 
will continue to attempt sequencing by transferring the shRNA insert from the pTripZ 
vector to a smaller vector, pCR8/GW/TOPO, which should make the inserts much easier 
to sequence. 
Viral vectors expressing shRNA have many advantages over the use of siRNA. The 
major advantage is that viral vectors expressing shRNA can be made in large amounts. 
siRNA must be purchased from a company that specializes in small RNA segment 
production and can be very costly. Viral vectors expressing shRNA can be made 
inducible or not. There are advantages to both systems. A knockout cell line can be 
produced when a non-inducible system is used. If the knockout is toxic to the cell long 
term, the system can be made inducible, so that expression can be turned on and off 
using an antibiotic, such as doxycycline. Silencing RNAs are always transient, and can 
be ineffective if performing long-term studies. A major disadvantage of shRNA-
expressing systems is that they can often be leaky. In inducible systems, shRNA can be 
expressed in the absence of induction, which can affect the outcome of the control cells 
and cause additional toxicity to the stable transgene-expressing cell lines. 
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In this lab, we planned to use the available shRNA-expressing cell lines to continue 
study of the interactions of NSP4 with Cav-1, CyPA, CyP40, and HSP56. However, 
after determining that these proteins may not play an important role in NSP4 transport to 
the PM, the stable shRNA-expressing cell lines may not be necessary for future studies. 
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5. ROTAVIRUSES: EXTRACTION AND ISOLATION OF RNA,
REASSORTANT STRAINS, AND NSP4 PROTEIN 
5.1 Introduction 
Group A rotaviruses (RVs) are readily and efficiently replicated in mammalian tissue 
culture as described in Basic Protocol 1 Unit 15C.3.  To further investigate these viruses, 
utilization of a variety of additional techniques is necessary. RV easily recombines upon 
co-infection of two or more strains, which becomes more prevalent as multiple strains 
are introduced in close proximity. Recombinant forms of RV function differently than 
the parental strain depending on which of the segments are swapped. To evaluate the 
recombinants and to sequence multiple viral strains, the isolation of viral RNA is critical. 
Viral RNAs reside within the inner-layer of the triple-layered virus particle, making it 
easier to isolate viral RNA in the absence of cellular mRNA. Once the viral RNA is 
isolated, electrophoretic typing will elucidate the electrophoretic pattern of the RNA 
genome, hence the virus strain. 
The RV enterotoxin, NSP4, is a nonstructural, multi-function viral glycoprotein that 
contributes to RV replication, morphogenesis and pathogenesis. NSP4 elicits diarrhea in 
the absence of virus in a murine model and is thought to be responsible for the early 
stages of diarrhea following infection with RV in mammals. Recent data reveal NSP4 
associates with autophagosomes before transport to the plasma membrane (PM) for  
*Reprinted with permission from “Rotaviruses: Extraction and isolation of RNA,
reassortant strains, and NSP4 protein” by Yakshe, K.A., Franklin, Z.D., and Ball, J.M., 
2015. Curr. Protoc. Microbiol, 37, 15C.6.1-15C.6.44., Copyright 2015 by Wiley.  
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secretion from the cell. NSP4 has been the focus of investigation for many years despite 
its many unique properties that frequently complicate these studies.  The isolated protein 
has a strong tendency to oligomerize, forming dimers, trimers and up to octamers.  
Isolation for detailed studies of NSP4 is essential to dissect the many parameters of 
NSP4’s multiple activities.  Several manuscripts note that there appears to be distinct 
pools of NSP4 within the cell with diverse functions. It is not surprising that multiple 
NSP4 isolation techniques have been reported.  
This unit covers techniques that are helpful for the study of rotavirus and NSP4. 
Generation of reassortant viruses (Basic Protocol 1) is important for studying the viral 
lifecycle and viral pathogenesis. Extraction (Basic Protocol 2, Alternate Protocol 1, 
Alternate Protocol 3) and analysis of viral RNAs via polyacrylamide gel electrophoresis 
(Basic Protocol 2) are essential for electrophoretic typing of the parental and reassortant 
virus strains. The expression and purification of NSP4 from the media of infected 
mammalian (Basic Protocol 3) and the lysates of recombinant baculovirus-infected Sf9 
insect cells (Alternate Protocol 3, Supporting Protocol 1, Basic Protocol 4) are described.  
5.2 Basic Protocol 1: Generation of Reassortant Rotavirus Strains from Parental  
 
Rotavirus Strains  
 
The segmented genome of rotavirus facilitates the generation of recombinant strains 
post infection. These newly formed reassortants may impact the virulence and host 
specificity of the infecting parental virus. To investigate the effect(s) on progeny RV and 
to determine the frequency of recombination, reassortants are generated in culture. Data 
collected on these viral recombinants are useful for detailed analyses of changes in 
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virulence, pathogenicity, and host specificity. In addition, reassortants can be used to 
model vaccines that are safe and efficacious. To generate the reassortants, the parental 
strains must be plaque purified and expanded for the co-infections. Two or more virus 
strains are mixed at a pre-determined multiplicity of infection (MOI) and then allowed to 
replicate in cell culture before additional plaque purification. 
5.2.1 Solutions and Specific Equipment 
 
Plaque-purified parental RV strains with known concentration based on plaque forming 
units (PFU) 
Minimum Essential Medium (MEM), 1X or 2X, supplemented with L-glutamine, non-
essential amino acids (NEAA), Sodium Pyruvate, Pen-Strep or equivalent (see 
recipe) 
MA104 cells (ATCC #CRL-2378™) 
Worthington trypsin (1 mg/ml) 
Low-melt agarose (It is recommended that you use SeaPlaque™ (Lonza) or GenePure 
(ISC BioExpress)) 
Sterile Serological Pipettes 
Sterile flint glass Pasteur pipettes 
Suction bulb 
6-well tissue culture plates with lids 
Autoclaved dH20 
Pancreatin 
Neutral Red Solution (see recipe) 
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15 ml polypropylene conical tubes 
Platform rocker 
-70°C Freezer 
Inverted light microscope 
37°C water bath 
Additional reagents and equipment for this procedure are included in  
 
Basic Protocol 3 Unit 15C.3.  
 
5.2.2 Steps and Annotations 
 
This protocol should be used in conjunction with Basic Protocol 1 and 
Basic Protocol 3 in Unit 15C.3. However the protocol below requires the 
use of two or more viruses, instead of one, and 6-well plates for co-
infections, instead of flasks. 
1. Plate MA104 cells in a 6-well plate at 3.0 × 105 cells per well with supplemented  
 
MEM containing 10% FBS. 
 
2. Incubate for 3 to 5 days or until 100% confluent. 
 
3. Calculate the amount of RV needed to infect at a MOI of 5 for each virus using the 
formula: No. cells × MOI = PFU needed. 
A six well plate generally supports 1.2x 106 cells in each well so 6.0 x 106 
(MOI 5) viral particles of each virus usually is sufficient (total virus 
particles per well is 1.2x107).  
4. Thaw the RV strains on ice. 
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5. Individually activate the viruses by adding 10 µl of a 1 mg/ml solution of 
Worthington trypsin per 1 ml of virus (final concentration of 10 µg/ml) and 
incubating for 1 h in a 37.5°C water bath to for allow for cleavage of the outer spike 
protein, VP4.  
Basic Protocol 1 UNIT 15C.3 uses porcine pancreatic type IX trypsin, but 
we find the Worthington trypsin more reliable. The amount of virus 
activated will depend on the amount needed to formulate a MOI of 5 for 
each viral strain (MOI 10 total for 2 viruses).  
6. Prepare the activated, plaque purified RV strains of choice in media without fetal 
bovine sera (FBS) by mixing the strains to yield a MOI of 5 each in a 15 ml conical 
tube. You will need at least 1 ml of media with virus to cover the cells in one well of 
a 6-well plate. Vortex well.  
Each individual strain can be activated in a separate tube and combined 
before addition to the cells. 
7. Wash the confluent MA104 cells in the 6-well plate twice with 2 ml/well of 
phosphate buffered saline (PBS) or serum free medium.  
In order to remove residual FBS, which can inhibit the activation of RV, 
the wells are rinsed. One change of serum free medium can also be 
incubated for several hours to ensure the removal of FBS.  
8. Carefully remove the serum-free MEM or PBS from the cell monolayer. Add at least 
1 ml of the diluted virus solution to each well of the MA104 cells. Incubate with 
gentle rocking at 37°C for 1 h for virus adsorption.  
 97 
9. Remove the virus inoculum and wash the cells once with 2 ml of pre-warmed PBS or 
serum-free MEM. 
10. Add 2 ml of pre-warmed serum-free MEM and allow the viruses to replicate for 72 
hours post infection or until 90% CPE. 
11. Freeze-thaw plates containing infected cells 3 times at -70 °C.  
 
12. Transfer the virus-containing media to 15 ml conical tubes. 
13. Sonicate in a cuphorn sonicator in an ice bath at 45 W for 5 min. 
The cell culture supernatant is sonicated on ice to break up membranes 
and release the virus particles. RV is known to be cell-associated. 
14. Clarify the supernatant containing RV to remove cellular debris by low-speed 
centrifugation at 300 x g for 10 min. Transfer the virus-enriched cell supernatant to 
another tube. 
15. Perform the plaque assay using the protocol described in Basic Protocol 3 Unit 
15C.3   
The individual reassortant viruses are isolated by 3 sequential plaque 
purifications. Each reassortant generally has distinct plaque morphology.  
RNA electrophoretic analyses of the plaques will ensure individual 
plaques contain discrete recombinants.  
16. Isolate the plaques using a Pasteur pipette with a bulb attached. The Pasteur pipet tip 
is gently pushed through the agarose overlay and the plaque is aspirated into a test 
tube as described in Basic Protocol 3 Unit 15C.3.  
17. Repeat the plaque purification 3 times (see Basic Protocol 3 Unit 15C.3).  
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18. Expand the plaque-purified RV strains in roller bottles or flasks (see Basic protocol 3 
and Alternate Protocol 1 Unit 15C.3), aliquot and store at -80°C. 
19. To verify the purity of the reassortant virus, the RNA is extracted and analyzed via 
sequencing and/or by PAGE with Silver Staining (under electrophoretic typing 
protocol, Basic Protocol 2). 
Note: It is important to run the parental strains and MW markers 
alongside the potential reassortants to allow for comparison.  
5.3 Basic Protocol 2: Phenol-Chloroform Extraction of RNA for Electrophoretic  
 
Typing of Rotavirus dsRNA Segments  
 
Electrophoretic typing is used as a diagnostic tool for the detection of RNA segments 
of the parental and recombinant strains. Viral RNA is extracted from RV grown in cell 
culture or collected from stool samples and classified into either group A, B, or C 
depending on its electrophoretic profile.  
Group A mammalian rotaviruses are composed of a (L) long or short electrophoretic 
profile depending on the length of gene segment 11. Gene segment 11 encodes for two 
proteins, non-structural protein-5 (NSP5) and non-structural protein-6 (NSP6). The short 
pattern is due to a larger gene segment 11 encoding a larger NSP5, resulting in slower 
migration. The large gene segment runs between segments 9 and 10 rather than after 
segments 9 and 10. There also are reports of super short profiles.  
When the 11 segments are separated on a polyacrylamide gel, there is a tendency for 
the RV RNA segments to group together dependent on their origin (Group A, Group B, 
or Group C rotavirus). The electrophoretic separation pattern of the RV dsRNA 
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segments will assign the virus into the proper group based on the RNA migration 
pattern. The dsRNA of Group A mammalian rotaviruses have four size classes: 4 large 
segments (more than 2000 base pairs), 2 medium-sized segments (above 1000 base 
pairs), 3 small segments (900-1000 base pairs), and 2 smallest segments (less than 900 
base pairs) for a 4-2-3-2 pattern (Table 5.1). 
 
 
Table 5.1.  Rotavirus Group RNA Segment Patterns 
Rotavirus strain RNA segments RNA pattern 
designation 
Mammalian Group A  4 large, 2 medium, 3 small, 2 smallest 4-2-3-2 
Avian Group A 5 large, 1 medium, 3 small, 2 smallest 5-1-3-2 
Rotavirus Group B 4 large, 2 medium, 1 small, 1 smallest 4-2-1-1 
Rotavirus Group C 4 large, 3 medium, 2 small, 2 smallest 4-3-2-2 
Avian Group D 5 large, 2 medium, 2 small, 2 smallest 5-2-2-2 
 
 
 
Viral RNA Extraction is best performed using purified virus, so that there is no 
contaminating cellular RNA. The two methods described herein are (1) phenol-
chloroform extraction for isolation of viral RNA from fecal samples in Basic Protocol 2 
and (2) TRIzol® extraction for isolation of viral RNA from cell-culture supernatants, as 
described in Alternate Protocol 1. 
5.3.1 Solutions and Specific Equipment 
 
Fecal samples 
0.1% sodium acetate buffer (pH 5) (see recipe) 
1% (w/v) sodium dodecyl sulfate (SDS) 
Phenol mixture (see recipe) 
Chloroform 
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1.5 ml microcentrifuge tubes 
Benchtop microcentrifuge 
5.3.2 Steps and Annotations 
1. Dilute the fecal sample 1:4 by weight with 0.1 M sodium acetate buffer (pH 5) 
containing 1% (wt/vol) SDS. 
0.25 g of feces will extract enough RNA for 10 separate electrophoretic 
analyses. 
2. Add an equal volume of a 3:2 (v/v) phenol:chloroform mixture and vortex for 1 min. 
 
3. Centrifuge at 1,200 x g for 10 min.  
 
4. Remove the upper aqueous layer containing the viral RNA. 
If the aqueous layer is absent, centrifuge again for 3 min at 16,000 x g in 
a microcentrifuge or add 0.5 ml of 0.1 M sodium acetate buffer, mix and 
centrifuge for 12,000 x g for 10 min.  
5. Aliquot the aqueous layer into 0.6 ml microcentrifuge tubes and store at -70 °C until 
ready for further analysis. 
5.4 Alternate Protocol 1: Extraction of Rotavirus RNA from Cultured Cells Using 
TRIzol® 
TRIzol® can be used to isolate rotavirus RNA from cultured cells by 
modifying the protocol reported in the World Health Organization (WHO) 
manual (Organization, 2009). Instead of using a stool suspension, RV-infected 
cell-culture supernatant is utilized. 
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5.4.1 Solutions and Specific Equipment 
 
TRIzol® (Life Technologies) 
Chloroform 
Isopropyl alcohol 
Molecular-biology-grade water 
Pipettors  
Screw-cap microcentrifuge tubes 
Filtered pipette tips  
Vortexer 
Benchtop microcentrifuge 
Sonicator with a cuphorn attachment, ice bath sonicator, (Misonix sonicator 300; 
Misonix Inc. Farmingdale, NY) or equivalent 
5.4.2 Steps and Annotations 
 
1. Incubate the RV-infected MA104 cells grown in T-75 or T-25 flasks until the 
monolayer is at least 90% disrupted due to CPE.  
2. Freeze and thaw the flask(s) containing the RV-rich cell lysates 3 times at -70°C and 
room temperature, respectively.  
3. Transfer the thawed supernatant to a sterile 50 ml conical tube and sonicate at 45 W 
for 5 minutes using a cuphorn attachment, ice bath sonicator.  
4. Remove the cellular debris by high-speed centrifugation at 8,000 x g for 30 min. 
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5. Transfer 250 μl of the clarified cell culture supernatant to a sterile 1.5-ml 
microcentrifuge tube, and add 750 μl of TRIzol®. Vortex the tube for 30 sec to 
thoroughly mix, and incubate at room temperature for 5 min. 
6. Add 200 μl of chloroform to the sample and vortex for 30 sec. Incubate the sample at 
room temperature for 3 min.  
7. Centrifuge the samples at 9,300 x g for 5 min at 4°C or room temperature to separate 
the phases. 
8. Carefully transfer the upper aqueous phase into a sterile microcentrifuge tube.  
 
It is important to avoid the white interface and pink/clear organic phase.  
 
9. Add 2 volumes (approximately 700 μl) of ice cold isopropyl alcohol. Mix gently by 
inverting the tube 4-6 times and incubate at -20°C for 20 min. 
10. Centrifuge at 9,300 x g at 4°C for 15 min to pellet the dsRNA. Discard the 
supernatant immediately. Carefully air dry the pellets for 10-15 min at room 
temperature. 
11. Resuspend the dried pellet in 20 μL of sterile deionized water.  The volume of water 
can be reduced to 15 μL. 
12. Store the sample at -20°C until ready for analysis. 
5.5 Alternate Protocol 2: Extraction of Rotavirus RNA from Cell Culture 
Supernatant Using QIAamp Viral RNA Mini Kit  
RNA can be isolated directly from cell culture supernatants using the QIAamp Viral 
RNA Mini kit. Although the kit is more costly than other RNA extraction methods, it is 
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fast, easy, and provides high quality and pure viral RNA. The manufacturer’s protocol 
should be followed for RV RNA extraction. The protocol briefly is described below. 
5.5.1 Solutions and Specific Equipment 
 
QIAamp Viral RNA Mini kit (Qiagen, cat # 52904) 
Ethanol (96-100%) 
1.5 ml microcentrifuge tubes 
Sterile, RNase-free pipet tips (aerosol barriers to prevent cross contamination are 
recommended) 
Benchtop Microcentrifuge capable of cooling to 4 °C. 
 Alternatively, the centrifuge may be placed in a refrigerated space. 
 
5.5.2 Steps and Annotations 
 
1. Infect the cells with RV and harvest as described in Alternate Protocol 1, steps 1-
4 
 
2. Follow the manufacturer’s protocol for the remainder of the RNA extraction. 
 
If the virus titer is low, you can double the amount of the cleared supernatant 
(280 μl instead of 140 μl) for a higher concentration of recovered RNA. 
5.6 Basic Protocol 3: Polyacrylamide Gel Electrophoresis (PAGE) for Electrotyping 
Rotavirus Strains  
RNA is best visualized using PAGE and silver staining. This section explains the setup 
and separation of the RNA samples on a polyacrylamide gel and subsequent staining of 
the gel for identification of the RNA segments. This protocol also explains how to prepare 
a 7.5% acrylamide gel for the best separation of RNA fragments. A higher percentage of 
acrylamide can be used but will show different migration patterns.  
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5.6.1 Solutions and Specific Equipment 
 
30% acrylamide stock (see recipe) 
Resolving gel buffer (see recipe) 
Stacking gel buffer (see recipe) 
10% ammonium persulfate (APS) 
Tris-glycine running buffer (see recipe) 
Mini-PROTEAN gel setup (BioRad) or equivalent 
PAGE sample loading buffer (see recipe) 
Silver Stain Kit (Thermo Scientific Pierce) (Cat #24612) 
95% Ethanol  
Acetic Acid 
Small glass dish to fit the gel 
Larger glass dish to fit the cellophane for gel drying 
Cellophane 
Gel drying frames 
Binder clips 
 
5.6.2 Steps and Annotations 
 
1. Degas all solutions for at least 15 min. 
 
2. Thoroughly clean the 0.75 mm mini-gel glass plates so they are free of dust, residue 
or fingerprints and assemble them in the casting apparatus.  
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The gel will leak if the glass plates are uneven or if the bottom is not 
sealed properly.  A piece of Parafilm M® at the bottom of the plates can 
be helpful if the gel leaks. 
3. Add the comb. Make a mark on the plate 1 cm below the teeth of the comb 
and then remove the comb.  
4. To prepare two mini gels, add the following reagents to a 25 ml Erlenmeyer flask: 
3.75 ml of 30% acrylamide/bis-acrylamide (29:1) mixture, 3.75 ml of resolving gel 
buffer, 7.43 ml of dH20, and 75 μl of freshly made 10% APS.  Mix well with a 
serological pipette before adding 14 μl of TEMED.  
Caution must be taken when working with acrylamide.  Gloves must be 
worn and if working with the powder form, a face mask is required. 
Acrylamide is a known neurotoxin. 
Some scientists recommend that additional degassing of the acrylamide 
solutions improve the clarity of the gel. 
5. Quickly mix the resolving gel solution and dispense between the glass plates up to 
the mark made in Step 3 (approximately 3.30 ml). 
6. Fill the remainder of the plates with sterile dH2O and allow the gel to solidify for 45-
60 min.  
7. Pour off the dH20 and dry the inside of the glass plates by blotting with a thin piece 
of absorbent filter paper to remove all water. Be careful not to touch the resolving 
gel with the filter paper. 
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8. In a 25 ml Erlenmeyer flask add 0.99 ml of 30% acrylamide/bis-acrylamide, 1.89 ml 
stacking buffer, 4.58 ml of dH20, 75 μl of  freshly made 10% APS. Mix the solution 
well pipetting up and down gently so that there are no bubbles formed. 
See caution above concerning acrylamide (step 4). 
 
9. Add 3.75 μl of TEMED and mix well with a pipette. Fill the glass plates to the top 
with the acrylamide solution. 
10. Add the comb to the newly added stacking gel solution and allow the gel to solidify 
for 45-60 min. 
The combs can vary in the number of teeth depending on the number and volume 
of the samples. 
11. Remove the comb and rinse the individual wells with running buffer. 
 
This can be accomplished using a syringe and 21-gauge needle or 
Hamilton syringe. 
12. Assemble the gel running apparatus per manufacturer’s instructions. 
 
13. Add the tris-glycine running buffer to the fill line of the gel tank and remove any air 
bubbles from the wells. 
14. Load the gel with the samples: 
 
a. Add the sample-loading buffer 1 to 1 (v/v) with the sample.  
 
b. For the marker lane, load 3-5 μl of marker, which is sufficient for most 
commercial, pre-stained markers.  If the marker is not pre-stained, QS to10 μl 
with dH2O and add sample-loading buffer 1:1 (i.e., add 3 μl marker and 7 μl 
dH20 for a total of 10 μl and mix with 10 μl of sample loading buffer).  
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All RNA samples should be thawed on ice and should remain in the -70°C freezer 
until needed. The amount of sample will depend on the size of the comb. A 20 μl 
volume will fit into a 10 well comb for a 0.75 mm mini gel.  
15.  Run mini gels at 150 V for 2 h. 
Note: Large and mid-sized gels should be run at 100 V for 16-20 h. 
 
Some equine RV strains have a different migration pattern for VP4 if run 
on an alternate % of acrylamide gel.  
16. When the gel stops running, add 1 cm of dH2O to a small dish. 
 
17. Take the plates out of the gel running apparatus and slowly wedge a plate separator 
between the glass plates at the top corner. Once the plates start to separate add a 
continuous amount of light force until the suction is released. 
Forcing the plate separator between the glass plates quickly and hard will cause 
the glass to break. 
18. Remove the stacking gel and add a small notch to one of the top corners of the gel to 
mark gel orientation.  
The gel is thin, delicate, and tears very easy. Take care not to pull too quickly 
when removing it from the glass plate. 
19. Release the sides of the gel by slowly running the plate separator down the left and 
right sides of the plate. 
20. Lift one corner of the gel and turn it upside down above the small plate with dH2O. 
Slowly peel the gel off and allow it to fall gently into the dish. 
21. Follow the manufacturer’s protocol for the silver staining process. 
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22. After the gel has been stained, developed, and stopped using the silver staining kit, 
rinse the gel in dH2O for 5 min, 2 times, with rocking. 
Note: At this step, the gel can be imaged using a gel imaging system, or by taking a 
digital photograph before drying. 
23. For drying, cut two pieces of cellophane to fit the gel-drying frames. 
 
24. Place 1 inch of dH2O in a large dish (large enough to fit the cellophane pieces) 
 
25. Wet the first piece of cellophane with dH2O and place it onto the back of the drying 
frame. Be sure to remove all air bubbles. This can be done by pressing one corner of 
the cellophane to the frame and working from one side to the other. 
If a bubble appears, pull the cellophane back from one corner to release the 
bubble. Gently rolling a test tube on the cellophane also may remove the bubbles. 
26. Add the gel to center of the frame removing any air bubbles. 
 
27. Wet the second piece of cellophane with dH2O and add the cellophane over the top 
of the gel to create a cellophane sandwich with the gel in the middle. Remove any air 
bubbles to prevent cracking while drying. If necessary, remove top cellophane layer 
and add more water to remove all air bubbles. 
28. Place the top layer of the frame over the top cellophane layer. 
 
Be sure that the frame is touching only the cellophane and not smashing the gel. 
 
29. Clamp all four sides of the frame and set it at an angle to dry for at least 24 h. 
 
The gel can be viewed while drying. 
 
Note: Alternatively, a gel dryer (BioRad) can be used to facilitate faster gel 
drying (2-3 h). 
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30. Take the dried gel out of the drying frame and place it under pressure with a heavy
object such as a textbook.
31. Use a ruler to visualize the migration pattern and compare the parental strains to the
reassortant strains. See Figure 1.
5.7 Basic Protocol 4: Purification of Rotavirus NSP4 from the Media of Cultured 
Mammalian Cells  
RV expresses a unique nonstructural glycoprotein, NSP4, which functions as an 
enterotoxin, eliciting a secretory diarrhea from enterocytes, even in the absence of virus 
(Ball et al., 1996). When NSP4 is extracellularly added to cultured cells or mouse pup 
unstripped intestinal mucosa, it initiates the influx of Ca2+ into the cytoplasm of the cells 
by a phospholipase C-dependent mechanism ((Tian, 1995). Recently NSP4 has been 
shown to function as a viroporin when expressed intracellularly. The viroporin 
stimulates the release of Ca2+ from the endoplasmic reticulum by activating 
calcium/calmodulin-dependent kinase kinase-β (CaMKK-β) and initiates autophagy 
(Crawford et al., 2012; Hyser et al., 2010). Purified NSP4 is a vital reagent for many 
studies as NSP4 plays an integral part of the viral life cycle and initiates fluid loss or 
diarrhea. This protocol describes the isolation of NSP4 from the media of RV-infected 
mammalian cells (Didsbury et al., 2011) employing ConA affinity chromatography, 
followed by separation on a Mono S 5/50 GL FPLC column, and NSP4 IgG affinity 
chromatography.  
An abundance of NSP4 is expressed in the media of Caco-2 cells, whereas MA104 
cells express less NSP4 in the media. The amount of NSP4 produced in the media is also 
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RV strain dependent. Thus the combination of cells and viral strain should carefully be 
considered.  
5.7.1 Solutions and Specific Equipment 
Caco-2 cells (ATCC® #HTB-37™) or MA104 cells (ATCC® #CRL-2378.1™) 
Rotavirus strain of choice  
Tissue Culture Flasks 
Minimum Essential Media, supplemented, with 10% fetal bovine serum (see recipe)  
Minimum Essential Media, supplemented, without 10% fetal bovine serum (see recipe) 
Phosphate Buffered Saline (PBS; see recipe) 
1 mg/ml Trypsin (Worthington #TRL3; see recipe) 
Ultra-Centrifugal Filter with 10kD cut off (Amicon #UFC901008 or equivalent) 
Glass Econo-Column® (Bio-Rad) or equivalent 
Econo-Column® flow adaptor (Bio-Rad) or equivalent 
Concanavalin A Sepharose™ 4B (GE Healthcare #71-7077-00 AG) 
Con A Binding Buffer (see recipe) 
Con A Elution Buffer (see recipe) 
HPLC or FPLC 
Mono S 5/50 GL column for FPLC (GE Healthcare Life Sciences #17-5168-01) 
Mono S Start Buffer (see recipe) 
Mono S Elution Buffer (see recipe) 
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5.7.2 Steps and Annotations 
5.7.2a Expression of NSP4 in Media of RV-infected Mammalian Cells 
1. In a T-160 flask, grow a monolayer of Caco-2 or MA104 cells until ~95% confluent 
in supplemented MEM with 10% FBS. 
2. Infect the cell monolayer (Basic Protocol 1, Unit 15C.3) using a high MOI of RV (10 
pfu/cell).  
3. At approximately 36 hours post infection (or other optimized time, dependent on the 
virus strain) collect the media from the cell monolayer.  
4. Clarify the media of cellular contaminants by high-speed centrifugation at 8,000 x g 
for 30 min. 
5. Ultracentrifuge the clarified media at 100,000 x g for 1 h to remove virus particles 
and other cellular debris from the media. Collect and save the supernatant without 
disturbing the pellet. 
6. Add the supernatant to an Amicon Ultra Centrifugal Filter with a 10 kD cutoff and 
centrifuge according to the manufacturer’s instructions.  
a. Pre-rinse the filter with 0.1 N NaOH followed by Milli-Q water to remove any 
interfering contaminants. 
b. Add up to 15 ml of sample if using a swinging bucket rotor or 12 ml of sample if 
using a fixed angle rotor. 
c. Centrifuge at 4,000 x g for 60 min in a swinging bucket rotor or 5,000 x g for 60 
min in a fixed angle rotor to concentrate the sample.   
d. Desalt if desired by adding solvent and repeating step c. 
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e. Collect the concentrated sample from the inside of the filter unit using a small-
tipped pipette and store at -80°C. 
5.7.2b ConA Affinity Chromatography 
7. Prepare the Concanavalin A Sepharose 4B (GE Healthcare) column and equilibrate 
according to the manufacturer’s instructions: 
Con A is known to bind α-D-mannopyranosyl, α-D-glucopyranosyl and 
sterically related residues and is frequently utilized in separation of 
glycoproteins. Note that columns can be purchased pre-packed. 
a. Bring the sepharose to room temperature and degas the slurry. 
Con A sepharose 4B is provided as a slurry in 0.1 M acetate buffer, pH 6, 
with essential sodium and magnesium salts, and 20% ethanol as a 
preservative.  
b. Remove the preservative by washing with about 10 bed volumes of binding 
buffer. 
The ligand density is 10 – 16 mg/ml of drained slurry, which can be utilized 
to determine the amount of slurry to use. 
c. Prepare the slurry at a ratio of 25% buffer to 75% settled sepharose. 
 
d. Allow the sample, buffers and slurry to equilibrate to room temperature and 
degas. 
e. Flush the end pieces and column with binding buffer to remove any trapped air 
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f. Pour the sepharose slurry into the column in one movement being careful not to 
introduce air bubbles, and then fill the column to the top with ConA Binding 
Buffer. 
g. Add the column top piece  
 
h. Connect a reservoir of ConA Binding Buffer to a peristaltic pump and fit to the 
column top piece 
i. Pack the slurry until a constant bed height is obtained. Open the outlet, pump 
the buffer at maximum flow rate, and leave 1 cm of buffer above the packed 
bed. (You will only use 75% speed during chromatography). 
To determine the flow rate the following formula is utilized: linear flow rate 
= volumetric flow rate (cm3/h) / column cross-sectional area (cm2). 
j. Maintain the maximum flow rate for 3 column volumes after the constant bed 
height is reached. 
k. Adjust adapter so that the O-ring sits against the column wall, but does not 
compress the beads. 
l.    Purge the flow adaptor with equilibration buffer to remove all air bubbles 
before attaching to the column. 
m.  Latch the flow adaptor onto the column and insert the flow adaptor into the 
column until it touches the buffer. 
n. Push the cam latch all the way down to the column bed and turn it slightly 
counterclockwise to lock it in place. 
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o. Run 3 column volumes of ConA Binding Buffer through the column after 
packing 
p. Mix the sample with ConA Binding Buffer and overlay onto column. 
q. Allow the sample to run through the column at a reduced flow rate and save all 
of the eluent. 
r. Elute with a gradient (linear or step) of elution buffer (see recipe).  Use a 
fraction collector to collect each fraction. 
Many glycoproteins elute at 0.1 – 0.2 M α-D-methylmannoside or α-D-
methyl-l glucoside, however higher concentrations may be necessary.  A 
lower pH also may contribute to elution of the glycoprotein, but do not go 
below pH 4 
An alternative elution buffer is 0.1 M borate buffer, pH 6.5, which forms 
complexes with the cis-diols of the sugar residues and consequently functions 
as a competing eluate. 
s. Repeat steps j through l for 3-5 times. Check final flow through for antigen 
using dot blot. 
t. Regenerate the column for re-use as recommended by the manufacturer and 
store at 4°C in 0.1 M acetate buffer, pH 6, with 1 mM sodium, calcium, 
manganese and magnesium salts.  Add 20% ethanol as a preservative. 
5.7.2c Mono S 5/50 GL Anion Exchange Chromatography 
 
8. After  elution of NSP4 from the ConA affinity column, continue the purification on a   
commercially acquired Mono S 5/50 GL cation exchange column for FPLC: 
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a. Exchange the buffer of the sample from step 7s to 20 mM MES, pH 6 (Mono S 
start buffer). 
i. Amicon Ultra Centrifugal Filter with a 10 kD cutoff and centrifuge 
according to the manufacturer’s instructions.  
ii. Pre-rinse the filter with 0.1 N NaOH followed by Milli-Q water to 
remove any interfering contaminants. 
iii. Add up to 15 ml of sample if using a swinging bucket rotor or 12 ml 
of sample if using a fixed angle rotor. 
iv. Centrifuge at 4,000 x g for 60 min in a swinging bucket rotor or 5,000 
x g for 60 min in a fixed angle rotor to concentrate the sample.   
v. Add the MES solvent and repeat step iv. 
 
vi. Collect the concentrated sample from the inside of the filter unit using 
a small-tipped pipette and store at -80°C. 
vii. For use, dilute the sample in 20 mM MES, pH 6 (Mono S start 
buffer). 
b. Equilibrate the Mono S 5/50 GL column according to Table 5.2: 
 
 
 
            Table 5.2. Mono S 5/50 GL Column Flow Rate 
Volume (ml) Flow Rate 
(ml/min) 
Buffers (see recipe) 
5 1 Milli-Q dH2O 
5 2 Start Buffer 
5 2 Elution Buffer 
5 2 Start Buffer 
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c. Once the column is equilibrated, set the flow rate to 1 ml/min and load the 
sample onto the column in Mono S start buffer. 
d. Wash the column with 5 – 10 column volumes of Mono S start buffer to 
remove unbound material. 
e. To elute, use a gradient of NaCl up to 0.5 M. Collect 1.0 ml fractions using a 
fraction collector while monitoring the UV absorbance to visualize the protein 
peaks. 
f. Once the sample is eluted, wash the column with 2 – 5 column volumes of 1 M 
NaCl. 
g. Flush the column with Milli-Q water and store in Milli-Q water with 0.2% 
sodium azide at 4°C. 
Sodium azide is a known mutagen, and can be explosive and toxic when in 
contact with certain metals and acids. Take precaution when working with 
sodium azide by wearing the proper personal protective equipment. 
9. Verify the purity of the protein corresponding to the UV peaks by running a small 
fraction of the eluate on a 15% SDS polyacrylamide gel (see Appendix 3M) and 
visualize by silver staining (see Basic Protocol 3, Step 21) or Coomassie Blue 
staining (see Appendix 3M). Pool the NSP4-rich samples and verify that the protein 
is RV NSP4 by SDS-PAGE and immunoblotting (see Unit 14E.1, Basic Protocol 6). 
NSP4 can be difficult to transfer for immunoblotting. From the lab’s 
experience, it has been shown that the best way to transfer NSP4 is to use a 
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0.45 um nitrocellulose membrane with tris-glycine transfer buffer containing 
20% methanol at 200 mA for 2 h at 4°C. 
10. Store the enriched NSP4 by preparing small aliquots of the sample and freeze at -
80°C.  It is critical to avoid freeze-thaw of the protein sample. Alternatively the 
sample can be dialyzed and lyophilized (see Support Protocol 1, steps 21 and 22). 
5.8 Alternate Protocol 3: Production of NSP4 in SF9 Cells Using a Recombinant 
Baculovirus 
NSP4 can be expressed by generating a recombinant baculovirus expressing NSP4 
and subsequently infecting Sf9 cells.  The protein is collected from the infected Sf9 cell 
lysates. The use of insect cells for glycoprotein production is preferred over the use of 
bacterial cells because of the glycosylation of NSP4 at residues 8 and 18 and the 
potential endotoxin contaminants associated with bacterial cultures (Adapted from 
Dong, et al. 1997).  
Sf9 cells are incubated at 27°C and require no CO2. To produce large 
quantities of NSP4, it is beneficial to use spinner cultures with increased 
volumes and aeration, rather than attached cultures. 
5.8.1 Solutions and Specific Equipment 
Spodoptera frugiperda 9 (Sf9) cells (ATCC® #CRL-1711™) 
6-well tissue culture plates 
Baculovirus pAC461-G10 plasmid expressing gene 10 of RV (Tian et al., 1996) or 
equivalent 
Hink’s Medium, unsupplemented 
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Hink’s Medium, supplemented, with 10% fetal bovine serum (see recipe) 
Fetal Bovine Serum (FBS) 
100X Penicillin-Streptomycin-Amphotericin B (Lonza, #17745) 
Cellfectin II reagent (Life Technologies #10362-100) 
Sterile Milli-Q water 
Beckman Ultracentrifuge with SW-28 rotor or equivalent 
Beckman Ultracentrifuge 25x89mm Ultra-Clear open top tubes that can hold up to 38ml, 
or equivalent 
Sucrose solutions (see recipes) 
SeaPlaque™ Agarose (Lonza #50101) 
FPLC (Waters or equivalent) that generates a binary gradient. 
Neutral Red Solution (see recipe) 
Spinner flasks 
Trypan Blue in PBS 
Hemocytometer 
Sterile 50 ml conical tubes 
Low-Speed Centrifuge 
27°C incubator; no CO2 required 
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5.8.2 Steps and Annotations 
5.8.2a Bacmid Transfection and Baculovirus Production 
1. Obtain or construct a bacmid plasmid as described by Tian, et al., 1995 or by 
inserting the NSP4 gene (RV gene 10) with the help of a system such as the Bac 
to Bac or BaculoDirect™ systems (Invitrogen).  
2. Seed the Sf9 cells in a 35-mm plate at a density of 8 x 105 cells/well in Hink’s 
media, supplemented and allow the cells to attach at 27°C for a minimum of 1 h. 
NOTE: The media should be free of antibiotics, as antibiotics negatively 
impact the transfection efficiency. 
3. Transfect the bacmid into plated Sf9 cells using Cellfectin II reagent according to 
the manufacturer’s protocol:  
a. Mix 8 of μl Cellfectin reagent with 100 μl Hink’s medium (no FBS) and 
vortex. 
b. Dilute 2 µg bacmid DNA in 100 μl Hink’s medium  
c. Gently mix the diluted Cellfectin II with the bacmid DNA, and incubate 
for 15-30 min at room temperature. 
d. Carefully add the mixture dropwise to the plated Sf9 cells and incubate 
for 3-5 h at 27°C. 
e. Remove the transfection mixture and replace with supplemented Hink’s 
medium with 10% FBS. 
4. Incubate the transfected Sf9 cells at 27°C for 36 h and collect the media 
containing the recombinant baculovirus (Tian, 1995). 
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This time can be optimized for maximal protein production depending on the 
bacmid you are using. 
5. Sediment the virus through a 3.0 ml, 20% sucrose cushion in a 25 x 89 mm 
Beckman Ultra-clear tube at 35,000 x g for 30 min. Resuspend the viral pellet in 
sterile Milli-Q water.  
6. Prepare a discontinuous sucrose gradient (20-60% w/v) by adding 5 mls of each of 
the of the following sucrose solutions: 20%, 30%, 35%, 40%, 50%, and 60%. Add 
each solution to a 25 x 89 mm Beckman Ultra-clear tube using sterile Pasteur 
pipettes from the most dense at the bottom of the tube to the least dense at the top 
of the tube. 
Add the sucrose solutions very slowly and be careful not to disturb the 
sucrose layers.  There are several ways to make the gradient.  You can use a 
gradient maker with the 60% sucrose solution in one chamber and the 20% 
sucrose solution in the other chamber.  Add a small amount of the 60% 
sucrose to the bottom of the tube then allow the 20% sucrose to slowly mix 
with the 60% solution, increasing the 20% sucrose solution portion as the 
gradient is made (continuous gradient). An alternative is to overlay the 
sucrose layers one by one from 60% at the bottom of the tube to 20% at the 
top of the tube making sure the solutions don’t mix (step gradient). Or 
prepare the gradient by underlaying with increasing glucose solutions.  Place 
a Pasteur pipette in the tube, slowly add 5 ml of 20% sucrose to the pipette 
and allow the solution to run into the bottom of the tube. Then add 30% 
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sucrose to the pipette and let it underlay the 20% sucrose. Continue to 
underlay the higher percentage of sucrose (step gradient). If a continuous 
gradient is preferred, simply incubate the step gradient at 4°C overnight and 
allow the concentrations to diffuse. 
7. Overlay the sucrose gradient with the sedimented virus. Weigh the tubes to ensure 
they are within 0.1 g of each other. Add dH2O to balance. Centrifuge at 82,000 x g at 
4°C for 1 h 
8. Collect the bands by puncturing the tube with a needle connected to a syringe 
immediately below the band and aspirate the solution including the band into the 
syringe.  Always start from the bottom of the tube so if there is any leakage from the 
puncture, it will not mix with the bands above it.   
Alternatively, the bands are collected by removing the sucrose from the top of 
the tube using a sterile Pasteur or serological pipette until a band is reached. 
9. Sediment the virus at 35,000 x g for 30 min. Resuspend in 1-3 ml of media, dependent 
on the pellet size. Store at 4°C. 
5.8.2b Expand Purified Baculovirus in Spinner Cultures 
10.  Add 1 x 106 Sf9 cells/ml of supplemented Hink’s media to a spinner flask.  
A small spinner culture can be started from an adherent culture and further 
subcultured into larger spinners with increasing volumes.  
The spinner flask must be filled at least 30% full of media so that the spinner 
paddle is submerged (i.e. A 100 ml flask needs to contain at least 30 ml of 
media). 
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11. If the Sf9 cells reach a density higher than 2.5 x 106 cells/ml, split the cells back to 1 
x 106 cells/ml.  
Cells normally reach the higher density in 24-72 h. 
12. Examine cell viability by removing 1 ml of Sf9 culture and mixing with 1 ml of 
0.4% Trypan Blue vital stain in PBS. Allow mixture to stand for 5 min but not more 
than 15 min. 
13.  Clean and dry the counting chamber and cover slip of the hemocytometer.  Using a 
Pasteur pipette, add the cell mixture to the counting chamber and view under the 
microscope (100 X)  
14. Count the cells in the 4 large corner squares noting the number of blue and clear 
cells.  
A hand tally counter is useful for this step. Note that each of the large corner 
squares are divided into 16 smaller squares. Cells that are dead will absorb 
the trypan blue and appear blue, while live cells will remain unstained.  
15. Cell viability must be around 95% before infection with the baculovirus. To calculate 
the numbers of viable cells/ml use the following formula: (total number of cells / 
number of squares counted) x counting chamber conversion factor x dilution = 
number of cells per ml.  To determine the % viable cells use: (number of unstained 
viable cells / total number of cells) x 100 
No of squares counted = 4; counting chamber conversion factor = 10,000; 
dilution = 2 
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When ready to infect the Sf9 cells, count them as in Step 15 and determine the 
MOI of infection based on the PFU/ml as determined below (steps 20-31). 
Suspend baculovirus from step 8 in Hink’s media with no serum. This is your 
virus inoculum.  
An MOI of 1 is typically used for production of a high baculovirus titer, but 
the MOI can be optimized. 
16. Pellet the cells by transferring the spinner flask culture to sterile 50 ml conical tubes 
and centrifuging at 2000 x g for 10 min. Resuspend the cells with the proper amount 
of virus inoculum at a cell density of 1 x 107 cells/ml. Incubate at 27°C for 1 h 
without agitation 
17. Remove the inoculum by pelleting the cells as above in Step 17 and resuspend the 
pellet in fresh Hink’s medium. Transfer the infected cells back to the spinner flask 
with an appropriate amount of media. 
18. Incubate the baculovirus-infected Sf9 cells for 72 h for optimal recombinant 
baculovirus production (Tian, 1995). 
5.8.2c Plaque Assay Using Sf9 Cells and Neutral Red Stain to Determine 
Baculovirus Titer 
19. Seed Sf9 cells in a 6-well plate at 8 x 105 cells/well 
20. Allow the cells to attach to the well at 27°C for 30 min. 
21. Prepare dilutions of virus from step 8 in supplemented Hink’s medium with 10% 
FBS in 1.5 ml microcentrifuge tubes. Make sure viral dilutions at 10-3, 10-4, 10-5,  
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10-6, and 10-7 are included. Dilutions lower or higher than these are usually not 
necessary. 
22. Add 0.7 ml of diluted virus to each well of a 6-well plate (can be done in duplicate). 
23. Rock for 1 h at 27°C for adsorption. 
24. Prepare overlay by microwaving 1.5 g of SeaPlaque™ agarose in 50 ml sterile 
MilliQ water until completely dissolved and allowing it to cool in a 37°C water bath. 
Pre-warm Hink’s media to 37°C. 
Warm the Hink’s media sufficiently or the agarose will solidify on contact with the 
cooler media. 
25. Mix the agarose and pre-warmed 2X Hink’s medium 1:1 and allow to cool, but not 
until it is solidified. 
26. Remove the virus and carefully overlay with the Hink’s/Agarose mixture. Allow 
Hink’s/Agarose mixture to cool slightly until solidified (about 10 min). 
27. Incubate for 4-5 days at 27°C in a humidity chamber. 
To make your own humidity chamber, place the 6-well plates in a sterile container 
within a bag filled with wet paper towels. 
28. Overlay the wells with a secondary overlay containing 0.6% SeaPlaque™ agarose, 
1X Hink’s medium, 10% FBS, and 0.03% neutral red. 
29. Incubate at 27°C until cells they absorb the neutral red (4 – 5 h). 
30. To determine the titer, count the number of plaques as described in Basic Protocol 3 
Unit 15C.3. 
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5.8.2d Recombinant Baculovirus Infection and Expression of NSP4 in Sf9 Spinner 
Cultures 
31. Prepare Sf9 spinner cultures as in steps 10-11, and infect with an MOI of 3 PFU/cell. 
 
32. Incubate the cells and virus for 36 h while spinning for optimal NSP4 expression 
(Tian, 1995). 
33. Pellet the cells at 2000 x g for 10 min and remove the supernatant. Wash the cells by 
resuspending in PBS and pelleting again.  Resuspend in Hink’s media, supplemented 
and store at 4°C, or lyse the cells by resuspending in DOC lysis buffer as described 
in step 2 of Support Protocol 1.  
5.9 Support Protocol 1: Quaternary Methylamine (QMA) Anion Exchange 
Chromatography for Semi-Purification of NSP4 from Sf9 Cell Lysates  
NSP4 expressed from recombinant baculovirus in Sf9 cells in media or lysis buffer 
must first be semi purified by anion exchange chromatography before further 
purification (affinity chromatography) described in Support Protocol 2 . 
5.9.1 Solutions and Specific Equipment 
AccellPlus Quaternary Methylamine Anion (QMA) packing (Waters #WAT010742) 
Advanced Purification 2 (AP-2) Column (20 x 300 mm) (Waters #WAT027503) 
HPLC grade methanol, filtered through 0.45 μm filter 
HPLC Milli-Q water, filtered through 0.45 μm filter 
0.2% Sodium Azide (see recipe) 
Waters FPLC or equivalent Capable of accurately generating specific gradients and a 
4.5 ml/min flow rate 
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Fraction Collector 
Test Tubes for Collection 
QMA Solution A: 0.1 M Tris-HCl, sterile filtered (see recipe) 
QMA Solution B: 0.1 M Tris-Base, sterile filtered (see recipe) 
QMA Solution C: 2.0 M NaCl, sterile filtered (see recipe) 
QMA Solution D: Milli-Q H2O, sterile filtered 
Deoxycholate (DOC) lysis buffer (See recipe) 
5.9.2 Steps and Annotations 
If cells were stored in media, re-pellet the cells at 2000 x g for 10 min and 
remove the supernatant. Add DOC lysis buffer to the Sf9 cell pellet as 
described in step 2 of Support Protocol 1.  
5.9.2a Preparation of QMA Column 
 
1. Weigh 44 grams of QMA beads for 88 mls of bed volume. 
 
Note: Each gram of beads will yield 2 ml of bed volume and can be adjusted 
to the size of the column. 
2. Swell the beads in HPLC grade methanol by adding 3-5 times the volume of the 
beads. 
3. Allow the beads to settle and remove the methanol. 
 
4. Wash the beads with 150 ml filtered, MilliQ water and degas. 
 
5. Attach an AP-2 column or equivalent to a support stand using utility clamps. 
 
6. Remove the inlet connector assembly from the column and place the packing funnel 
into the inlet cap. 
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7. Pour the water and bead slurry into the funnel and plug the outlet cap when finished. 
 
8. Let the beads settle and remove excess water from the top of the column. 
 
The column bed may be too high. If this is the case, remove some of the slurry 
so that the bed fits into the column. 
9. Attach the inlet connector and adjust the inlet connector assembly until the plunger 
contacts the column bed. 
10. Store the column in 0.2% sodium azide at 4°C with the column inlet and outlet 
plugged. 
Sodium azide is a known mutagen, and can be explosive and toxic when in 
contact with certain metals and acids. Take precaution when working with 
sodium azide by wearing the proper personal protective equipment. 
5.9.2b Quaternary Methylamine Anion Chromatography 
 
11. Prepare QMA Solutions A, B, C, and D. 
 
12. Attach the prepared column to the FPLC. 
 
13. Equilibrate the QMA column as follows: 
 
a. Run QMA Solution D (MilliQ sterile water) at a rate of 4.5 ml/min for 30 min. 
  
b. Run 80% QMA Solution C + 20% QMA Solution D at 4.5 ml/min for 30 min. 
 
c. Repeat steps a and b at least 3-5 times or until the baseline UV (280 nm) signal 
is stable. 
d. Run QMA Solution D at a rate of 4.5 ml/min for 60 min. 
 
e. Run 10% QMA Solution A + 10% QMA Solution B + 80% QMA Solution D at 
4.5 ml/min until the pH of the eluate is consistently 8.1. 
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14. Sonicate the infected Sf9 cells in lysis buffer at 45 W for 3 min. 
 
15. Dilute the lysate to 50 ml with 10% QMA Solution A + 10% QMA Solution B + 
80% QMA Solution D. 
16.  Filter the diluted lysate through a 0.22 um filter.  
 
17. Load the filtered lysate in the inlet port of an FPLC with the equilibrated QMA 
column attached and run the sample through the column at a speed of 2 ml/min. 
18. Wash the column with 10% Solution A + 10% Solution B + 80% Solution D with a 
flow speed of 4.5 ml/min for 360 min until the Abs 280 nm drops to the background 
levels. 
NOTE: You may run this overnight at a flow rate of 1.5 ml/min for a total 
volume of 1500 ml. 
19. Elute NSP4 from the column using the following parameters: 
 
Minute Flow A% B% C% D% Curve 
0 0.5 10 10 -- 80 -- 
2 4.5 10 10 8 72 6 (linear) 
20 4.5 10 10 8 72 6 
120 4.5 10 10 80 -- 6 
121 0.0 -- -- -- -- -- 
 
20. Collect all fractions for each min (4.5 ml per fraction after the first 2 min).  
 
21. Fractions corresponding to the presence of NSP4 (based on dot blot data) are pooled, 
dialyzed and lyophilized 
a. Dialyze in a large (2 L beaker) with a large volume of 50 mM NH4HCO3 and 
mixing slowly with a stir bar.  A minimum of 3 buffer changes should be made 
to ensure the fractions are now in the ammonium bicarbonate solution.   
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b. Remove the sample from the dialysis bag or cassette and shell freeze by placing 
in a 1:1 solution of dry ice and ethanol and swirling the solution should go up 
onto the sides of the tube and freeze. Store sample at -70°C until ready for 
lyophilization. 
To remove the samples from the dialysis bag, it is best to initially use 
a syringe and needle. When most of the solution is recovered then you 
can wring out the dialysis tubing into the lyophilization tube. The 
sample can be recovered from the cassettes using a 16G needle as 
described by the manufacturer.  
c. Precool the lyophilizer and turn the vacuum on.  Follow the instructions 
provided with the lyophilizer to add your sample. 
Generally when a sample initially is added to a lyophilizer, the vacuum will 
drop temporarily.  It is important that you wait and watch the vacuum 
gauge to ensure the vacuum is reestablished.  Check you samples for the 
first couple of hours to make sure they are not melting.  If there is evidence 
of melting (bubbles, dampness), remove the samples from the lyophilizer, 
repeat the shell freeze and then add to the lyophilizer again. 
22. Lyophilize until dry and store in a desiccator at -20°C. To achieve greater 
purification, continue to Support Protocol 2 for affinity purification.  
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5.10 Support Protocol 2: Generate and Enrich NSP4-Specific IgG for Use as Ligand 
in the NSP4 Affinity Column  
There are many types of affinity columns, chemistries and ligands that can be used, 
but the author is more experienced with the cyanogen bromide-activated column. 
Alternately, you may use the Affi-Gel Hz column (Bio-Rad) according to the 
manufacturer’s instructions. In this unit, the generation and purification of NSP4 peptide 
or protein-specific IgG is described for the preparation of the NSP4 antibody affinity 
column. 
Given the difficulties in acquiring a significant quantity of purified NSP4 this 
protocol will focus on NSP4-specific peptides.  We have been successful using NSP4114-
135, 120-147, or 90-140 peptide alone or in combination. 
5.10.1 Solutions and Specific Equipment 
HCl, 1 mM 
Coupling buffer (see recipe) 
Blocking buffer (see recipe) 
Washing buffers of alternate pH (see recipe) 
Binding buffer (sterile filtered PBS, pH 7.5, see recipe) 
Elution buffers (pH 4.5 and 3.0, see recipe) 
NaOH, 0.5 M 
Ammonium bicarbonate, 0.05 mM in dH2O 
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CnBr-activated Sepharose 4B (GE Healthcare) (catalog # 17-0430-01), 4% agarose, 
average bead size of 90 μm, coupling capacity of 25-60 mg of α-chymotrypsinogen, 
stable pH 3-11 
Sintered glass filter, porosity of G3, or Büchner funnel #6 
Stoppered flask 
Pipettes 
Collection tubes 
Glass column with or without adaptor   
NSP4-specific, purified antibody or other ligand (5-10 mg of protein per ml of column 
gel) 
NSP4-specific immune-dominant synthetic peptides 
Dialysis tubing, 12 kD MWCO, or dialysis cassette (Slide-A-Lyzer Dialysis Cassette, 10 
kD MWCO, Thermo Scientific #66810) 
Balance 
Lyophilizer 
Rotator 
Peristaltic pump (Cole Palmer or equivalent) 
UV detector (Isco UA6 or equivalent) 
Chart recorder 
Fraction collector 
Spectrophotometer 
Peristaltic Pump 
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Saturated ammonium sulfate  
Keyhole limpet hemocyanin 
Glutaraldehyde (EM grade) 
Dialysis tubing or dialysis cassette (3000 MWCO) 
Glycine, 1 M, pH 7.5 
Freund’s Complete and Incomplete adjuvant 
Emulsifying needle 
New Zealand white rabbits 
Protein A sepharose 4G    
Ammonium bicarbonate, 50 mM 
Glycine-HCl, 0.1 M, pH 3.5  
MicroBCA kit (Thermo Pierce, catalog # 23235) 
5.10.2 Steps and Annotations 
If availability of pure NSP4 is problematic, synthetic peptides are a 
good alternative. Previous studies have shown peptides to be highly 
immunogenic and reactive to the native protein if carefully selected. 
However, the peptides must be cross-linked to a carrier protein such 
as keyhole limpet hemocyanin (KLH) prior to immunization of the 
laboratory animals. 
5.10.2a Preparation of Antigen 
1. NSP4 protein (70-75% pure) can be directly emulsified in a suitable adjuvant for 
immunization, whereas synthetic peptides (90-95% pure) must be cross-linked to a 
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carrier protein.  An alternative is to employ the protein separated by SDS-PAGE by 
removing the gel band. Another alternative is the solubilization of nitrocellulose 
filters in which the protein has been absorbed.  Proteins isolated from a gel band have 
the advantages of being highly immunogenic due to the polyacrylamide and can be 
used when only small quantities of protein are available. 
The gel band is frozen, pulverized, and lyophilized.  The gel pieces 
then can be removed from the tube, weighed, dissolved in PBS, pH 
7.5, and emulsified.  
When using synthetic peptides, the peptides must be carefully 
selected.  Check the literature to determine if immune-dominant 
epitopes are published. If not, there are several programs that predict 
antigenic sites on the web.  Use of multiple peptides may be best if the 
immune reactivity is not known. 
2. To glutaraldehyde-link the peptides to KLH, mix the KLH and peptide solutions at a 
ratio of 1 nmol KLH to 100 nmol peptide (or 1:100).  This can be scaled up or down 
as long as the ratio remains the same.  
The KLH and peptide solutions are prepared in water or PBS. The volume is 
independent since you are working in nmol.  Mix the 2 solutions in a small 
beaker or vial with a stir bar. 
3. Add glutaraldehyde to a final concentration of 0.4%. 
4. Stir for 1 h at room temperature. 
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The solution may become cloudy.  Continue with the protocol as the 
efficiency of cross-linking is not altered. 
5. Quench the reaction by adding 1 M glycine to a final concentration of 200 mM and 
stir for another 30-45 min. 
6. Transfer the solution to a dialysis bag (Spectra/Por CE) or cassette (Thermo 
Scientific), 3000 MWCO. 
7. Dialyze against PBS, pH 7.5, or 50 mM ammonium bicarbonate depending on the 
desired final volume of cross-linked peptide.  The dialysis solutions should be sterile 
and endotoxin free. Change the dialysis buffer a minimum of 3 times over a minimum 
of 24 h using large volumes.   
8. If dialyzed against PBS, remove the cross-linked peptide solution from dialysis and 
emulsify with an equal volume of adjuvant.  If dialyzed against ammonium 
bicarbonate, shell freeze and lyophilize, which enables you to hydrate the lyophilized 
powder in the desired volume. Emulsify in adjuvant using an emulsifying needle. 
There are a number of adjuvants available.  Animal care personnel 
should be consulted about the adjuvants shown to enhance the 
immune response and allowed in the animal facility. When using 
synthetic peptides as the immunogen, we find Freund’s adjuvant to be 
the best despite the well-documented problems with Freund’s 
Complete, which only is used for the first injection. We generally 
write a justification for its use and clearly state that Freund’s 
Complete only will be administered intramuscularly (IM). Subsequent 
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boosts are given in Incomplete Freund’s IM, subcutaneously (SC) 
across the neck, and intraperitoneally (IP) in the abdomen. 
9. Follow established protocols for antibody generation in terms of number of injections 
and bleeds. Final bleeds should be completed only after serum from a test bleed is 
shown to be reactive to the native protein at a reasonable titer (ELISA and/or Western 
blot). Test bleeds should be acquired after the second and all subsequent boosts.  
When working with peptides, at least 3 boosting doses generally are 
required. 
All animals must be humanely treated and the investigator must follow 
Animal Use guidelines.  Any discomfort or stress to the animals must be 
limited to that which is absolutely necessary.  Anesthetics, analgesics and 
tranquilizing drugs will be used when appropriate to minimize discomfort to the 
animals. 
The species of the laboratory animals used for antibody production varies. 
However we obtain higher titers with New Zealand white rabbits; and rabbit 
IgG readily binds Protein A.  If rabbits are employed, the following guidelines 
should be followed: for the first immunization, a maximum of 0.1 ml can be 
injected into each hip containing a maximum of 150 nmol of peptide or 3 nmol 
of protein. Subsequent boosting inoculations are a maximum of 0.05 ml when 
administered subcutaneously (SC) and the total volume should not exceed 0.5 
ml.  About the same amount of peptide/protein will be given in each boost. 
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10. Once the immune sera from the final bleed has been collected, and shown to be 
reactive with the cognate protein by ELISA and/or Western blot, the IgG is isolated 
from the serum. The goal here is the removal of non-protein components and non-
IgG proteins such that the IgG is enriched with minimal contaminants. 
There are many recommended IgG isolation protocols and several 
commercial kits are available. We typically utilize ammonium sulfate 
precipitation, desalting, and reactivity with Protein A on magnetic 
beads.  Various HPLC columns are available as well as a variety of 
ion exchange methods.   
5.10.2b Ammonium Sulfate Precipitation 
11. For (NH4)2SO4 precipitation, clarify the serum by centrifugation at 10,000 
rpm for 10 min. Remove supernatant and chill in an ice bucket. 
12. While the serum is stirring at 4°C, slowly add the saturated ammonium 
sulfate solution to a final concentration of 40% (volume of saturated 
ammonium sulfate is 0.66 x the volume of serum) and let the solution slowly 
stir at 4°C for 4 h. 
13. Pellet the precipitate by centrifugation at 10,000 rpm for 20 min at 4°C. 
Remove the supernatant. 
14. Dissolve the pellet in half the initial volume of the serum with either sterile 
dH2O or PBS, pH 7.5.  The precipitation reaction can be repeated to ensure all 
of the IgG is precipitated. 
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The total protein concentration of the serum usually is 60-70 mg/ml 
with immunoglobulins representing 20-24% of the total protein with 
IgG as the primary antibody component. 
15. Dialyze against sterile PBS, pH 7.5, following the protocol above (see step 6) 
using dialysis tubing with a 100 kD MWCO.    
It is helpful to determine the protein concentration of the IgG prior to 
starting the next step. Any commercial kit can be used. We 
recommend the Micro BCA Kit (Pierce Thermo). 
5.10.2c Protein A Affinity Column 
16. Protein A binds 2 immunoglobulin molecules with a strong affinity for the Fc region. 
Protein A-Sepharose is commercially available from a number of sources.  A column 
can be prepared with the Protein A-Sepharose or a batch method can be used.  
17. For the batch method, which is quick and easy, add PBS to the hydrated sepharose 
beads and equilibrate for 1 h at 4°C.  Centrifuge the beads at 2000 x g for 5 min and 
discard the supernatant.  Add the dialyzed IgG, which is now in PBS to the 
equilibrated Protein A beads and mix on a platform rotator in the cold (4°C) for 4 – 12 
h.   
Similarly, the beads can be poured into a column and attached to a 
peristaltic pump for equilibration (see above steps 1-3). Slowly Add 
the IgG solution to the top of the column and collect the flow-through 
for protein concentration analysis.  
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18. Again pellet the beads as in step 17, and this time, keep the supernatant for 
determining protein concentration (should be significantly lower).  If the 
concentration of the supernatant fails to significantly drop, repeat step 17. 
19. For elution of the IgG from the beads, the company from which the beads were 
purchased will provide recommendations and should be followed.  A commonly 
recommended elution buffer is 50 mM glycine, pH 3.0.  To elute, pellet the beads, 
keep the supernatant for protein concentration assay, and add the elution buffer.  
Note: The elution buffer should not be incubated for an extended length of 
time.  After the antibody is eluted, immediately neutralize the slurry with 1M 
Tris, pH 8.0.  
20. Pellet the beads again and transfer the supernatant to dialysis tubing (12,000 
MWCO) or dialysis cassettes (Pierce Thermo).  The molecular weight of IgG is 
around 150,000. 
a. Dialyze in a large (2 L beaker) with a large volume of 50 mM NH4HCO3 and 
mixing slowly with a stir bar.  A minimum of 3 buffer changes should be made 
to ensure the fractions are now in the ammonium bicarbonate solution.   
b. Remove the sample from the dialysis bag or cassette and shell freeze by placing 
in a 1:1 solution of dry ice and ethanol and swirling to cause the solution to go 
up onto the sides of the tube and freeze. Store sample at -70°C until ready for 
lyophilization. 
To remove the IgG sample from the dialysis bag, it is best to initially 
use a syringe and needle. When most of the solution is recovered then 
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you can wring out the dialysis tubing into the lyophilization tube. The 
sample can be recovered from the cassettes using a 16G needle as 
described by the manufacturer.  
c. Precool the lyophilizer and turn the vacuum on.  Follow the instructions 
provided with the lyophilizer to add your sample. 
Generally when a sample is added to a lyophilizer, the vacuum will drop 
temporarily.  It is important that you wait and watch the vacuum gauge to 
ensure the vacuum is reestablished.  Check the samples for the first couple 
of hours to make sure they are not melting.  If there is evidence of melting 
(bubbles, dampness), remove the samples from the lyophilizer, repeat the 
shell freeze and then add to the lyophilizer again. 
d. Lyophilize until dry and store in a desiccator at -20°C. 
5.10.2d Isolation of NSP4-specific IgG Employing a NSP4-peptide or Protein 
Affinity Column  
Since the purpose of the affinity column is to isolate NSP4 expressed in the 
media of mammalian cells or insect cell lysates (Alternate Protocol 3) the use 
of NSP4-specific peptides is recommended as the ligand if immune-dominant 
peptides are available. 
21.  To isolate NSP4-specific antibody, the IgG must be bound with either NSP4 or 
NSP4-specific peptides.  Since we generally employ synthetic peptides for this step, 
the focus of the protocol will be on the NSP4-specific peptides as ligand. Because of 
the size of KLH, many of the antibodies will be directed against the carrier protein. 
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Thus separation of the IgG specific to NSP4 from anti-KLH and other rabbit IgG is 
important.  Immuno-affinity purification is the most frequently utilized method to 
purify antigen-specific antibodies from polyclonal antibodies.    
An alternative to isolating the NSP4-specific IgG by NSP4 peptide affinity is 
to prepare a KLH affinity column to remove the abundant KLH antibodies 
from the IgG pool (see below).  In this case, the ligand is KLH and the 
supernatant is collected, dialyzed and lyophilized. The KLH IgG can be 
eluted from the column, the column restored and subsequently stored at 4°C 
for future use. 
If using a KLH affinity column, the NSP4-specific IgG is enriched but other 
rabbit immunoglobulins to other antigens are still present. 
22. To prepare the NSP4-peptide or protein affinity column CnBr-activated beads are 
employed. 
a. Activate the CnBr-activated Sepharose 4B beads by suspending the appropriate 
amount of the Sepharose product in 1 mM HCl (pH 3 is recommended) and 
allow to swell for 1 to 2 min. 
1 g of lyophilized CnBr-activated Sepharose 4B swells to about 3.5 ml 
of column volume.  The amount of resin to swell depends on the 
column size and the amount of NSP4 to be purified. 
b. Remove additives from the activated sepharose by washing for 15 min 
with the 1 mM HCl on a sintered glass filter with a porosity of G3 or 
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Büchner funnel #6.  200 ml of 1 mM HCl per gram of dried CnBr-
activated sepharose is sufficient and should be added in aliquots. 
c. Dissolve the ligand (for our purposes, enriched NSP4 protein or NSP4-specific 
peptide will be the ligand) in coupling buffer at a ratio of 5 ml coupling buffer to 
1 g of ligand. The ligand should be in a powdered or freeze-dried form. It is 
recommended to employ 5-10 mg of ligand per ml of gel slurry.  
Take an Absorbance280 reading of the ligand solution prior to adding 
to sepharose beads as an indication of NSP4 peptide or protein 
(ligand) concentration.  
d. Add the coupling buffer with the dissolved ligand to the prepared sepharose 
suspension in a stoppered flask.  Gently rotate the mixture end-over-end for 1 h 
at room temperature or overnight at 4°C.  
Other methods of mixing can be employed, however a magnetic 
stirrer should be avoided as it damages the sepharose beads. 
23. Pellet the beads at 350 x g for 1 min.  Take an Absorbance280 reading of the 
supernatant  
The Absorbance280 should be at least 10-fold lower than that in step c 
insuring the ligand has been bound.  If there is no drop in the 
absorbance reading, this indicates that there is a problem with the 
activation of the sepharose 4B and the ligand failed to bind the 
sepharose beads.  You should start over with the activation step (step 
a).  
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24. Remove unbound ligand by washing with 5 column volumes of the coupling buffer. 
25. Block the active groups by mixing the beads with the blocking buffer and incubating 
for 2 h at room temperature or 16 h at 4°C. 
26. Treat the sepharose slurry with alternate pH washing buffers. Wash for a minimum 
of 3 cycles, preferably 4 cycles, of the alternating pH with 5 ml of volume in each 
wash. 
27. Pack the column with the NSP4 or peptide-bound CnBr-activated Sepharose 4B (for 
purification of the specific IgG). 
a. Prepare the slurry with PBS, pH 7.5 (binding buffer) in a ratio of 75% settled 
beads to 25% binding buffer. 
It is important that the buffers lack amines as these will couple to the 
gel.  NSP4 should also be prepared in the PBS binding buffer.  
b. De-gas the gel slurry to reduce bubbles and flush the end pieces of the column 
with binding buffer to eliminate trapped air. Close the column outlet with a few 
cm of buffer remaining. 
c. Equilibrate all material to be used to the same temperature. 
d. Pour the slurry into the column in one smooth movement being careful not to 
form bubbles (see Basic Protocol 4, step 7a-7d).  
To further reduce bubbles, pour the slurry down a glass rod that is 
held against the wall of the column. 
e. Fill the remainder of the column with binding buffer.  Mount the top piece onto 
the column and attach to a peristaltic pump (Cole Parmer) 
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f. As with the preparation of the ConA affinity column (Basic Protocol 4) the 
maximum flow rate for the Sepharose 4B beads is 75 cm/h at room temperature, 
which is limited to packing of the column.  75% of the maximum flow should 
be use for the remainder of the chromatographic procedure. 
g. Pump a minimum of 3 column volumes of binding buffer through the column.  
Ensure a constant bed height is reached.  
28. Attach the adaptor to the column (same as in Basic Protocol 4, step 7e-7h) 
 
a. Adjust adapter so that the O-ring sits against the column wall, but does not 
compress the beads. 
b. Purge the flow adaptor with equilibration buffer to remove all air bubbles. 
 
c. Latch the flow adaptor onto the column and insert the flow adaptor into the 
column until it touches the buffer. 
d. Push the cam latch all the way down to the column bed and turn it slightly 
counterclockwise to lock it in place. 
29. Binding and elution of NSP4-specific IgG. 
a. The IgG lyophilized sample should be diluted in the same PBS, pH 7.5, in 
which the column was equilibrated. 
b. Carefully add the IgG solution to the top of the column and allow the solution to 
enter the column bed. Immediately add additional binding buffer. 
c. Establish an air-free connection between the column and the UV detector.  Also 
set up the fraction collector (the flow should go from the column-peristaltic 
pump to the UV detector to the chart recorder and fraction collector) 
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d. Continue to pump binding buffer until the baseline is stable (wash with about 5 
columns of binding buffer while watching the UV monitor). 
e. Elution of NSP4 IgG can be accomplished by changing the pH or ionic strength 
of the buffer.  In this system altering the pH works well.  Add about 5 column 
volumes of elution buffer A (pH 4.3) while watching the UV monitor.  Be sure 
the absorption at 280 nm has returned to baseline before the next step.  
It is useful to add 0.05 ml or more depending on the fraction size of 
0.5 M NaOH to each collection tube to neutralize the acid as it exits 
the column.  
f. Elute with about 5 column volumes of elution buffer B (pH 2.3) while watching 
the UV monitor. Be sure the absorption at 280 nm has returned to baseline 
before equilibrating the column with binding buffer containing 0.02% sodium 
azide. Store at 4°C. 
g. Collect the tubes from the fraction collector that corresponds to the UV 280 nm 
peaks. Pool fractions as appropriate. 
h. Immediately transfer the fractions to dialysis tubing or dialysis cassettes for 
dialysis and lyophilization (step 20d – 20g above).  
5.11 Support Protocol 3: Affinity Chromatography of Semi-Purified NSP4 Using 
Purified NSP4 IgG as Ligand 
5.11.1 Solutions and Specific Equipment 
 
HCl, 1 mM 
Coupling solution (see recipe) 
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Blocking buffer (see recipe) 
Washing buffers of alternate pH (see recipe) 
Binding buffer (sterile filtered PBS, pH 7.5, see recipe) 
Elution buffers (pH 4.5 and 3.0, see recipe) 
NaOH, 0.5 M 
Ammonium bicarbonate, 0.05 mM in dH2O 
CnBr-activated Sepharose 4B (GE Healthcare) (catalog # 17-0430-01), 4% agarose, 
average bead size of 90 μm, coupling capacity of 25-60 mg of α-chymotrypsinogen, 
stable pH 3-11 
Sintered glass filter, porosity of G3, or Büchner funnel #6 
Stoppered flask 
Pipettes 
Collection tubes 
Glass column with or without adaptor   
NSP4-specific, purified antibody or other ligand (5-10 mg of protein per ml of column 
gel) 
Dialysis tubing, 12,000 MWCO, or dialysis cassette (Slide-A-Lyzer Dialysis Cassette, 
10,000 MWCO, Thermo Scientific #66810) 
Balance 
Lyophilizer 
Rotator 
Peristaltic pump (Cole Parmer or equivalent) 
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UV detector (Isco or equivalent) 
Chart recorder 
Fraction collector 
Spectrophotometer 
Saturated ammonium sulfate  
Keyhole limpet hemocyanin 
Glutaraldehyde (EM grade) 
Dialysis tubing or dialysis cassette (3000 MWCO) 
Glycine, 1 M, pH 7.5 
Freund’s Complete and Incomplete adjuvant 
New Zealand white rabbits 
Protein A or G agarose beads   
Ammonium bicarbonate, 50 mM 
Glycine-HCl, 0.1 M, pH 3.5  
MicroBCA kit (Thermo Pierce, catalog # 23235) 
5.11.2 Steps and Annotations 
Protocols below are adapted from The Protein Protocols Handbook and Cell 
Biology: A Laboratory Manual (Walker, 1996). 
Most of the steps are identical to Support Protocol 2 except that the NSP4 IgG 
is used as the ligand to purify the expressed NSP4 from the baculovirus 
recombinant-infected Sf9 lysates prepared in Alternate Protocol 2. 
1. Immobilization of purified NSP4-specific IgG (see Support Protocol 2). 
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a. Activate the CnBr-activated Sepharose 4B beads by suspending the appropriate 
amount of the Sepharose product in 1 mM HCl (pH 3 is recommended) and 
allow to swell for 1 - 2 min. 
1 g of lyophilized CnBr-activated Sepharose 4B swells to about 3.5 ml 
of volume. Weigh out an adequate amount of activated sepharose to 
prepare the column to be used. 
b. Remove the additives from the activated sepharose by washing for 15 min with 
1 mM HCl on a sintered glass filter with a porosity of G3 or Büchner funnel #6.  
200 ml of 1 mM HCl per gram of dried CnBr-activated sepharose is sufficient 
and should be added in aliquots. 
c. Dissolve the lyophilized NSP4-specific purified IgG in coupling buffer at a ratio 
of 5 ml coupling buffer to 1 g of ligand. It is recommended to use 5-10 mg per 
ml of gel slurry.  
Take an Absorbance280 reading of the antibody solution prior to 
adding to the sepharose beads as an indication of antibody 
concentration.  
d. Add the coupling buffer with the dissolved NSP4-specific IgG to the prepared 
sepharose suspension in a stoppered flask.  Gently rotate the mixture end-over-
end for 1 h at room temperature or overnight at 4°C.  
Avoid a magnetic stirrer for mixing as it damages the sepharose 
beads. 
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e. Spin down the beads at 350 x g for 1 min.  Take an Absorbance280 reading of the 
supernatant.  
The Absorbance280 should be at least 10-fold lower than that in step b 
insuring the IgG has been bound.  If there is no drop in the 
absorbance reading, this indicates that there is a problem with 
activation of the sepharose 4B and the antibody (ligand) failed to be 
bound by the sepharose beads.  You should start over with the 
activation step (step a).  
f. Remove unbound ligand by washing with 5 column volumes of coupling buffer. 
g. Block active groups by mixing the beads with the blocking buffer and 
incubating for 2 h at room temperature or 16 h at 4°C. 
h. Treat the sepharose slurry with alternate pH washing buffers. Wash for 4 cycles 
of the alternating pH with 5 ml of volume in each wash. 
2. Pack the column with the purified IgG-bound CnBr-activated Sepharose 4B (for 
purification of the NSP4-specific IgG, see Support Protocol 2 above). 
a. Prepare the slurry with PBS, pH 7.5 (binding buffer) in a ratio of 75% settled 
beads to 25% binding buffer. 
It is important that the buffers lack amines as these will couple to the 
gel.  The Sf9 lysates containing NSP4 should also be prepared in the 
PBS binding buffer.  
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b. De-gas the gel slurry to reduce bubbles and flush the end pieces of the column 
with binding buffer to eliminate any trapped air. Close the column outlet with a 
few cm of buffer remaining. 
c. Equilibrate all solutions to the same temperature. 
d. Pour the sepharose slurry into the column in one smooth movement. 
To further reduce bubbles, pour the slurry down a glass rod that is 
held against the wall of the column. 
e. Fill the remainder of the column with binding buffer.  Mount the top piece onto 
the column and attach to a peristaltic pump (Cole Parmer). 
f. The maximum flow rate for the Sepharose 4B beads is 75 cm3/h at room 
temperature, which should only be used when packing the column.  75% of the 
maximum flow should be use for the remainder of the chromatographic 
procedure. 
g. Pump a minimum of 3 column volumes of binding buffer through the column.  
Ensure a constant bed height is reached.  
3. If using an adaptor, the adaptor should be fitted at this point. Note that the protocol 
can be achieved in the absence of an adaptor. 
a. Close the column outlet and remove the top piece from the column.  Carefully 
fill the remainder of the column with binding buffer. 
b. Insert the adaptor onto the top of the column at an angle, making sure that no air 
is trapped.  Ensure that the tubing that connects the adaptor to the peristaltic 
pump is bubble-free. 
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c. Insert the plunger by slowly sliding it down the column.  The capillary tubing 
should be displaced with eluent. 
d. Lock the adaptor in place when it reaches the bed surface and open the column 
outlet. Pass eluent through the column to ensure the column bed is stable. The 
detector should be at baseline. 
4. Binding and Elution of NSP4. 
a. Dilute the NSP4 from the QMA column in the same PBS, pH 7.5, in which the 
affinity column was equilibrated. 
b. Carefully add the lysates to the top of the column and allow entry into the 
column bed. Immediately add additional binding buffer. 
c. Establish an air-free connection between the column and the UV detector.  Also 
set up the fraction collector. 
d. Continue to pump binding buffer until the baseline is stable (wash with about 5 
columns of binding buffer while watching the UV monitor). 
e. Elution of NSP4 can be accomplished by changing the pH or ionic strength of 
the buffer.  For NSP4, altering the pH works well.  Add about 5 column 
volumes of elution buffer A (pH 4.3) while watching the UV monitor.  Be sure 
the Absorbance280 has returned to baseline before the next step.  
It is useful to add 0.05 ml or more depending on the fraction size of 
0.5 M NaOH to each collection tube to neutralize the acid.  
 151 
f. Elute NSP4 with about 5 column volumes of elution buffer B (pH 2.3) while 
watching the UV monitor. Be sure the absorption at 280 nm has returned to 
baseline.  
g. Collect the tubes from the fraction collector that corresponds to the UV 280 nm 
peaks. Pool fractions as appropriate. 
h. The column is equilibrated with binding buffer containing 0.02% sodium azide. 
Store at 4°C. 
i. Immediately transfer the fractions to dialysis tubing or dialysis cassettes.  
5. Dialyze in a large (2 L beaker) with a large volume of 50 mM NH4HCO3 and mix 
slowly with a stir bar.  A minimum of 3 buffer changes should be made to ensure the 
fractions are now in the ammonium bicarbonate solution.   
6. Remove the samples from the dialysis bag or cassette.  Shell freeze sample by 
placing in a 1:1 solution of dry ice and ethanol and swirling the solution up onto the 
sides of the tube. Store sample at -70°C until ready for lyophilization. 
To remove the fractions from the dialysis bags, it is best to initially use a 
syringe and needle. When most of the solution is recovered then you can 
wring out the dialysis tubing into the lyophilization tube. The sample can 
be recovered from the cassettes using a 16G needle as described by the 
manufacturer. 
7. Precool the lyophilizer and turn the vacuum on.  Follow the instructions provided 
with the lyophilizer to add your samples. 
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Generally when a sample is added to a lyophilizer, the vacuum will drop 
temporarily.  It is important that you wait and watch the vacuum gauge to 
ensure the vacuum is reestablished.  Check you samples for the first couple of 
hours to make sure they are not melting.  If there is evidence of melting 
(bubbles, dampness), remove the samples from the lyophilizer, repeat the 
shell freeze and then add to the lyophilizer again. 
8. Store the semi-purified NSP4 in a desiccator at -20°C. 
 
5.12 Reagents and Solutions 
 
5.12.1 Tissue Culture Reagents 
 
5.12.1a Minimum Essential Media, Supplemented with 10% FBS 
To 860 mL of a 1X solution of MEM, add 10 mL of 200 mM L-Glutamine, 10 mL of 10 
mM Sodium Pyruvate, 10 mL of 100X Non-Essential Amino Acids, 10 mL of 10,000 
U/ml -10 µg/ml Pen-Strep Antibiotics, and 100 mL Fetal Bovine Serum. Mix well and 
sterile filter through a 0.22 µm filter. For a 2X solution, repeat the above using a 2X 
solution of MEM and two times the amount of supplements. Store supplemented media 
for up to 2 months at 4°C. 
5.12.1b Minimum Essential Media, Supplemented with 10% FBS 
To 960 mL of a 1X solution of MEM, add 10 mL of 200 mM L-Glutamine, 10 mL of 10 
mM Sodium Pyruvate, 10 mL of 100X Non-Essential Amino Acids, and 10 mL of 
10,000 U/ml -10 µg/ml Pen-Strep Antibiotics. Mix well and sterile filter through a 0.22 
µm filter. Store supplemented media for up to 2 months at 4°C. 
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5.12.1c Hink’s Medium, Supplemented, with 10% FBS  
To 445 ml of Hink’s medium, add 5 ml of Penicillin-Streptomycin-Amphotericin B, and 
50 ml FBS. Filter sterilize and store at 4°C. 
5.12.1d Worthington Trypsin 
Dissolve 1 mg of Worthington in 1 mL of autoclaved dH2O. Filter sterilize with a 
syringe filter (0.22 μm). Aliquot 100 µL in microcentrifuge tubes and store at -20°C. 
5.12.1e Sf9 Lysis Buffer (10 mM Tris, 0.1 mM EDTA, 2% Sodium Deoxycholate) 
To 900 mL, add 1.21 g Tris-HCl, 50 mL of 2 M EDTA, pH 8, and 2 g DOC. Filter 
sterilize and store at 4°C for up to 3 months. 
5.12.1f Sucrose Solutions 
Add solutions to ~20 mls H2O, dissolve, and transfer to a graduate cylinder and fill to 30 
mls. Filter sterilize all solutions. It may be necessary to warm the solutions to 42°C to 
dissolve the sucrose completely. 
20%: 6 g in 30 mls H2O 
30%: 9 g in 30 mls H2O 
35%: 10.5 g in 30 mls H2O 
40%: 12 g in 30 mls H2O 
50%: 15 g in 30 mls H2O 
60%: 18 g in 30 mls H2O 
65%: 19.5 g in 30 mls H2O 
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5.12.2 RNA Purification Reagents 
5.12.2a 0.1 M Sodium Acetate Buffer (pH 5) 
To 950 mL of dH2O, add 2.06 ml of acetic acid and 5.25 g of sodium acetate. Q.S. to 1 
L, autoclave, and store at room temperature for up to 6 months. 
5.12.2b Phenol Mixture 
Add 500 g of phenol and 70 g of m-cresol, to 200 ml of water containing 0.5 g of 8-
hydroxquinoline. Keep protected from light and store at 4°C. 
5.12.2c 30% Acrylamide Stock 
Dissolve 30 g of acrylamide and 0.8 g of N,N’methylenebisacrylamide in 60 ml of 
distilled water. Q.S. to 100 mL and filter through 0.45 μm. Store in a dark or foil-
covered bottle, and store at 4°C for up to 1 month.  
5.12.2d Resolving Gel Buffer 
Dissolve 18.15 g of Tris base in 40 ml of dH2O. Adjust the pH to 8.8 with 1N HCl. Q.S. 
to 100 ml with dH2O. Store at 4°C for up to 1 month. 
5.12.2e Stacking Gel Buffer 
Dissolve 5.98 g of Tris base in 50 ml of distilled water. Adjust the pH to 6.8 with 1N 
HCl. Q.S. to 100 ml with distilled water. Store at 4°C for up to 1 month. 
5.12.2f 10% Ammonium Persulfate 
Dissolve 0.1 g of APS in 1 ml of autoclaved dH2O before use and store for a maximum 
of 3 days at 4°C. It is best if 10% APS is made fresh immediately before use. 
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5.12.2g 5X Tris-glycine Running Buffer 
Dissolve 15.1 g of Tris-base and 94 g of glycine in 800 mL dH2O. Q.S. to 1,000 ml with 
dH2O. Store at 4°C for up to 3 months. 
5.12.2h 1X Tris-glycine Running Buffer 
Dilute 200 ml 5X Tris-glycine buffer with 800 ml of dH2O. Store at 4°C for up to 3 
months. 
5.12.2i PAGE Sample Loading Buffer 
Dissolve 10 mg of bromophenol blue and 1 ml of glycerol in 5 ml of stacking gel buffer. 
Q.S. to 10 mL with dH2O. Store at room temperature for up to 1 month. 
5.12.3 Protein Purification Reagents 
5.12.3a Con A Binding Buffer (20 mM Tris-HCl, pH 7.4 with 0.5 M NaCl) 
Dissolve 1.21 g Tris-HCl and 14.61 g NaCl in 350 mL dH2O. Adjust the pH to 7.4 with 
10 N KOH. Adjust the volume to 500 ml with Milli-Q® H2O and sterile filter. Store at 
room temperature for up to 3 months. 
5.12.3b Con A Elution Buffer (0.5 M α-D-methyl-mannopyranoside in ConA 
Binding Buffer) 
Dissolve 24.27 g of α–methyl-mannopyranoside in ConA Binding Buffer. Q.S. to 250 
mL with ConA Binding Buffer. Sterile filter and store at 4°C for up to 1 month. 
5.12.3c Mono S Start Buffer (20 mM 2-[N-morpholino] Ethanesulphonic Acid 
(MES), pH 6.0) 
To 350 mL dH2O, add 2.13 g of MES free acid monohydrate. Adjust the pH to 6.0 with 
10N NaOH. Q.S. to 500 mL with dH2O. Filter sterilize and store at 4°C for 1 month. 
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5.12.3d Mono S Elution Buffer (20 mM MES, 1.0 M NaCl, pH 6.0) 
Dissolve 14.61 NaCl in 200 mL 20 mM MES. Q.S. to 250 mL with 20 mM MES. Filter 
sterilize and store at 4°C for 1 month. 
5.12.3e 0.2% Sodium Azide 
Dissolve 2 g sodium azide in 1000 ml Milli-Q H2O. Filter through a 0.45 μm filter and 
store at 4°C. 
5.12.3f QMA Solution A 
Dissolve 31.52 g of Tris-HCl in 2 L of dH2O. Filter solution through a 0.45 μm filter. 
Store at room temperature for 3 months. 
5.12.3g QMA Solution B  
Dissolve 24.23 g of Tris-Base in 2 L of dH2O. Filter solution through a 0.45 μm filter. 
Store at room temperature for 3 months. 
5.12.3h QMA Solution C  
Dissolve 233.76 g NaCl in 2 L of dH2O. Filter sterilize and store at room temperature for 
3 months. 
5.12.3i Saturated Ammonium Sulfate 
Dissolve 53.1 g of (NH4)2SO4 per 100 ml dH2O; prepare at room temperature and cool to 
4°C. Store overnight at 4°C prior to using. 
5.12.3j Glycine-HCl, 0.1 M, pH 3.5  
Dissolve 1.12 g glycine-HCl in 75 mL dH2O. Adjust the pH with 2 M HCl and q.s. to 
100 ml. 
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5.12.3k 50 mM NH4HCO3 Dialysis Buffer 
To 3.5 L of dH2O, add 15.81 g of NH4HCO3. Q.S. to 4 L and filter sterilize. 
5.12.3l Coupling Buffer (0. 1M NaHCO3, 0.5 M NaCl)    
Dissolve 0.84 g of NaHCO3 and 2.92 g NaCl in 80 mL MilliQ H2O and pH to 8.3 with 
HCl. Q.S. to 100 ml and filter sterilize. 
5.12.3m Blocking Buffer  
Can use either 0.1 M Tris-HCl, pH 8.0 or 1 M ethylamine, pH 8.0, filter sterilize 
5.12.3n Washing Buffers of Alternate pH (0.1 M Acetate buffer with 0.5 M NaCl 
and 0.1 M Tris-HCl)   
Dissolve 5.25 g sodium acetate in 850 ml dH2O. Add 2.06 mL acetic acid. Dissolve 
29.22 g NaCl and 15.76 g Tris-HCl. Adjust the pH using 1 M HCl or 1 M NaOH. Q.S. to 
1 L. 
5.12.3o Binding Buffer PBS, pH 7.5  
Dissolve 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4 and 0.24 g of KH2PO4 in 800 ml 
of dH2O; Adjust pH to 7.5 with HCl; QS to 1000 ml; Autoclave or filter sterilize and 
store at room temperature for up to 1 year. 
5.12.3p Elution Buffer A  
0.5 M sodium acetate, 0.15 M NaCl, adjust pH to 4.5 
5.12.3q Elution Buffer B  
0.5 M glycine, 0.15 M NaCl, adjust pH to 3.0                                
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5.13 Commentary 
 
5.13.1 Background Information  
 
Rotaviruses (RV) are the major cause of severe, viral gastroenteritis in young 
children worldwide and are associated with sporadic outbreaks of diarrhea in elderly and 
immunocompromised patients (Estes, 2013).  An established pathophysiologic 
mechanism by which RV induces diarrhea is malabsorption secondary to the destruction 
of infected enterocytes.  Other mechanisms have been proposed including a reduction in 
epithelial surface area by replacing the absorptive enterocytes with immature, crypt-like, 
secretory cells; activation of the enteric nervous system; and villus ischemia. The 
enterotoxic activity of NSP4 represents another possible mechanism of RV-induced 
diarrhea (Ball et al., 1996).  It is likely multiple mechanisms are responsible for the 
severe fluid loss associated with RV infections. 
Rotaviruses are structurally complex with three concentric protein coats forming a 
capsid that encloses eleven double-stranded RNA segments. A spike protein composed 
of dimers of VP4 extend through the outermost layer, composed of 260 trimers of VP7, 
and interacts with the middle protein layer, which is composed of 260 trimers of VP6. 
The inner protein layer is primarily composed of 60 dimers of VP2 with VP1, a RNA-
dependent polymerase and VP3, a guanyl and methyl transferase are located on the inner 
side of the channels.  This inner layer also interacts with the genomic viral RNA (Estes, 
2013). 
The complete infectious virion is called a triple-layered particle (TLP).  The double-
layered rotaviral intermediates are called double-layered particles (DLPs).  Due to the 
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calcium dependence of VP7, the outer coat is lost upon viral entry into the low-calcium 
environment of the cell cytosol forming DLPs, which are transcriptionally active but 
non-infectious.  Transcription occurs within the confines of the DLPs once VP7 and VP4 
are removed.  RV contains 132 aqueous channels, spanning the outer two-capsid layers, 
which allow influx of molecules into the DLPs and efflux of newly formed viral mRNAs 
(Pesavento et al., 2001).  Following translation of viral transcripts, newly formed core 
particles (single shelled) and DLP-like replication intermediates (RI) assemble into 
electron-dense, perinuclear, non-membrane-bound inclusions (viroplasms) adjacent to 
the ER.  RNA replication occurs in concert with the packaging of the RNAs into the RI.  
Synthesis and packaging of the genomic dsRNAs are complex, tightly controlled, and 
described in detail in recent reviews (Patton et al., 2004; Trask et al., 2012). For more 
detailed background on the RV lifecycle, see Background Information in Unit 15C.3. 
A unique step in RV morphogenesis is the budding of DLPs through the membrane 
of the ER, during which VP7 (outer layer), VP4 (spike protein), and a transient ER 
membrane is added to the immature particle.  This budding event is mediated by the ER-
localized nonstructural glycoprotein NSP4 (Estes, 2013), which functions as an 
intracellular receptor by binding VP6 (the outer layer of DLPs) (Taylor et al., 1996) and 
initiating translocation into the ER for addition of the outer protein layer.  NSP4 contains 
a single transmembrane domain (residues 24-44) that traverses the ER bilayer such that 
the N-terminal 24 amino acids remain in the lumen of the ER and residues 45-175 form 
an extended, cytoplasmic domain.  Two N-linked high mannose glycosylation sites are 
located within the short ER luminal domain at residues 8 and 18.  Classical ER retention 
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signals are lacking in the NSP4 sequence and the mechanism of NSP4 retention in the 
ER remains unknown.  NSP4 does not appear to be retrieved from the Golgi by 
retrograde transport since NSP4 carbohydrate moieties remain sensitive to 
endoglycosidase H digestion (oligosaccharide processing stops at Man8GlcNAc).  
Mutational analyses have revealed that the receptor activity of NSP4 is localized to 
the C-terminus of the fully-glycosylated 28 kD protein and has disclosed that only the C-
terminal 20 aa are required for DLP binding (Taylor et al., 1996).  Limited NSP4 
proteolysis and mass spectroscopic analyses similarly reveal the NSP4 C-terminal 
residues as the binding domain for VP6 (O'Brien et al., 2000).  To facilitate the addition 
of the outer coat and spike, NSP4 forms a complex with VP4 and VP7.  The binding site 
for VP4 has been localized to NSP4 residues 112-148.  Thus, maturation of infectious 
particles takes place in the ER lumen where the ER membrane and NSP4 are removed 
by an unknown mechanism and the outer layer and spike protein are added.  There is 
some controversy as to where the spike protein is added to the TLP. Delmas et al. 
demonstrate that VP4 is added at the PM, and the discrepancy has not been resolved 
(Delmas et al., 2004). 
RNA interference (RNAi) has revealed a 75% reduction in progeny RV when cells 
are transfected with siRNANSP4 or siRNAVP7.  This inhibition of virus production is 
specific, as siRNANSP4 fails to silence a RV strain with a four-nucleotide difference in 
the NSP4 gene sequence (Lopez et al., 2005).  In cells transfected with siRNANSP4, there 
is a reduction in VP2 (20%), NSP2 (25%), VP7 (30%), VP4 (40%), and NSP5 (50%), 
and a two-fold increase in NSP3 (170%).  Both DLPs and TLPs are reduced to 
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undetected levels in NSP4 silenced cells, and could explain the absence of defined viral 
particles and the condensed, sporadic viroplasms in cells with siRNANSP4 (Lopez et al., 
2005).   
The results with siRNAVP7-transfected cells are distinct from those of siRNANSP4.  In 
addition to the altered accumulation of several RV-encoded proteins when only NSP4 is 
silenced, there is a redistribution of other RV proteins.  Instead of localization to 
viroplasms, VP6 is extended to the periphery of the cell in filaments, likewise VP2 
distributes throughout the cytoplasm rather than in viroplasms as in siRNANSP4-
transfected cells.  This is less surprising given the interactions of NSP4 with VP4 and 
VP7. The typically perinuclear and filamentous VP4 is found homogenously distributed 
in the cytoplasm and VP7 is no longer located at the ER in semicircular structures 
around viroplasms, but is perinuclear and more diffuse (Lopez et al., 2005).  The 
relocalization of VP2, VP6, VP4 and VP7 can be explained by the protein associations 
with NSP4.  NSP4 forms a complex with VP4 and VP7, directly interacts with VP4 and 
VP6, and VP6 interacts with VP2. 
In contrast, alteration of the quantity and distribution of other RV proteins are not 
seen with siRNAVP7, however a similar 75-80% reduction in progeny virus is noted with 
the silencing of VP7.  In contrast to NSP4-silenced RV expression, DLPs and TLPs are 
not diminished with siRNAVP7–transfected cells, but an accumulation of noninfectious, 
enveloped particles is seen within the lumen of the ER (Lopez et al., 2005).  Notably in 
the absence of VP7 as well as VP4, NSP4 is sufficient for the budding of DLPs into the 
ER lumen (Lopez et al., 2005).  Hence, NSP4 is critical to the late stages of RV 
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morphogenesis. 
Full-length NSP4 and its active synthetic peptide, NSP4114-135, induces Cl- secretory 
currents across unstripped, mouse intestinal mucosa similar to carbachol, an endogenous 
Ca2+-mobilizing agonist that potentiates cAMP-induced effects, as measured in Ussing 
chambers (Ball et al., 1996).  To extend these observations, cystic fibrosis 
transmembrane conductance regulator (CFTR) gene knock out mice have been exploited 
since they are deficient in cAMP-mediated ion transport.  In these studies, RV infection, 
NSP4 and NSP4114-135 overcame the cAMP-promoted Cl- secretion deficiency and 
induced an age-dependent diarrhea in the null mutation mouse pups.  NSP4 also elicits 
iodide influx into isolated crypt cells from CFTR+/+ wild type, CFTR+/- heterozygous, 
and CFTR-/- homozygous mouse pups, whereas both carbochol and forskolin fail to 
produce halide influx in the CFTR-/- genotype verifying the unique properties of NSP4 
activity.  NSP4 mobilizes [Ca2+]i in all regions of the crypt cells from all three RV 
genotypes (A-C).  However, the crypt cell [Ca2+]i response is independent of cell 
maturity or the age of the mice from which the crypts are isolated.  In contrast, the iodide 
influx is age-dependent, only occurring in crypts isolated from neonatal mice, and 
requires the presence of Ca2+.  Thus, NSP4-induced diarrhea may occur via the 
activation of an age- and Ca2+-dependent, anionic halide permeability pathway.   
RV infection directly inhibits Na+-D-glucose (SGLT1) and Na+-L-leucine symporter 
activity across young rabbit intestinal brush border membrane vesicles (Halaihel et al., 
2000).  This symporter inhibition is seen with NSP4 and NSP4114-135 suggesting NSP4 is 
responsible for the inhibition of SGLT1 in intestinal brush border membrane vesicles 
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isolated from young rabbits (Halaihel et al., 2000).  Because SGLT1 functions in the 
reabsorption of water, disruption of its activity would result in fluid accumulation in the 
lumen of the intestine and could contribute to the diarrheal disease caused by RV 
infection and/or NSP4.  Hence, these data present another mechanism by which NSP4 
could induce diarrhea.  
Expression of NSP4 up-regulates the expression of cellular proteins, including the 
ER, Ca2+-binding, host glucose-regulated chaperone proteins BiP (GRP78) and 
endoplasmin (GRP94), as well as the translationally controlled tumor protein (TCTP).  
Glycosylated NSP4 transiently associates with calnexin both in vivo and in vitro 
(Mirazimi et al., 1998).  Calnexin is a trans-ER type I membrane chaperone that interacts 
with assembly intermediates of numerous membrane glycoproteins.  The NSP4-calnexin 
association is lost upon complete enzymatic removal of the NSP4 glycan moieties.  
NSP4 (i) has a microtubule-binding domain, (ii) functions as a microtubule-
associated protein (MAP), and (iii) prevents ER-to-Golgi trafficking.  Removal of the 
NSP4 C-terminal residues 140-175 results in loss of tubulin binding and NSP4 no longer 
redistributes ERGIC53 or β-COP to discrete structures in the cytoplasm that co-localize 
with NSP4 (Xu et al., 2000).  Thus, the microtubule-binding domain has been localized 
to the C-terminus of NSP4 adjacent to the coiled-coil region.  The authors postulate that 
by blocking the transport from the ER to the Golgi, NSP4 limits the activity of intestinal 
brush border disaccharidases in the plasma membrane and hence promotes the onset 
and/or the persistence of diarrheal disease (Xu et al., 2000). 
There is compelling evidence that RV infection stimulates nerve reflexes in the ENS 
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to induce intestinal fluid losses (Lundgren et al., 2000).  Given the activity of NSP4 in 
[Ca2+]i mobilization, it is reasonable to postulate that NSP4 also functions as an enteric 
nerve secretagogue.  Thus, in addition to activating intracellular secretory pathways in 
enterocytes, NSP4 may activate the secretory reflexes of the ENS that are dependent on 
Ca2+ flux. 
Other binding partners of NSP4 have been disclosed (Boshuizen et al., 2003). Genes 
encoding the extracellular matrix (ECM) proteins laminin-β3 and fibronectin 
consistently are bound in a yeast two-hybrid screen, and NSP4-ECM protein interactions 
have been confirmed by co-immunoprecipitation reactions.  The NSP4 binding domain 
of the ECM proteins maps to residues 87-145 as determined by deletion analyses 
(Boshuizen et al., 2003).  An intriguing finding in this study is the localization of NSP4 
to the basement membrane of RV-infected and uninfected small intestinal epithelium in 
mice.  These data suggest a basal release of NSP4 in agreement with our findings 
(Mitchell and Ball, 2004) and subsequent interaction with uninfected cells (Boshuizen et 
al., 2003).   
The enterotoxin can be isolated with plasma membrane caveolae that lack ER 
markers (Storey et al., 2007), and the C-terminus of NSP4 interacts directly with 
caveolin-1. The binding domain has been mapped to 3 hydrophobic residues indicating a 
hydrophobic interaction between NSP4 and caveolin-1 (Parr et al., 2006; Storey et al., 
2007). The C-terminus of NSP4 is exposed on the exofacial surface of the plasma 
membrane and the transport kinetics vary in cell lines of different origins (Gibbons et al., 
2011). The mechanism by which NSP4 traffics to the plasma membrane via an 
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unconventional pathway remains unclear.   
NSP4 purified from culture media of RV infected mammalian cells or rNSP4 
expressed in insect cells shows strong enterotoxic activity when administered to neonatal 
mice or exogenously added to cultured intestinal cells.  NSP4112-175 induces an age- and 
dose-dependent diarrhea in young mouse pups equivalent to full-length NSP4 and in 
agreement with the 114-135 peptide.  Moreover, NSP4112-175 mobilizes [Ca2+]i when 
added exogenously to intestinal cells or expressed endogenously in insect cells (Zhang et 
al., 2000).  NSP4 has recently been shown to act as a viroporin, inducing release of Ca2+ 
from ER stores and activating calcium/calmodulin-dependent kinase kinase β (CaMKK-
β) signaling (Crawford et al., 2012; Hyser et al., 2010). Induction of the CaMKK-β  
pathway by NSP4 leads to induction of autophagy, which is vital to virus morphogenesis 
(Crawford et al., 2012). 
We report that NSP4 traffics to the cell surface by a unique, Golgi-independent, 
unconventional pathway.  Treatment of cells with brefeldin A has no effect on the 
release of NSP4, and the released NSP4 is sensitive to endoglycosidase H (EndoH) 
(Gibbons et al., 2011; Storey et al., 2007). Secretion of NSP4 into culture media is 
abolished by treatment with the cytoskeletal altering drugs nocodazole and cytochalasin 
D.  We also have shown NSP4 secretion and binding to naïve cells in experimentally 
infected cells. Further, NSP4 binds microtubules, redistributes ER-Golgi intermediate 
compartment markers to structures that align along linear tracks and radiate through the 
cytoplasm, and co-localizes with ERGIC53 and β-COP when examined by confocal 
microscopy (Xu et al., 2000).  Detailed studies are needed to fully elucidate the transport 
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pathway of a pool of NSP4 from the ER to the cell surface.   
RV infections have been shown to cross species barriers, both animal-to-human and 
human-to-animal, and interspecies reassortment of RV genes can occur during co-
infections producing novel RV strains (Iturriza-Gomara et al., 2001).  Mixing of genes 
from different RV strains during a co-infection can lead to the packaging of genomic 
dsRNAs from different strains into subviral particles.  This provides a mechanism for the 
production of genetic and antigenic reassortants.  
Several studies suggest that interspecies transmission of RV may occur at a relatively 
high frequency, especially in developing countries, where mixed infections are more 
common and humans and animals live in close proximity (Jain et al., 2001). One study 
suggests that pigs are a reservoir of multiple species of RV and play a crucial role in 
newly adapted, emerging RV strains in other species (Parra et al., 2008). The unusual 
genotypes, vaccine evasion, and viruses with enhanced virulence in one or more species 
raises questions about the effectiveness of current live attenuated vaccines. Co-infection 
of simian strain SA11 and rhesus RV had 25% progeny virus reassortants as early as 12 
hours post-infection, which increased to 80-100% by 72-96 hours post infection 
(Gombold and Ramig, 1986). With this in mind, there is a higher chance of interspecies 
reassortment than previously realized, which could result in enhanced RV virulence and 
vaccine failure.  
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5.13.2 Critical Parameters and Troubleshooting 
 
5.13.2a Growth and Titering of RV and Generation of Reassortants 
 
Plaque size is irregular or inconsistent-Adding 100 µg/ml of dextran in the primary 
overlay may help prevent plaquing inconsistencies. There are several other reasons that 
may cause a plaque assay to fail. For a helpful chart, refer to Table 2 in Arnold, et al. 
which lists common problems associated with plaque assays and how they can be 
managed.  
Virus cannot be produced at high titer- Low passage virus may not be tissue-culture 
adapted, which can be problematic for viral growth in culture.  Parental strains, 
especially those isolated from clinical specimens, likely will need to be passaged several 
times in culture before the titer will increase. For example, RV can be passaged every 
seven days in MA104 cells until there is evidence of tissue-culture adaptation by the 
presence of CPE.  
Unable to generate the reassortant of interest- Addition of neutralizing monoclonal 
antibodies as a means of selection will eliminate packaging of the unwanted segment(s) 
(Gorrell and Bishop, 1997). 
Acrylamide gel not polymerizing-It is imperative to degas the casting solutions 
properly. The solutions need to be room temperature before mixing together. APS must 
be made fresh daily for best results. 
Gel solution solidifying too quickly-Be sure to add APS before adding TEMED. Once 
the APS is added, you must work quickly to ensure that the gel does not solidify too 
soon. 
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Rotavirus RNA contaminated with cellular RNA- The virus can be isolated on a 
cesium chloride gradient and then pelleted through a 35% sucrose cushion (Alternate 
Protocol 3 Unit 15C.3). TRIzol® can be added directly to this virus pellet, which will 
eliminate most cellular RNA contaminants. If the RNA on the PAGE gel looks smeared 
or bands are not visible, it is possible the RNA is degraded during or after the isolation 
process. The initial lysis buffer protects the RNA from degradation during extraction, 
but it is common that the RNA is contaminated with RNases during the isolation. Use of 
RNase inhibitors and sterile filter tips will reduce this problem. It is recommended to 
work in an RNA hood and use RNAse spray to reduce RNA degradation. Keep isolated 
RNA in the freezer at -20°C and when in use, keep RNA on ice at all times. The amount 
of time the RNA is left on ice should be limited to the time it takes to carry out the 
experiment.   
Silver stain reveals no RNA nor DNA markers- Do not destain longer than 20 sec for 
2 times before adding the developer solution. If the bands fail to be visible after the 
addition of developer, remove all of the developer from the gel by washing for 30 min 
with multiple changes of dH2O. Start the process over starting from the sensitizing of the 
gel to staining and developing.  If the bands are still not apparent the second time 
around, make a new 30% acrylamide solution and check the pH of the gel buffers. The 
pH of the gel buffers can significantly affect the way the RNA segments run and whether 
they stain well. Run a test gel with new 30% acrylamide with only markers to optimize 
your conditions. 
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5.13.2b Production and Purification of NSP4 from Cells 
Low NSP4 production from infected cells-There is evidence showing that NSP4 
production and release into the media is not only cell dependent, but also virus strain 
dependent. You can determine the maximum production time by testing media at 
different times post infection by dot blot. If the recovery of NSP4 remains low, the 
production scale may need to be increased by using roller bottles, or choose another cell 
line/viral strain combination. 
Low recovery of NSP4 from the ConA column- It is critical that you run the 
concentrated media through the ConA column multiple times.  Examine an aliquot of the 
flow through via dot blot each time the sample is passed through the column.  This will 
ensure that additional NSP4 efficiently binds the column with each passage and that 
NSP4 is binding to the ConA ligand. 
No plaques are formed in Sf9 plaque assays- Although it is common for baculovirus 
to replicate efficiently to form plaques in 4 or 5 days, some viruses may grow more 
slowly than others. In this case, extend the incubation time to 8 or 9 days and reexamine 
for plaques. If the plaques are still absent after 9 days of incubation, the titer is likely too 
low and requires concentration. 
Sf9 cells die during the plaque assay - The titer of the virus may be too high, so dilute 
the virus prior to determining plaque forming units. Another cause of dead cells is not 
allowing the media/agarose mixture to sufficiently cool before adding the agarose to the 
cells. A good test is to test a drop on the inside of your wrist.  It should be really warm 
but not scalding. 
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Low viability of SF9 suspension culture-Check the cell density. The cell suspension 
should contain 1 x 106 cells/ml. If they are too low, spin them down as in Alternate 
Protocol #3, Step 5 and resuspend in less media. Also ensure that there is adequate 
serum in the suspension. There should be at least 5% serum. 10% serum is ideal while 
expanding the cells. 
Cells are clumping together in Sf9 spinner cultures-The suspension is too confluent 
or too old. If too confluent, split them down to 1 x 106 cell/ml. If they are too old, start 
new spinner cultures with fresh cells and media. 
Absence of protein expression in Sf9 cells-The bacmid may be constructed incorrectly. 
Make sure that the bacmid contains a start codon (ATG) and is in the correct reading 
frame.  
Low NSP4 expression in Sf9 cells-Make sure your reagents are fresh and stored 
properly. Old transfection reagent (Cellfectin II) can affect the transfection efficiency of 
the Sf9 cells. The Sf9 cells are best transfected in log phase growth (90%-95% viability) 
and are between 50%-70% confluent. The baculovirus infection should be completed at 
a high MOI. If inadequate baculovirus is used, the protein expression will be low. 
Anti-NSP4 titer is low-This generally is seen when using peptides as the antigen.  Even 
though the peptide is cross-linked to a larger protein, many of the antibodies are directed 
against the carrier protein, KLH for example.  It may be necessary to set up a KLH 
affinity column in which KLH is used as the ligand.  In this case, the antibody solution is 
added to the column and the anti-KLH is bound.  The flow-through primarily is against 
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the target peptide.  Concentration of IgG can be accomplished by dialysis using a 
volatile buffer such as ammonium sulfate and lyophilization.  
Anti-NSP4 peptides fail to recognize the native protein-This is always a potential 
problem when working with synthetic peptides rather than the full protein.  It is 
important to check the literature to determine the immune-dominant sites.  You can use a 
mixture of synthetic peptides representing different regions of the protein to increase the 
possibility that the antisera will recognize the native protein.  Alternatively you may 
have to use partially purified (~75%) protein as antigen. In addition, recognize that the 
peptide antibodies will have a lower titer for the protein than to the peptide.  This can be 
overcome by concentrating and using a higher concentration of the purified IgG. Be 
cautious when selecting the peptide to be synthesized and ensure the quality and purity 
of the peptide sequence.  
Purifying the antibody ligand for affinity chromatography- Polyclonal antibodies 
often are difficult to purify at a concentration greater than 2-3 mg/ml.  In addition, the 
IgG can slowly precipitate at 4 °C.  Storage in 50% glycerol in PBS is recommended to 
prevent this precipitation. Alternatively, the antibody remains very stable when 
lyophilized and stored under desiccation at -20 °C. 
Preparation of the antibody affinity chromatography column-Unsuccessful coupling 
of the IgG can be due to the presence of amino groups in the sample or buffers.  
Typically it comes from the ammonium sulfate used to precipitate the antibody or the 
use of Tris buffers.  Dialyze the IgG solution very carefully ensuring that multiple 
changes of large volumes are used.  Be sure not to store buffers in plastic containers as 
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water may have amines that has leached from the plastic.  When eluting with a low acid 
solution, elute quickly to avoid exposing the column to the acid for an extended length 
of time. The column should be regenerated for additional uses by washing the column 
several times with coupling buffer and store in sodium azide at 4 °C. 
Dialysis- Because a solute's permeability is also dependent upon molecular shape, 
degree of hydration, ionic charge and polarity, it is recommended to select a MWCO that 
is half the size of the MW of the protein you want retained. 
5.13.3 Time Considerations 
Generation of rotavirus reassortants-Initially, 3 days are necessary to grow MA104 
cells. Infection of the cells takes 2 hours and virus growth takes 1-3 days.  
Plaque assay-Setting up the plaque assay generally will take about 3 h. Growth of the 
plaques will take 3-5 days, and staining with neutral red will take 4-24 h. 
Viral RNA Isolation-RNA extraction takes 1- 2 hours, depending on the method is 
used. 
PAGE-From beginning to end, PAGE and staining can be completed in one day. It takes 
generally takes 6-8 hours. 
Purification of NSP4 from mammalian cells-The production of NSP4 takes several 
days. You will need a few days to grow the cell monolayers and after infection with RV, 
it may take 24-72 h for production and secretion of NSP4. Once the media is collected, 
purification is faster, generally taking 1-2 days. 
Construction of Bacmid-The construction of the bacmid varies significantly depending 
on the method used. It should be expected to take at least a few days, unless the gene is 
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purchased already cloned into a vector. The construction will vary with the source of the 
components. It is best to follow manufacturer’s instructions. 
Production of recombinant baculovirus-The production of recombinant baculovirus 
should take 2-3 days if transfection efficiency is good. If transfection efficiency is lower, 
it will take longer. 
Plaque assay for recombinant baculovirus-Setting up the baculovirus plaque assay 
will take 2-3 h. The plates need to incubate for 4-7 days to properly visualize the 
plaques. It is useful to check for plaques every 24 h. 
Expression of NSP4 in Sf9 cells-The production of NSP4 will take ~36 hours, but may 
vary depending on the bacmid used. 
NSP4 purification-It generally takes several days to purify any protein depending on 
the number of contaminants and the number of purification steps.  If using antibody 
affinity chromatography, it will take at least a day to bind the ligand and complete the 
washes.  The antibody must be purified before use, which also takes several days; and 
tested for specificity by ELISA and or Western blot, which takes one day.  
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6. SUMMARY AND CONCLUSIONS
6.1 Overview: Further Understanding the Role(s) of NSP4 Interactions with Cav-1, 
CyPA, CyP40, HSP56 and Cholesterol  
This work began by building on the evidence that NSP4 interacts directly or 
indirectly with Cav-1, CyPA, CyP40, HSP56, and cholesterol. In this study, we showed 
that the silencing of the proteins fails to inhibit transport of NSP4 to the PM, but does 
change the intracellular distribution of NSP4 during RV infection. In addition, we 
presented evidence that the inhibition of cholesterol does impact NSP4 transport to the 
PM. We showed an interaction of NSP4 with HSP56 with FRET but not with yeast two-
hybrid analysis, and presented evidence that expression of the cyclophilins are up-
regulated during infection, while the expression of Cav-1 remains relatively consistent. 
Taking this study as a whole, we are left with many questions about the exact role of the 
interactions of NSP4 with Cav-1, the immunophilins and cholesterol. 
6.1.1. Inhibition of Cav-1, CyPA, and CyP40 with siRNA Does Not Prevent NSP4 
Transport to the PM 
Silencing of Cav-1, CyPA, and CyP40 proved to be difficult in the cell lines we were 
working with (MDCK, MA104, and HT29.f8). However, as we moved forward with the 
project better reagents became available on the market for working with siRNA in 
difficult to transfect cell lines. Therefore, we were able to work not only with the much 
studied MA104 cell line but also with a more biologically-relevant, cloned human 
intestinal cell-line, HT29.f8. Since NSP4 displays different transport kinetics in a kidney 
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cell line (MDCK) when compared to the intestinal HT29.f8 cell line (Gibbons et al., 
2011), we expected to see some influence of silencing on NSP4 transport to the cell 
surface albeit unique to each cell line. To our surprise, NSP4 was able to traffic to the 
cell surface upon silencing of Cav-1 and the cyclophilins in both MA104 and HT29.f8 
cells. 
Unpublished research in our lab showed that during RV infection of a cell line 
lacking Cav-1 (Fischer rat thyroid cells), NSP4 can bind to Cav-2 instead of Cav-1 and 
is transported to the cell surface. This indicated that certain proteins could compensate 
for others when one is not available. We determined that there was a good possibility 
that silencing only one of the proteins at a time would not inhibit NSP4 from trafficking 
to the PM, because the proteins could be compensating for each other. Therefore, we 
attempted to silence multiple proteins at a time, in combinations of two as well as all 
three. However, NSP4 still trafficked to the cell surface with the same kinetics, 
indicating that none of these proteins were necessary for NSP4 transport to the PM, 
alone or in combination. 
6.1.2. Inhibition of Cav-1, CyPA, CyP40, and HSP56 with siRNA Altered the 
Intracellular Distribution of NSP4  
Silencing of HSP56 could not be measured via Western blot due to limited antibody 
reactivity using this method. However, the silencing of HSP56 could be clearly seen by 
immunofluorescence. Therefore, we were able to evaluate the effect(s) of silencing Cav-
1 and all three immunophilins on the intracellular distribution of NSP4. We determined 
that silencing of HSP56 had very little influence on intracellular NSP4 distribution. 
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However, there were significant intracellular changes in distribution of NSP4 and 
cellular proteins upon silencing of Cav-1 and CyPA. 
It is known that a pool of intracellular Cav-1 localizes to the trans-Golgi network 
(TGN) (Fielding and Fielding, 2003). Upon silencing of Cav-1, NSP4 appears to co-
localize with the Golgi protein, golgin-97. Therefore, silencing of Cav-1 may be altering 
intracellular distribution of NSP4 by reorganization of host-cell structures. The silencing 
of CyPA had a similar effect on the co-localization of NSP4 when compared to golgin-
97. This increase of NSP4 co-localization with golgin-97 appeared to be due to a TGN 
re-distribution, rather than to localization of NSP4 to the Golgi, as NSP4 remained 
Endoglycosidase H sensitive upon silencing. There are reports of CyPA association with 
Golgi-associated vesicles (McDonald et al., 1992; Sarris et al., 1992), although most 
reports indicate that CyPA is a cytoplasmic protein with some nuclear localization 
(Krummrei et al., 1995; Zhu et al., 2007). The reason for perturbation of the Golgi 
complex upon silencing of Cav-1 and CyPA should be further investigated, but was 
beyond the scope of this project.  
6.1.3. Expression of CyPA and CyP40 Are Up-regulated During Infection  
During immunofluorescence studies, it was noted that the signal for CyP40 was 
much higher in infected cells than in uninfected cells. This led us to perform time course 
experiments to determine if protein expression of CyPA and CyP40 were up-regulated 
throughout RV infection. CypA and CyP40 did not increase until 3-4 hpi. The increase 
in expression of these two immunophilins could be due to an excess of unfolded non-
native protein present in the cell later during infection since they are both important for 
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protein folding. It would be useful to determine whether the increase in protein 
expression occurs only in the presence of NSP4, or if RV infection as a whole increases 
expression.  
CyPA plays a role in regulation of the IFN-β response during RV infection. 
Silencing of CyPA increases RV production and overexpression of CyPA causes a 
decrease in RV production (He et al., 2012). In addition, CyPA expression is increased 
during RV Wa infection and in intestines following RV infection of BALB/c mice (He et 
al., 2013). When CyPA is silenced, several viral mRNA levels are up-regulated 
including RV NSP4 (He et al., 2013). While these studies point to RV NSP1 activation 
of the PI3K/Akt pathway as a potential cause of up-regulation of CyPA expression, it is 
possible that NSP4 up-regulation of cytoplasmic [Ca2+] may play a role as well. 
Interestingly, one study noted cell-type dependent differences in expression of CyPA 
during RV infection (He et al., 2013). This further supports our hypothesis that the 
interaction of NSP4 with immunophilins may be cell-type dependent. 
CyPA plays a major role in many types of viral infections, including influenza, 
coronavirus, hepatitis C, and cytomegalovirus (Anderson et al., 2011; Keyes et al., 2012; 
Tanaka et al., 2013). Notably, in hepatitis B infection, CyPA is secreted from cells that is 
induced by viral infection (Tian et al., 2010). In vaccinia virus infection, CyPA is 
packaged into the virion and secreted from the cell (Castro et al., 2003). Although we 
showed that CyPA is not required for NSP4 transport to the PM, we did not investigate 
the role of CyPA in secretion of NSP4 nor did we explore whether CyPA is secreted 
during RV infection. 
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6.1.4. HSP56 Localized in Close Proximity to NSP4 Intracellularly, But May Not 
Directly Interact 
Although it was determined that NSP4 and HSP56 localize within 10 nm of each 
other via intracellular FRET experiments, a direct interaction could not be confirmed by 
co-immunoprecipitation or yeast two-hybrid assay. Co-immunoprecipitation of HSP56 
was not possible due to limited antibody reactivity, although it was attempted with 
antibodies from several sources. It is reasonable to propose that if NSP4 interacts with 
CyP40, it would be in close association with HSP56, since CyP40 and HSP56 both 
interact within the same protein complexes (Czar et al., 1994; Davies and Sanchez, 
2005). A lack of interaction of HSP56 and NSP4 could explain why there was no 
alteration of intracellular NSP4 distribution upon silencing of HSP56. 
6.2 Pitfalls 
We set out to investigate a complex consisting of Cav-1, CyPA, CyP40, and HSP56, 
which was reported to transport cholesterol directly from the endoplasmic reticulum to 
the plasma membrane (Uittenbogaard et al., 2002; Uittenbogaard and Smart, 2000; 
Uittenbogaard et al., 1998). It seemed logical that NSP4 would utilize this complex for 
intracellular transport, since NSP4 interacts with several of the proteins as well as 
cholesterol. As we delved further into the research, it became apparent that the proteins 
did not affect the transport of NSP4 to the PM. Unfortunately, the studies describing the 
complex were retracted due to falsification of data (Office of the Secretary, 2012). 
Although we found that NSP4 interacts with several of these proteins, there are no other 
 179 
reports that describe the complex, and our research did not focus on proving its 
existence, as it had been published for many years in top Journals. 
The cost of the silencing RNAs led to another pitfall in our research. We set out to 
quantify the amount of NSP4 that reached the cell surface when Cav-1 and the 
immunophilins were inhibited. We ran into several problems when trying to quantitate 
NSP4 concentration at the exofacial PM. We initially tried to use sodium-potassium 
ATPase as a loading control for Western blot analysis. However, the amount of sodium-
potassium ATPase varied significantly depending on the protein silenced and could not 
be used as an internal loading control. We tested a few other exofacially-expressed 
proteins, but they were either not expressed in the cell-lines we were using, or we had 
the same problem of getting consistent expression. Silencing of Cav-1 and the 
immunophilins or RV infection causes the distribution of PM-localized proteins to 
change and we therefore could not find a reliable internal loading control for our surface 
biotinylation assays.  
We attempted to remedy this problem by quantifying protein at the cell surface. 
However, due to the cost of siRNA and the limitations of protein quantification kits, we 
were not able to scale up the reactions to a level high enough to acquire enough sample 
for both protein quantification and evaluation of NSP4 transport. We decided to 
overcome this by constructing a shRNA expression system using a lentivirus vector 
system. While this method would have overcome our inability to quantify NSP4 
transport to the PM, sequencing of the shRNA segment was problematic and not 
successful. 
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Overall, the research presented in this work provided more questions than it did 
answers. While we now know that Cav-1, CyPA, CyP40, and HSP56 are not required for 
transport of NSP4 to the PM, the question remains, what is responsible for its 
unconventional transport? In addition, how are Cav-1 and the immunophilins involved in 
other intracellular transport pathways of NSP4? Elucidation of these other intracellular 
pathways may provide more insight into how NSP4 reaches the cell surface and is 
secreted. 
6.3 Future Research 
This research provided us with a few key findings: 1) Cav-1, CyPA, CyP40, and 
HSP56 are not required for NSP4 transport to the PM, 2) Cholesterol depletion does 
affect the amount of NSP4 that traffics to the PM, 3) Protein concentrations of the 
cyclophilins are up-regulated throughout RV infection, and 4) NSP4 is located in close 
proximity to HSP56, but may not be directly interacting. Details of the unconventional 
transport pathway that NSP4 utilizes to traffic to the PM still need to be explored.  
6.3.1. Cholesterol, Lipid Bodies, and Caveolin 
We found that lovastatin inhibition of de novo cholesterol synthesis decreased the 
amount of NSP4 that reached the PM using surface biotinylation. These studies cannot 
be performed with a PM-cholesterol depletion agent, such as methyl-β-cyclodextrin, 
since PM cholesterol is required for RV-infection. In addition, methyl-β-cyclodextrin 
treatment was toxic to MA104 cells when added 3 h after RV-infection (data not shown). 
At lower concentrations, methyl-β-cyclodextrin treatment did not lower cholesterol 
enough to affect NSP4 transport to the cell surface (data not shown). 
 181 
NSP4 interacts directly with cholesterol (Schroeder, 2009) and cholesterol is 
important for NSP4 interaction with highly-curved membranes (Huang et al., 2001). 
However, the function of cholesterol in transport of NSP4 has yet to be evaluated. Our 
findings suggest that NSP4 may rely on cholesterol in order for transport to the PM. 
Lovastatin inhibition of cholesterol synthesis impacts the transport of free cholesterol to 
the PM (Cignarella et al., 1998). Upon RV infection of lovastatin-treated MA104 cells, 
there is a dramatic decrease of exofacial PM-localized NSP4. However, the decrease is 
less noticeable in HT29.f8 cells. This leads us to believe that NSP4 may rely on PM-
directed cholesterol transport for its trafficking to the PM. The fact that the effect of 
lovastatin treatment on HT29.f8 cells is different than in MA104 cells further supports 
our hypothesis that NSP4 is trafficking via different pathways, which are cell-type 
dependent. 
It is known that lipid droplets are important for RV replication in viroplasms 
(Cheung et al., 2010; Gaunt et al., 2013a; Gaunt et al., 2013b). In addition, autophagy 
plays a role in the breakdown of lipid droplets, and there is a known interaction of NSP4 
with autophagy (Crawford et al., 2012). Whether this interaction is dependent upon lipid 
droplet formation is unknown. To investigate the possibility that lipid droplets play a 
role in NSP4 transport, small-molecule inhibitors of lipid droplet formation, such as 
compound C75 or TOFA (5-(Tetradecyloxy)-2-furoic acid) to inhibit the fatty acid 
synthase complex and acetyl-CoA carboxylase enzyme, respectively (Gaunt et al., 
2013a), could be utilized. In addition, performing the cholesterol and lipid droplet 
inhibition studies on cells transfected with NSP4 only could be useful to distinguish their 
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roles in NSP4 transport without interference from other RV proteins. 
The reason for studying the role of cholesterol in NSP4 transport becomes stronger 
when it is considered that cavolin-1 directly binds cholesterol in a 1:1 stoichiometry 
(Murata et al., 1995). Furthermore, Cav-1 is associated with lipid bodies, and this 
association may be part of caveolin-regulated cell signaling (Pol et al., 2004). We know 
NSP4 directly binds both caveolin-1 and cholesterol (Parr et al., 2006; Schroeder, 2009), 
and localizes to caveolae on the PM (Storey et al., 2007), which leads us to believe these 
molecules likely play a role in transport of NSP4 to distinct cell locations. 
6.3.2. Cyclophilin 40 and Autophagy 
In addition to its many other functions, cyclophilin 40 is a resident mitochondrial 
protein and is a component of the mitochondrial permeability transition pore (MTP) 
complex. This complex consists of voltage-dependent anion channel protein, adenine-
nucleotide translocator, and CyP40, is activated under oxidative stress, and is Ca2+ 
regulated (Armstrong, 2006). In addition, the role of CyP40 in this complex is important 
for autophagy initiation for mitochondrial disposal. When CyP40 function is inhibited, 
autophagy is inhibited, which also inhibits cell death (Carreira et al., 2010; Chen et al., 
2012). Therefore, CyP40 is necessary for the initiation of autophagic disposal of 
mitochondria.  
We now know that RV NSP4 is also a regulator of autophagy. NSP4 initiates 
autophagy through calcium/calmodulin dependent kinase kinase-β signaling, which is 
required for virus maturation (Crawford et al., 2012). However, NSP4 prevents 
autophagic maturation and autophagy vesicle fusion with the lysosome for degradation. 
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In addition, this process is mediated through Ca2+ release following viroporin formation 
in the ER membrane (Crawford et al., 2012). It is not yet known if there is a connection 
between NSP4-induced autophagy and MTP-induced autophagy. Small molecule 
inhibitors (siRNA and CsA) to block CyP40 function and bafilomycin A1, chloroquine, 
or other autophagic inhibitors will be useful for examination of the possible role that 
CyP40 may play in autophagy during RV infection. 
Autophagy also has been insinuated to play a role in unconventional transport of 
secretory proteins (Zhang and Schekman, 2013). A unique, chaperone-mediated 
autophagy pathway has been suggested to play a role in this type of transport through 
lysosomes (Kaushik and Cuervo, 2012). Chaperone-mediated transport into the 
lysosome is controlled through the cytosolic hsc70 family of heat-shock proteins, where 
proteins are loaded through a channel into the lysosome for degradation or secretion. It is 
known that CyP40 directly binds to hsc70 and may modulate its activity (Carrello et al., 
2004). The known interactions of NSP4 with autophagy and CyP40 need to be further 
evaluated to determine if they play a role in transport of NSP4. 
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APPENDIX A 
 
 
 
 
 
 
Figure A-1. Map of pMD.G. pMD.G is used in packaging of the pTripZ vector and 
expresses VSV-G for efficient entry into a wide variety of cell types. It possesses an 
Ampicillin resistance gene and an hCMV promoter for high expression of the VSV-G 
cDNA.  
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Figure A-2. Map of the pTripZ shRNA-expressing vector. The pTripZ contains several 
features that are listed in the table below (adapted from the pTripZ technical manual, 
Dharmacon). 
 
Vector Element Function 
5’ LTR Long terminal repeat for incorporation into genomic DNA 
3’ SIN LTR Self-inactivating long terminal repeat for incorporation into genomic DNA 
and to prevent lentiviral reproduction 
RRE Lentiviral packaging enhancer for production of lentivirus particles 
TRE Doxycycline inducible promoter 
TurboRFP Red fluorescent protein for analyzing induction and shRNA expression 
shRNA shRNA flanked by mir30 sequence for efficient gene knockdown 
IRES Internal ribosomal entry site for expression of rtTa3 and puromycin resistance 
genes 
Zeocin Resistance For bacterial selection inside the LTRs 
Ampicillin Resistance For bacterial selection outside the LTRs 
Puromycin Resistance For mammalian selection inside LTRs 
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Figure A-3. Map of pCMVΔR8.91. This vector contains the packaging genes for the 
production of lentivirus particles that will package the shRNA expressed within the 
LTRs of the shRNA insert. Additionally, it contains an Ampicillin resistance gene. 
 
 
